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Abstract : 
 Multiple Endocrine Neoplasia Type I syndrome (MEN1) is a rare hereditary tumoral disease characterized by the 
apparition of tumors in multiple endocrine organs including the endocrine pancreas. MEN1 patients generally carry a 
germinal mutation on one allele of the predisposing gene to the disease, the tumor suppressor MEN1.  
 Pancreatic endocrine tumors are rare, slowly evolving and often present with metastasis at diagnosis. These tumors 
constitute a heterogeneous group defined by their hormonal secretions. Evolution and development of these tumors is far 
from being understood. The cell of origin of the different pancreatic endocrine tumor types is enigmatic, notably for tumors 
secreting non-pancreatic hormones such as gastrinomas. 
 My thesis project was structured toward the characterization of a new murine model allowing the specific disruption 
of the Men1 gene in Ngn3+ pancreatic endocrine progenitors, the PancEndoMen1 KO model. 
 The combined study of this new model and previous model generated in the team, allowed us to demonstrate that 
pancreatic gastrinomas related to Men1 inactivation, originate from the endogenous pancreatic endocrine cells. In parallel, 
our results demonstrated that the mutant mice having Men1-deficient Ngn3+-progenitors resulted in differential cell 
proliferation alterations in different pancreatic endocrine cells. Importantly, Men1-disruption in either pancreatic endocrine 
or pan-pancreatic progenitors displayed tumors with impaired differentiation features. 
 Thus, this thesis works allowed to better characterize pancreatic endocrine tumors histogenesis by addressing the role 
of pancreatic endocrine progenitors targeted Men1 disruption during development in tumorigenesis. 
 
Titre : Etude des effets au cours du développement et pendant la vie adulte de l’invalidation du gène Men1 dans les 
progéniteurs endocrine pancréatiques.  
Résumé: 
Le syndrome des Néoplasies Endocriniennes Multiples de type I (NEM1) est une maladie tumorale héréditaire rare 
caractérisée par l’apparition de tumeurs notamment du pancréas endocrine. Le gène de prédisposition est le suppresseur de 
tumeur MEN1, généralement retrouvé muté sur un des 2 allèles au niveau germinal chez les patients NEM1. 
Les tumeurs endocrines pancréatiques sont rares mais souvent métastatiques lors du diagnostic. Ces tumeurs forment 
un groupe hétérogène de par le type d’hormone qu’elles peuvent sécréter. Le développement et l’évolution de ces tumeurs 
sont encore très mal compris. L’origine cellulaire des différents types de tumeurs endocrines pancréatiques reste 
énigmatique, notamment en ce qui concerne les tumeurs exprimant des hormones non-pancréatiques tels que les gastrinomes.  
Mon projet de thèse s’est articulé autour de la caractérisation d’un nouveau modèle murin d’invalidation du gène 
Men1 spécifiquement dans les cellules progénitrices endocrine pancréatiques Ngn3+ (PEPs), le modèle PancEndoMen1 KO. 
Ces travaux nous ont permis de démontrer que les gastrinomes pancréatiques liés à l’inactivation du gène Men1, 
avaient pour origines les cellules pancréatiques endocrines elles-mêmes. 
De plus, les souris PancEndoMen1 KO, développent des altérations de prolifération différentes suivant les lignages 
endocrines. De surcroît, l’invalidation du gène Men1 soit dans les cellules progénitrices pancréatiques, soit dans les cellules 
PEPs conduit au développement de tumeurs caractérisées par une altération de leur différentiation endocrine. 
Ainsi, mes travaux de thèse ont permis de mieux renseigner l’histogenèse des tumeurs endocrines pancréatiques en 
adressant le rôle dans la tumorigenèse de l’invalidation de Men1 dans les cellules PEPs au cours du développement. 
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1 INTRODUCTION 
1.1 PART I THE GASTROENTEROPANCREATIC ENDOCRINE AXIS 
1.1.1 GUT DEVELOPMENT. 
 The stomach, intestine and pancreas are different organs deriving from the developing 
gut during embryogenesis. During early development, the gut forms a tube with a lumen, 
composed of an outer tissue layer of mainly smooth muscle derived from the mesoderm, and 
an inner epithelial layer essentially derived from the endoderm excepted for mouth and anal 
region derived from the ectoderm. The early formation of the tube involves two invaginations 
of the definitive endoderm occurring at the anterior and posterior part of the embryo called 
respectively Anterior Intestinal Portal (AIP) and Caudal Intestinal Portal (CIP). Each lip of 
invaginations then grows and elongates toward each other and meets in the middle of the 
embryo, with a gut finally closing during the turning of the embryo at E9.0 in mouse (Lewis 
and Tam 2006). During formation, the gut tube is patternized into three different portions 
along the Anterior-Posterior axis that are respectively the foregut, midgut and hindgut. This 
patterning is controlled by crucial transcription factors that are differentially expressed along 
the antero-posterior axis. Foxa2 is required for foregut formation(Dufort et al. 1998, 
McKnight et al.), whereas Cdx1, 2 and 4 are necessary for that of the hindgut. 
 The gut formation is accompanied by the generation of different territories from which 
will differentiate gut-derived organs. The oesophagus, trachea, lungs, thyroid, parathyroids, 
stomach, the proximal part of the duodenum, pancreas and hepatobiliary system originate 
from the foregut. The midgut gives rise to the distal part of the duodenum and small intestine, 
whereas the hindgut leads to large intestine development (Wells and Melton 1999). Three 
foregut-derived organs that were studied during the thesis work are introduced more in detail 
in the following. 
 
1.1.2 THE STOMACH  
1.1.2.1 STOMACH DEVELOPMENT 
Figure 1. Anatomy of human (A) and mouse (B) 
stomachs. 
A 
B 
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The stomach begins to be formed during antero-posterior regionalization of the gut 
tube. The cytodifferentiation of the stomach begins at E13.5 in the mouse. At E16.5, the 
developing stomach is morphologically composed of two regions, the anterior region which 
will give rise to the forestomach composed of stratified, keratinized squamous epithelium 
(which does not exist in human) and the posterior part composed of a glandular epithelium 
(Khurana and Mills 2010). After birth, the stomach development continues and growth 
rapidly with a peak at three weeks after birth in mouse. The adult stomach epithelium is 
constantly renewed during life as the intestine (Khurana and Mills 2010). 
1.1.2.2  STOMACH EPITHELIUM COMPOSITION 
The stomach, as the intestine or colon, is mainly composed of different layers. The 
exterior one called the serosal layer, is a fine layer of epithelial tissue; then the muscularis 
externa layer composed of three layers of smooth muscle and enteric nervous system plexi; 
the submucosa composed of undifferentiated connective tissue and vascular tissue; and finally 
the most interior layer, the mucosa composed of epithelial cells adjacent to the overlying 
mesoderm that includes a thin smooth muscle layer called muscularis mucosa (Smith et al. 
2000). The stomach in human is regionalized in two functionally and anatomically different 
zones (Figure 1A). The most rostral part is called the fundus and body (corpus) that contains 
invaginated thick gastric glands secreting pepsinogen and hydrochloric acid continuous to pits 
that secrete mucus. The caudal part is called the antrum or pyloric antrum that is also 
composed of villus-like pit-gland units that secrete mucus and the major part of gastrin 
(Karam 1999, Smith et al. 2000). The junction with duodenum appears at the most caudal part 
of the antrum(Smith et al. 2000). In addition, there is another region between esophagus and 
fundus called cardia which is not well studied (Smith et al. 2000). The development and 
function of chicken stomach has been much more studied than mammals’ stomach. The body 
and the pylorus regions were shown to be highly similar to chicken proventriculus and gizzard 
stomach regions (Smith et al. 2000). 
In the body/fundus of the stomach the glands forms the oxyntic epithelium which is 
composed of several cell types (Figure 2 A). Under the pits containing mucus secreting cells, 
the glands are organized in three parts, the isthmus that contains precursors cells and probably 
multipotent progenitors, the neck that contains mucus secreting cells, and the base in which 
reside zymogenic cells (chief cells) producing enzymes such as pepsinogen. Acid-secreting 
A 
B 
Figure 2. Cytoarchitecture of (A)body/fundus gastric 
pit/gland units and (B)pyloric/antral pit/gland units 
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parietal (oxyntic) cells, caveolated (tuft) cells and endocrine cells are dispersed in the gland 
(Karam 1999, Khurana and Mills 2010). 
The pyloric pit/gland units are also similarly regionalized in isthmus, neck and base as 
in the corpus (Figure 2B). The pit cells secrete mucus. The isthmus is mainly composed of 
precursor cells. The neck and base are mainly composed of gland mucus producing cells and 
rare parietal acid-secreting cells. Caveolated cells (tuft cells) and endocrine cells are scattered 
in the pit-gland pyloric units(Karam 1999, Khurana and Mills 2010). A specificity of antral 
pyloric glands compared to corpus glands is the presence of Lgr5+ multipotent stem cells at 
the very base of the glands. These cells give rise to cells that migrate rapidly in the isthmus 
where they will proliferate and differentiate into all the epithelial lineages of the antrum 
(Barker et al. 2010). 
1.1.2.3  ENDOCRINE CELLS OF THE STOMACH 
 Several endocrine cell-types are present in the stomach, their distribution being 
differential between corpus and antrum. The endocrine cells represent 7% of all epithelial 
cells in the body and 3% in the antrum (Karam 1999). 
 The histamine-secreting ECL cells (Enterochromaffin-like cells) are the most abundant 
endocrine population in the corpus/fundus but are absent in the antrum. Gastric ECL cells 
appear only after birth in the mouse (Jenny et al. 2002). Ghrelin-secreting cells (P/D1) 
represent about 12% of corpus endocrine cells and are also present but rare in the antrum. The 
less abundant enterochromaffin (EC) cells secreting serotonin and somatostatin-secreting D 
cells are scattered through the corpus and antrum. The major endocrine population of the 
antrum is represented by gastrin-secreting G cells, which are absent in the corpus, residing at 
the base of the glands (Rindi et al. 2004). Finally, an extremely rare population of glucagon 
expressing cells that also express ghrelin is found in the corpus/fundus (Solcia et al. 2000). 
 The mechanisms controlling differentiation of gastric endocrine cells have not been 
well studied. In the corpus/fundus and the antrum glands, reside endocrine progenitors 
expressing the bHLH transcription factor Neurogenin 3 (Ngn3). These progenitors originate 
from multipotent stem-cells localized in the gastric glands. It was demonstrated that all 
endocrine cell types (ghrelin+, ECL cells, EC cells, gastrin+ and somatostatin+) can be derived 
from Ngn3+ progenitors by lineage tracing (Jenny et al. 2002). However, if most endocrine 
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cells of the antrum derive from Ngn3 expressing precursor, only 40% of body/fundus 
endocrine cells are deriving from Ngn3+ precursors (Schonhoff et al. 2004). Interestingly, it 
was demonstrated in Ngn3 null mice, that Ngn3 is necessary for the development of most 
gastrin+ and somatostatin+ cells in the stomach whereas ghrelin+, EC cells and ECL cells can 
still develop (Jenny et al. 2002). The precise quantification of the remaining endocrine 
populations was not assessed, so it is still unknown whether all EC, ECL and ghrelin+ cells 
can develop independently of Ngn3 or that subpopulations sensitive to Ngn3 loss exist or not. 
However, it was shown that the majority of EC cells require Ngn3 for their development as 
EC cell number is reduced by 6-folds in the glandular stomach of 2-3-days-old Ngn3 KO mice 
(Lee et al. 2002). Pancreatic duodenal homeobox 1 (Pdx1) is expressed in potential 
progenitors in antral glands and in 10 to 20% of antral hormone expressing cells (Larsson et 
al. 1996). Pdx1 is necessary for G cells development in mouse antrum, as the stomach from 
Pdx1 null mice is devoid of gastrin+ cells (Larsson et al. 1996). Interestingly, gastric antrum 
from Pdx1 null mice demonstrated a three-fold increase in serotonin producing cells, without 
change in D cells.(Larsson et al. 1996). The role of Pdx1 in the development of endocrine 
cells from the corpus/fundus was never assessed. 
1.1.3 DUODENUM 
1.1.3.1 DUODENAL DEVELOPMENT 
The duodenum represents the proximal part of the intestine, directly after the pylorus. 
When the gut tube is formed, the epithelium derived from the endoderm begins to condense 
and will forms a pseudostratified epithelium at E9.5 in mouse. Then, the developing intestine 
elongates while both the epithelium and surrounding gut mesenchyme thicken until E13.5. 
During this period the disorganized pseudostratified epithelium progressively changes to a 
stratified epithelium where apically located cells are tightly connected by junctionnal 
complexes. At E14 in the mouse (9 weeks in humans), the stratified epithelium begins to be 
massively reorganized to form a simple columnar epithelium surrounding the lumen of the 
intestine. This process is concomitantly associated with the emergence of intraepithelial 
cavities (secondary lumina) in the basal part of the stratified epithelium (Matsumoto et al. 
2002). The restructuration of the epithelium which progresses in a rostro-caudal manner along 
the intestine, allows the emergence of villi at E15 in mouse.  The latter will further grow 
secondary to the invagination of surrounding intestinal mesenchyme. Even if, during the villi 
Figure 3. Cytoarchitecture of duodenal Crypt/villus 
unit. 
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emergence, cell proliferation occurs in the whole epithelium, the growth of villi is rapidly 
supported by the proliferation of cells at their base that is progressively restricted to the 
intervillus epithelium at E17 and finally crypts of Lieberkühn that develop postnatally in 
rodents (Hirano and Kataoka 1986) but are already formed during gestation in human 
(Drozdowski et al.) (Figure 3). 
During villi emergence, two groups of differentiated cells emerge in the epithelium, 
the absorptive lineage represented by enterocytes in duodenum and small intestine and the 
secretory lineages, respectively. Secretory lineages are composed of goblet cells that secrete 
mucus; and enteroendocrine cells that secrete different hormones (see next part). In humans, 
two other secretory lineages, crypt localized Paneth cells that secrete antimicrobial peptides, 
and tuft cells can be readily found in the developing embryo whereas these populations appear 
postnatally in the mouse (Figure 3). The origin and process of differentiation of all these post-
mitotic differentiated lineages are well studied and described in adult intestine (van der Flier 
and Clevers 2009). Actually, intestinal crypts are the host of self-renewing adult multi-potent 
stem cells giving rise to transient amplifying cells that proliferate and then differentiate into 
enterocytes or different secretory lineages, ensuring the constant renewing of the intestinal 
epithelium(Spence et al.). However, the existence of such stem cells during embryonic 
development is not well established in the mouse. In mouse, crypts are characterized by multi-
clonality during the first week after birth. This means that several stem cells contribute to the 
epithelium of a given villi. However, all crypts tend to monoclonality at 2 weeks after birth, 
that is multiple stem cells of a single crypt are originating from a single stem cells (Shiojiri 
and Mori 2003). This process may be likely due to the high proliferation rate and fissions of 
the crypts that allow the generation of new crypts (Spence et al.). This tendency of the crypts 
to drift toward monoclonality seems to occur also in aged intestine (Snippert et al.).   
1.1.3.2 DUODENAL ENDOCRINE CELLS 
The endocrine population of the intestine is a discrete one in terms of number as 
compared with other intestinal epithelial cells, as they represent only about 1% of total 
intestinal epithelial cells (Schonhoff et al. 2004). Throughout the intestine, enteroendocrine 
cells comprise at least 10 different types of endocrine cells on the basis of their hormonal 
secretion (Rindi et al. 2004). The latters are differentially distributed along the proximal-distal 
axis in the intestine (Aiken et al. 1994). Most enteroendocrine cells are localized in the villi 
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but some endocrine cells can be found within the upper crypt and crypt base (Aiken et al. 
1994, Sei et al.).  
In the duodenum, ghrelin, serotonin, somatostain, Glucagon-like immunoreactants 
(such as GLP-1), PYY, gastrin, cholecystokinin, secretin, gastric inhibitory polypeptide 
(GIP), motilin and neurotensin producing cells can be detected (Rindi et al. 2004), with 
serotonin+ and GIP+ cells being the prevalent cells in quantity. The gene encoding motilin is 
present in humans but neither in mouse nor rat genome. The duodenum is not the main site of 
expression of GLP-1 nor ghrelin, but is the main site of CCK expression even if the latter is 
not the main population of endocrine cells of the duodenum. Several reports have 
demonstrated, by colocalisation experiments and cell ablation studies, that some endocrine 
cells can be multi-hormonal and co-express different combinations of hormones (Aiken et al. 
1994, Egerod et al. , Habib et al.). Aiken and colleagues demonstrated that most crypt 
localized gastrin+ cells were also expressing GLP-1 but not secretin, whereas more than half 
of villus gastrin+ cells were expressing GLP-1 and about 30% of them also co-express secretin 
in the duodenal mouse mucosa. On the contrary, they found that most serotonin+ and GIP+ 
cells were negative for the other tested hormones. However, in contrast with this study, 
Egerod and colleagues recently demonstrated that GIP+ cells also express CCK and secretin in 
human duodenum by double immunofluorescent stainings, and also provided evidence 
suggesting the possible existence of GLP and CCK double positive cells in mouse duodenum 
(Egerod et al.). However, since they did not perform double immunostaining for both GIP and 
CCK in mouse duodenum, the existence of the endocrine cells expressing both CCK and GIP 
in mouse duodenum remains to be elucidated. In both mouse and humans, the few ghrelin 
positive cells in the duodenum do not express any of other gut hormones except motilin in 
human. 
The endocrine cells in the duodenum, as in other parts of the intestine, are all derived 
from adult stem cells localized at the base of the crypts, and this was definitely confirmed 
recently by lineage tracing experiments in the mouse (Barker et al. 2007). These stem-cells 
give rise to the transient-amplifying cells upper in the crypts. They actively proliferate and 
then engage in a differentiation process leading to the formation of the different lineages of 
the duodenum (and more broadly of the intestine). However we still do not know if the 
differentiation process occurs before the TA compartment or after as shown by recent studies 
(Li et al. 2011, Sei et al. 2011, Buczacki et al. 2013). The differentiation towards the 
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endocrine lineage is widely dependent on lateral inhibition mechanisms by Notch pathway. 
Indeed, it was shown that mice overexpressing the intracellular domain (NICD) of Notch 1 
receptor specifically in all the epithelial compartment of the intestine, displayed impaired 
differentiation of the secretory lineages analyzed (gobelet and enteroendocrine) (Fre et al. 
2005), via the activation of the nuclear transcription factor RBP-Jκ leading to the transcription 
of Hes1, a bHLH transcriptional repressor (Jarriault et al. 1998) that represses the endocrine 
lineage (and other secretory lineages) cell fate choice. Mice lacking Hes1 die during 
embryogenesis, but still develop an intestine with an increase in secretory lineages, 
specifically in enteroendocrine cells (Jensen et al. 2000). Several lines of evidence indicate 
that Hes1-mediated repression of secretory lineage is dependent on the inhibition of the 
expression of the bHLH activator Math1 (also called Atoh1) (Jensen et al. 2000, Kim and 
Shivdasani 2011). Math1 expression is required for the secretory lineages specification both 
during development and in adult, and its expression persists in gobelet and paneth cells (Yang 
et al. 2001, Shroyer et al. 2007). Once the secretory lineage is chosen over the absorptive 
lineage, the enteroendocrine cell fate still has to be engaged. One of Math1 positive target is 
the zinc-finger transcription factor Gfi1. Several observations led to the concept that in Math1 
progenitors, Gfi1 expression favors the differentiation of secretory lineage precursors towards 
non-endocrine secretory lineages (Paneth and goblet), though this has been recently debated 
(Bjerknes and Cheng 2010).  
Even if the precise molecular mechanisms allowing the allocation of endocrine versus 
Paneth/goblet cell lineage remain elusive, the intestinal endocrine lineage has been shown to 
be dependent on the bHLH transcription factor Ngn3. Newborns constitutively lacking Ngn3 
and mice lacking specifically Ngn3 in the intestine do not develop any endocrine cells in the 
intestine (Jenny et al. 2002, Mellitzer et al. 2010). Lineage tracing experiments confirmed that 
all intestinal endocrine cell subtypes were derived from Ngn3+ progenitors (Jenny et al. 2002). 
Conversely, an increase in endocrine cells number and a decrease in goblet cells occur in 
transgenic embryo expressing Ngn3 under the widely active Villin promoter, (Paneth cells 
were not studied because of their absence before birth in mouse) strongly suggesting that 
Ngn3 actively drives uncommitted secretory precursors toward endocrine lineages (Lopez-
Diaz et al. 2007). Math1 mRNA expression was not altered in Ngn3 KO animals, and goblet 
and Paneth cell populations are not altered in these mice, suggesting that Ngn3 acts 
downstream of Math1+ progenitors. The importance of Ngn3 in enteroendocrine lineage 
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specification has also been reported in human. A severe loss of the endocrine cell population 
in the intestine, leading to congenital malabsorptive diarrhea was reported in several patients 
carrying homozygous point mutation in the coding sequence of NGN3 or biallelic mutations 
of NGN3 (Wang et al. 2006, Pinney et al. 2011, Rubio-Cabezas et al. 2011).  
Once the enteroendocrine lineage is selected upon Ngn3 expression, several other 
transcription factors were shown to be important for the differentiation of different endocrine 
cell subtypes in the intestine. The bHLH transcription factor Neurod1 (also denominated 
BETA2) is necessary for  secretin+ and CCK+ cell lineages in the intestine, since NeuroD1-/- 
mutant mice develop neither secretin+ nor CCK+ cells in the intestine, whereas other 
enteroendocrine lineages are unaffected (Mutoh et al. 1997, Naya et al. 1997). Nkx2.2 was 
shown to be expressed in 80% Ngn3+ intestinal progenitors and several endocrine cell-types 
of the intestine (Wang et al. 2009), and involved in the differentiation of serotonin, CCK, 
GIP, and gastrin expressing cells as they are absent or severely reduced in the developing 
intestine of Nkx2.2-/- embryos (Desai et al. 2008, Wang et al. 2009). Ghrelin expressing 
lineage was dramatically increased in these mice, showing that Ghrelin is an independent 
lineage branching as compared to other endocrine lineages. However, due to postnatal 
lethality, the role of Nkx2.2 in the differentiation of intestinal endocrine cells in adult intestine 
remains to be elucidated. Foxa1 and Foxa2 are expressed in the crypts in the intestine and 
scattered cells of the villi. The concomitant loss of Foxa1 and Foxa2 in intestinal epithelium 
using conditional inactivation led to a loss of GLP+ cells and decrease in somatostatin+ and 
PYY+ cells differentiation (Ye and Kaestner 2009). Pax6 deficiency principally leads to GIP+ 
cells loss in the duodenum, while Pax4 deficient mice lose the expression of endocrine 
hormones such as serotonin, secretin, GIP, PYY and CCK in the duodenum and jejunum but 
not in distal parts of the intestine (Larsson et al. 1998). More recently it was demonstrated that 
Pax4 deficient mice lost the expression of Gastrin, Somatostatin mRNA expression in the 
small intestine whereas Ghrelin and Proglucagon mRNA levels are increased (Beucher et al. 
2012). Interestingly, Beucher and colleagues showed that Pax4 deficiency led to an increase 
in Arx expression, a transcription factors that is expressed in some Ngn3+ progenitors and 
some subsets of early differentiating endocrine cells in the crypts (Beucher et al. 2012). In the 
same study, the authors showed that mice with disrupted Arx had an increase in somatostatin 
and ghrelin expressing cells without any change in serotonin expressing cells and a sever loss 
of GLP-1, GIP and PYY expressing cells. Pdx1 loss led to decrease in GIP, neurotensin, and 
A 
B 
Figure 4. Schematic representations of macro-(A) and 
microscopic (B) anatomy of the pancreas.  
INTRODUCTION.  
PART I the Gastroenteropancreatic endocrine axis: The endocrine pancreas 
 
16 
 
secretin cells number in the duodenum whereas CCK population is not affected and gastrin 
cells of the duodenum are lost (Larsson et al. 1996).  
 
1.1.4  THE ENDOCRINE PANCREAS 
The pancreas is an organ consisting of different functional units, with the major part 
being the exocrine pancreas comprising acinar cells and ductal cells (Figure 4A and 4B). The 
former produce and secrete several digestive enzymes in the lumen of the ducts, while the 
latter secrete bicarbonates, participating in duodenal pH regulation. The ductal tree is 
connected to the duodenum, through the main pancreatic duct, in a structure where it joins the 
common bile duct called ampulla of Vater or hepatopancreatic ampulla. In the exocrine 
pancreas are dispersed the islets of Langerhans which constitute the endocrine part of the 
pancreas. The islets are constituted of several endocrine cell types that are defined on the 
basis of their hormonal secretions. To date, five adult pancreatic endocrine cell-types have 
been described: α-cells secreting glucagon, β-cells secreting insulin, δ-cells secreting 
somatostatin, PP-cells secreting the pancreatic polypeptide and the rare ε-cells secreting 
ghrelin (Figure 4B). The islets are intimately associated with blood vessels, but also neurons 
and stroma, in order to ensure their endocrine functions.  
 In mammals, the pancreas derives from two different buds that emerge dorsally and 
ventrally from gut endoderm. Dorsal pancreatic bud will form body, tail and most of the head 
of the pancreas, whereas the ventral bud will contribute in part to the mature pancreatic head 
[reviewed in (Pan and Wright 2011)]. The cytoarchitecture of islets largely differs between 
rodents and human (Figure 5A and 5B). Mouse islets are mainly composed of a dense and 
large beta cell core with segregation of non-beta cells (such as alpha cells) in the periphery of 
the islets. In human, non-beta cells are more dispersed in the islets, with beta cells forming 
contiguous small clusters, providing equal access for all endocrine cells to blood vessels 
(Brissova et al. 2005, Cabrera et al. 2006, Kim et al. 2009). The proportion of the pancreatic 
endocrine population is different between species. In mouse, beta cells represent more than 
75% of the total endocrine mass, alpha cells account for nearly 20% and delta cells 6%, 
whereas human pancreas is composed of 55% beta cells, 35-40% alpha cells and 11% delta 
cells in average (Brissova et al. 2005, Cabrera et al. 2006). In both rodents and human, this 
A 
B 
Figure 5. Schematic representation of mouse (A) and 
human (B) pancreatic islet cytoarchitecture. 
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endocrine distribution differs between the different parts of the pancreas according to their 
ventral or dorsal origin with a highest representation of PP cells in pancreatic region ventrally 
derived (Suckale and Solimena 2008). In human, this PP rich region was accurately monitored 
to lie in the uncinate process (Wang et al. 2013). It seems that some insulin+ cells that appear 
between E16.5 and E18.5 would derive from PP expressing cells generated between E14.5 
and E16.5(Johansson et al. 2007), consistent with lineage tracing works (Herrera et al. 1994, 
Herrera 2000). The specificity of the transgenic PPY-promoter driven Cre recombinase has 
nevertheless never been studied during the pancreas development and the contribution of PP 
expressing cells to the beta lineage is still not clear. Also, PP expression during pancreatic 
development remains controversial (Herrera et al. 1991) (Teitelman et al. 1993, Myrsen-
Axcrona et al. 1997) (Jorgensen et al. 2007). (Huang et al. 2009). Ghrelin is expressed in 
different cells during development. The true epsilon lineage that express only ghrelin, appears 
at E10.5, then increases and is rapidly lost after birth. But most ghrelin+ cells are glucagon+ 
from E10.5 to P1 in mouse (Heller et al. 2005), but less frequently seen in the rat (Wierup et 
al. 2004). Some ghrelin+ cells also co-express PP during development and after birth (Wierup 
et al. 2004). Recently, a lineage tracing study, using a mouse knock-in model in which the 
Cre recombinase gene replaces the Ghrelin gene, demonstrated that about 10% of both alpha 
and PP cells were expressing the genetic reporter at P0, and that, even in adult, 14% of alpha 
cells and 25% of PP cells were expressing the reporter but no more ghrelin (Arnes et al. 
2012). Thus it seems that a subpopulation of alpha and a subpopulation of PP cells are derived 
from cells that expressed ghrelin (but do not represent epsilon cells) and that these 
subpopulations which will not express ghrelin anymore are maintained in adult islets. 
Furthermore, the authors suggest that the decrease in epsilon cells that occurs after birth is not 
due to the death of these cells but due to a further differentiation into PP cells and extinction 
of ghrelin expression in these cells.  
Other hormones such as CCK and gastrin are transiently expressed during pancreas 
development. Gastrin mRNA can be detected as early as E10 in mouse pancreatic epithelium 
(Gittes et al. 1993) (Brand and Fuller 1988). Immunohistochemical studies showed that 
gastrin protein expression is first detected at E15 in rat pancreas in periphery of endocrine 
clusters (Shimizu et al. 1999). Depending on the study, gastrin expressing cells in islets from 
Wistar rat pancreases are found until P2 (Shimizu et al. 1999) or until two weeks after birth 
(Furukawa et al. 2001). However, the total number of gastrin expressing cells rapidly decrease 
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after birth. Interestingly, scattered gastrin expressing cells within exocrine pancreas can be 
detected until 1 month in rat pancreas (Furukawa et al. 2001). Neonatal gastrin production is 
also observed in human, and was confirmed to be fully processed bioactive gastrin in both rat 
and human as well as other mammalian species (Bardram et al. 1990). Few or no precise 
investigations were performed in mouse. Nevertheless it was shown with a transgenic mouse 
line harboring a BAC construct in which gastrin coding sequence was replaced by the eGFP 
gene that some GFP positive cells are found in neonatal pancreas (Takaishi et al. 2011). It was 
shown by restaining method that some of these gastrin cells may also express insulin 
(Furukawa et al. 2001). The functional significance of the transient appearance of gastrin+ 
cells in the pancreas is yet not known.  
 The highly related peptide hormone CCK was also shown to be expressed in 
pancreatic islets. Indeed, CCK protein expressing cells could be detected in rat pancreatic islet 
after weaning (P21) and also at P35 in the same region as beta cells (but was not tested after), 
but not during development (Shimizu et al. 1999). However this was not confirmed in the 
mouse, where it was shown indirectly with GFP reporter that CCK expressing cells are not 
found in adult transgenic CCK-eGFP C57BL/6 mouse islets (Lavine et al. 2010). Another 
study showed that CCK was expressed at E16 in exocrine pancreatic compartment, but after 
birth and in adult CCK is expressed in virtually all glucagon expressing cells in BALB/c mice 
(Liu et al. 2001). Thus more studies are needed to better characterize CCK expression in 
human pancreas and in rodent. 
1.1.4.1 MORPHOGENESIS 
During regionalization of gut endoderm, the prospective region for dorsal pancreas 
formation comes in close contact to notochord until E8.5 in the mouse from which it is then 
separated by the formation of dorsal aorta. At E9.5 (26th day of gestation in humans), the 
mesenchyme surrounding the prospective dorsal pancreas has condensed, a pancreatic 
rudiment evaginates in the mesenchyme. Twelve hours after dorsal budding (6 days in 
humans), at nearly E10, the prospective ventral pancreas and common bile duct that is closely 
associated with vitellin veins emerge from the ventral gut epithelium. During this process, the 
ventral pancreatic bud emerges caudally from the common bile duct bud. The two buds grow 
in the surrounding mesenchyme by elongation of a stratified epithelium delineating a primary 
central lumen (Villasenor et al. 2010).  
Figure 6. Pancreatic epithelium evolution during 
embryogenesis. 
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As early as E9.5, and until E12.5 occurs the first developmental transition (primary 
transition) during which proliferate multipotent pancreatic progenitors 
Pdx1+Ptf1a+cMycHighCpa1+(MPCs) (Zhou et al. 2007) and appear early-differentiated 
endocrine cells that are mostly expressing glucagon and that can be detected 
immunohistochemically at E9.5 in ventral pancreas (Jorgensen et al. 2007). This early 
differentiation process allows the appearance of glucagon+ cells, a part of them coexpressing 
both insulin and glucagon, and having a short life and not contributing to pancreatic endocrine 
mass at P7 or after weaning (Herrera 2000). These multihormonal cells have also been 
observed in human at 8 weeks of gestation, but it remains unknown what are their functions 
and if they contribute to adult endocrine population (Polak et al. 2000). Jorgensen and 
colleagues showed that cells positive for somatostatin, insulin and ghrelin that do not express 
glucagon are also readily detectable at E9.5 in ventral pancreas but to a far fewer extent than 
glucagon+ cells (Jorgensen et al. 2007). The contribution of early-differentiated endocrine 
cells to the pool of endocrine cells after birth is still not completely established and accepted 
(Gu et al. 2002). During the primary transition, the stratification of the epithelium results in 
the formation of microlumens following the polarization of some epithelial cells forming 
rosette-like structures. This then leads to the formation of tree like structures, a process called 
tubulogenesis, before the end of the primary transition. The branches that are thus formed are 
separated in two functional domains, the "tip" and the "trunk". MPCs progressively reside in 
the tips of the branches and are able to give rise to the 3 types of pancreatic cells, acinar, 
ductal and endocrine cells (Figure 6). The cells in the trunk are restricted to give rise to duct 
and endocrine cells only. Interestingly it has been proposed and elegantly demonstrated that 
the total number of MPCs emerging in the two pancreatic buds would determine the final size 
of the pancreas and that no compensation occurs during development if one part of MPCs is 
ablated (Stanger et al. 2007).  
After E12.5 occurs the secondary transition marked by the fusion of dorsal and ventral 
pancreatic buds (occurring at 6 weeks of gestation in humans) (Jorgensen et al. 2007) (Pan 
and Wright 2011). The pancreatic epithelium expands and massive differentiation of the three 
pancreatic cell types takes place. The tips MPC become restricted precursors with only acinar 
differentiation potential (Zhou et al. 2007), whereas trunk cells are still able to differentiate in 
both ductal and endocrine cells (Figure 6). Most endocrine cells constituting the pool of islets 
are believed to originate from this secondary transition that last until birth in mouse. The 
 
 
 
INTRODUCTION.  
PART I the Gastroenteropancreatic endocrine axis: The endocrine pancreas 
 
20 
 
expansion of the endocrine cell pool (Ngn3+) at this secondary transition. These premature 
endocrine cells are not proliferating at least until E16.5 for beta cells (Zhang et al. 2006). Just 
before birth, pseudo islets are forming by fission/aggregation mechanisms between alpha and 
beta cells.  Islet formation and shaping will continue after birth to form mature islets (Miller et 
al. 2009). At the end of embryogenesis, alpha, beta, delta and PP cells highly proliferate. This 
proliferation rate slightly decrease at birth but alpha and beta cells re-enter high proliferative 
state,   and finally progressively decrease as the endocrine cell mass increase until weaning 
(Kaung 1994, Zhang et al. 2006, Miller et al. 2009). In contrast delta and PP cells 
proliferation was shown to be decreasing as soon as birth and seems not to be biphasic as 
alpha and beta cells, at least in rat (Kaung 1994). In the mouse, postnatal period is also 
accompanied by functional maturation of islet cells in particular beta cells that will acquire 
the glucose induced insulin stimulation response. However, it was shown that beta cells can 
mature and be fully differentiated during embryonic development (Piper et al. 2004). Until the 
end of life, islet mass increase slowly due to a weak proliferating rate (Rankin and Kushner 
2009). Mechanisms controlling islet cells proliferation and death will be discussed in a later 
part.  
 
1.1.4.2 TRANSCRIPTION FACTORS DETERMINING PANCREATIC LINEAGES SPECIFICATION 
The development of pancreatic endocrine cells relies on several extrinsic and intrinsic 
factors. The importance of several transcription factors has been highlighted to date. 
Hlxb9 (Mnx1) is expressed (Harrison et al. 1999, Li et al. 1999) at E8.0 in the 
prospective dorsal pancreatic bud, later, at E9.5, in the ventral bud (Jorgensen et al. 2007), 
and is restricted to beta cells in adult pancreas. This transcription factor is necessary for dorsal 
pancreatic bud development (Harrison et al. 1999, Li et al. 1999). 
Pdx1 (Pancreatic duodenal homeobox 1) expression begins at E8.5 at pre-pancreatic 
regions in the foregut endoderm (Jonsson et al. 1995, Ahlgren et al. 1996, Jorgensen et al. 
2007) but is restricted to beta cells in mature mouse pancreas (Jonsson et al. 1995), and to 
beta cells and centro-acinar cells in human adult pancreas (Park et al. 2011). Low levels of 
Pdx1 can be detected in early glucagon+ cells from the first transition at E10.5 (Mastracci et 
al. 2013), and is expressed at low levels in the trunk domain during the secondary transition 
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(Rukstalis and Habener 2007, Yang et al. 2011). Several mouse models targeting Pdx1 were 
generated, and demonstrated that Pdx1 loss leads to pancreas agenesis but are still able to 
form dorsal bud rudiments containing some glucagon producing cells and early insulin 
expressing cells (Jonsson et al. 1995, Ahlgren et al. 1996, Offield et al. 1996). Lineage tracing 
experiments demonstrated that exocrine, ductal and pancreatic endocrine cells lineages are 
derived from Pdx1 expressing cells. However, it seems that Pdx1+ cells give rise to duct 
compartment only between E10.5 and E12.5 as demonstrated by conditional lineage tracing of 
Pdx1+ cells by administration of tamoxifen at different times (Gu et al. 2002).  
Onset of Ptf1a expression occurs after onset of Pdx1 expression. Ptf1a is coexpressed 
with Pdx1 in dorsal and ventral pancreatic epithelium at E9.5, but is not expressed in other 
region of the gut endoderm (Jorgensen et al. 2007). In mouse and human adult pancreas, Ptf1a 
expression is restricted to acinar cells (Hald et al. 2008). Genetic lineage tracing showed that 
all acinar cells are derived from Ptf1a expressing cells (however Ptf1a is normally expressed 
in acinar cells, biasing the result), the same as 95% of ductal cells and virtually all pancreatic 
endocrine cells, excepted for about 25% of alpha cells (Kawaguchi et al. 2002). Ptf1a is 
crucial for the pancreas development as Ptf1a knock-out mice only develop a small residual 
ventral pancreatic bud (Krapp et al. 1998, Kawaguchi et al. 2002). Intrinsically, Ptf1a is 
believed not to be essential for the pancreatic endocrine differentiation as alpha, beta, delta, 
and PP cells can develop in pancreatic rudiments of  Ptf1a null mice and in the spleen by 
migration through the mesenchyme (Krapp et al. 1998). It remains intriguing that lineage 
tracing experiments demonstrated that the early first wave glucagon producing cells were not 
derived from Ptf1a expressing cells (Kawaguchi et al. 2002). In this case one could speculate 
that endocrine cells that develop in Ptf1a null embryos may result from the differentiation of 
cells that normally do not derive from Ptf1a+ cells.  
Several other transcription factors have been involved in the development or 
maintenance of the ensemble of the three pancreatic cell types, such as Sox9, Nkx6.1, Nkx6.2 
and Hnf1β which are co-expressed with Pdx1 and Ptf1a in MPCs. The pancreatic epithelium 
becomes regionally restricted for the endocrine cell fate differentiation as it organizes in tips 
leading to acinar cells and bipotent ductal/endocrine trunks since E12.5 (Beucher et al. 2012).  
1.1.4.3 ENDOCRINE SPECIFICATION 
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The endocrine cell emergence from MPC and bipotent progenitors during first 
transition or from trunk bipotent progenitors during the second transition largely and 
indispensably requires Ngn3 expression. Ngn3 can be detected in early dorsal pancreatic 
endoderm since E8.5 (Jorgensen et al. 2007). In adult normal pancreas, Ngn3 is not expressed 
even if it has been suggested (Wang et al. 2009). Most Ngn3+ cells express high-level-Pdx1 
until E10.5, and they express no longer or only low-level-Pdx1 during the second transition 
(Schwitzgebel et al. 2000, Jorgensen et al. 2007, Nelson et al. 2007{Rukstalis, 2007 #108 ). 
Ngn3 seems to be expressed in several phases, with a peak at E10.5 during first transition, 
then decrease and another peak of expression appears during the secondary transition, 
decreasing after E17.5, being undetectable in adult islets (Apelqvist et al. 1999, Schwitzgebel 
et al. 2000, Villasenor et al. 2008). Ngn3 expression is essential for all pancreatic endocrine 
cell-types development as demonstrated by the absence of endocrine cells in pancreas of 
newborn Ngn3 null mice that die of hyperglycemia within 3 days after birth (Gradwohl et al. 
2000). However, it was recently reported that some residual glucagon+ cells are present at 
E10.5 and persist until E15.5 in Ngn3 null pancreases (Wang et al. 2008), and that rare 
ghrelin+ cells also subsist at P0 in these animals (Arnes et al. 2012). The existence of these 
cells not deriving from Ngn3+ cells in wild-type pancreases remains elusive. Conversely, 
Pdx1 promoter-mediated Ngn3 overexpression in transgenic mice leads to hypomorphic 
pancreas development and differentiation of early pancreatic progenitor pool into endocrine 
cells (Schwitzgebel et al. 2000). Taken together, most of the above mentioned observations 
argue for the fact that pancreatic Ngn3+ cells are universal pancreatic endocrine progenitors.  
The recent report from Herrera's group by clonal mosaic analysis suggests that each 
Ngn3 expressing progenitors are unipotent and give rise to only one type of endocrine cells. 
Interestingly, it was shown that the generation of the different endocrine cell types relies on 
competence windows during pancreatic development, and that each endocrine cell type is 
generated differentially depending on the stage of pancreatic development. It was 
demonstrated that conditional and temporally controlled expression of Ngn3 in Pdx1+ cells in 
a Ngn3 null background resulted in differential differentiation of each endocrine cell types 
depending on the stage of induction (Johansson et al. 2007). This study showed that these 
competence windows were intrinsic to the epithelium with Ngn3+ progenitors giving rise to 
alpha cells starting at E8.7, then acquiring the competence to differentiate into beta cells at 
E11.5 but more pronounced at E14.5, then PP cells at E12.5 with the highest peak of 
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competence at E14.5, followed by late somatostatin+ cell competence at E14.5 concomitant 
with a decrease in the competence of generating alpha cells. 
Ngn3+ progenitors are not proliferating (Desgraz and Herrera 2009), even if they were 
erroneously previously thought to be actively dividing because of the reported co-expression 
of Ki67 with cells expressing Ngn3 mRNA by in situ hybridization (Jensen et al. 2000). It was 
demonstrated that Ngn3 expression drives cell-cycle exit of pancreatic progenitors by 
activating the expression of the cell cycle repressor Cdkn1a (p21) whose expression is later 
inhibited to ensure normal endocrine cell expansion by proliferation (Miyatsuka et al. 2011). 
In the same study, the authors also demonstrated that ectopic Ngn3 expression in beta cells 
after birth dramatically repressed beta cell proliferation that physiologically occurs during 
postnatal islet development. However, the repression of the proliferation by itself is not 
important for endocrine cell differentiation, because Cdkn1a null pancreases exhibit normal 
endocrine differentiation (Miyatsuka et al. 2011). In addition, it is now pretty accepted that 
Ngn3 protein expression is transient and very rapid, lasting less than 24 hours in vivo 
(Desgraz and Herrera 2009, Beucher et al. 2012), strongly suggesting active Ngn3 
degradation between the endocrine progenitor state and the endocrine precursor state as 
recently observed in vitro (Roark et al. 2012). Consistent with the short lived Ngn3+ 
progenitors, it was shown in vitro that Ngn3 can repress its own expression at transcriptional 
level, which may participate in the transient Ngn3 expression during endocrine differentiation 
(Smith et al. 2004). Ngn3 mediates cell delamination from the pancreatic epithelium by 
positively regulating the expression of the Epithelial-to-mesenchymal transition regulator 
Snail2 whose expression persists in subsets of endocrine cells hereafter and becomes 
restricted to insulin+ and somatostatin+ cells in mature islets (Rukstalis and Habener 2007, 
Gouzi et al. 2011).  
1.1.4.4 PANCREATIC ENDOCRINE LINEAGES SPECIFICATION 
Ngn3 expression triggers the expression of several transcription factors necessary for 
the pancreatic endocrine differentiation, incuding NeuroD1 (Gradwohl et al. 2000, Huang et 
al. 2000), Islet1 (Gradwohl et al. 2000), Insm-1 (Mellitzer et al. 2006, Breslin et al. 2007), 
and Rfx6 (Smith et al. 2010, Soyer et al. 2010). Several other transcription factors are not the 
direct targets of Ngn3 but are important for endocrine differentiation. 
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NeuroD1 is a direct target of Ngn3. However, its expression seems to be restricted to a 
subpopulation of Ngn3+ progenitors in the developing pancreatic epithelium (Mastracci et al. 
2013), and mainly in beta cells in mature adult islet as demonstrated by reporter expression 
due to lack of specific antibody (Itkin-Ansari et al. 2005). NeuroD1 deficient mice have a 
reduced pancreatic endocrine cell population but only after E14.5 and mainly due to defect in 
insulin+ cell number (Naya et al. 1997). Importantly, the remaining endocrine cells undergo a 
massive apoptosis after birth of the mutants but it is still not known if apoptosis occurs in 
alpha, beta or other endocrine cell-types. 
Insm-1 (or IA1 for Insulinoma-associated 1), is also a Ngn3 target and expressed in 
pancreatic Ngn3+ progenitors and likely in all adult endocrine cells (Gierl et al. 2006, 
Mellitzer et al. 2006). However, the exact pattern of Insm-1 expression at protein level still 
needs to be determined. Mice lacking Insm1 show a slight decrease of glucagon+ cells during 
the first wave and a decrease in insulin+ cells after E12.5, but the total absolute quantification 
of the different types of endocrine cells was not accurately assessed (Gierl et al. 2006). These 
results were corroborated by ex-vivo analysis showing that knocking down Insm1 in 
embryonic pancreatic explants resulted in decrease in insulin+ and glucagon+ cells number 
{Mellitzer, 2006 #122  
Islet1, whose expression is Ngn3 dependent, is expressed in subsets of Pdx1+ cells in 
developing pancreatic epithelium {Du, 2009 #127} and its expression is maintained in adult 
pancreatic endocrine cells. Islet1 null embryos die around E9.5 and do not develop first wave 
glucagon producing cells in dorsal pancreatic epithelium, but develop a ventral pancreatic bud 
(Ahlgren et al. 1997). Islet1-disruption using Pdx1-Cre mediated recombination led to a 
strong loss in alpha, beta, delta and PP cells and double positive glucagon + ghrelin+ cells 
starting at E13.5, whereas single hormone+ ghrelin cells were not affected (Du et al. 2009). 
No difference in hormone+ cells number was detected before E13.5 due to the lack of Islet1 
disruption efficiency. Thus Islet1 is required for the differentiation of all major pancreatic 
endocrine lineages.  
Rfx6 is another transcription factor regulated by Ngn3, since its expression is lost in 
Ngn3-null pancreas. Rfx6 is expressed in gut endoderm overlapping Pdx1 expression, 
becomes excluded at E10 from multipotent and bipotent progenitors cells, but is expressed 
later on in Ngn3+ cells and hormone+ cells during development, and in all adult endocrine islet 
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lineages (Smith et al. 2010, Soyer et al. 2010). Rfx6 deficient mice, albeit normal Ngn3 
expression in the developing pancreas, do not develop any alpha, beta, delta or epsilon cells, 
whereas PP cells are still differentiating, largely similar to the phenotype reported by the 
authors for patients with Rfx6 mutation (Smith et al. 2010). Interestingly, a high proportion of 
cells stained positively for chromograninA or synaptophysin, but negative for PP, can be 
detected in mutant pancreases. The endocrine nature of these cells is still unknown even if the 
study showed that gastrin and VIP mRNA were rather decreased in Rfx6-/- pancreases. 
Nkx6.1 is a NK-type homeodomain transcription factor that is expressed in the whole 
pancreatic epithelium at E10.5 largely co-localizing with Pdx1+ and Ptf1a+ cells, but restricted 
to the trunk domain and excluded from Ptf1a tip domain during the secondary transition 
(Sander et al. 2000, Nelson et al. 2007, Schaffer et al. 2010). Nkx6.1 is also expressed in 
Ngn3+ cells and developing insulin+ cells, becoming restricted to pancreatic beta cells in adult 
islets (Sander et al. 2000). Loss of Nkx6.1 does not affect alpha, delta, or PP cell population 
but results in a highly decreased beta cell population from the secondary transition, whereas 
insulin+ cells before E12.5 are not affected (Sander et al. 2000). Nkx6.1 loss also affects 
maturation of beta cells but this will be discussed elsewhere. Maike Sander's group recently 
demonstrated that Ngn3+ cell population was reduced by 38% at E10.5 and profoundly 
decreased until E12.5, but was normal at E14.5 in pancreas of Nkx6.1 null embryos (Schaffer 
et al. 2010). More recently, it was reported that targeted disruption of Nkx6.1 in Ngn3+ 
progenitors lead to a differentiation of targeted cells toward non-beta endocrine cells 
(Schaffer et al. 2013). Thus it remains unknown by which mechanisms the early endocrine 
cells from first wave are present in normal number in Nkx6.1 deficient mice.  
A related member of Nkx6 family, Nkx6.2 is also broadly expressed in the early 
pancreatic epithelium at E9.5 in same cells as Nkx6.1. At E10.5, Nkx6.2 is expressed in 70% 
of Pdx1+ cells but quickly becomes restricted in subsets of pancreatic epithelial cells that 
mostly express Pdx1 and is not expressed in Ngn3+ progenitors (Henseleit et al. 2005). 
Nkx6.2 is expressed in some glucagon expressing cells (and some exocrine cells) at E12.5 and 
to a larger extent at E15.5. Insulin+ cells do not express Nkx6.2 during pancreatic 
development (other endocrine cells were not assessed). Nkx6.2 expression is absent from all 
endocrine cells in adult islets (Henseleit et al. 2005, Nelson et al. 2005). Interestingly, in 
Nkx6.1 mutants, Nkx6.2 whose expression is normal until E10.5 is ectopically expressed in 
pancreatic epithelial cells that normally express neither Nkx6.2, nor Ngn3, nor insulin. Nkx6.2 
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null mice develop a normal pancreas with a normal endocrine cell population (Henseleit et al. 
2005). However in double mutants Nkx6.1-/- Nkx6.2-/- embryos, insulin positive cells are 
further reduced as compared to single Nkx6.1-/- mutant and a dramatic loss of glucagon 
producing cells is also observed at E18.5, while early endocrine cells from first wave of 
differentiation are not affected, neither were somatostatin nor PP and epsilon lineages during 
whole development (Henseleit et al. 2005, Schaffer et al. 2010). Recent observations from 
Sander's group demonstrated that loss of both Nkx6.1 and Nkx6.2 results in increased acinar 
cell number at E14.5 due to Ptf1a misexpression in trunk domain accompanied with a 
decrease in Ngn3+ cells in the trunk domain at E12.5 (Schaffer et al. 2010), suggesting that 
Nkx6.1 and Ptf1a are mutually repressing each other in the late first transition. Altogether, it 
seems that these factors are necessary to allocate sufficient numbers of endocrine progenitors 
from MPCs expressing Ptf1a to allow normal alpha and beta cells number to differentiate in 
late first transition and the beginning of secondary transition.  
 Another member of the Nkx family, Nkx2.2, is important for pancreatic endocrine 
differentiation. Nkx2.2 is broadly expressed in nascent pancreatic epithelium at E9.5 and 
becomes restricted to trunks at E12.5 with high expression in Ngn3+ progenitors and low 
expression in the bipotent progenitors expressing Nkx6.1+ Ngn3-. In mature islets, Nkx2.2 is 
expressed in all beta cells, a high proportion of alpha and PP cells but not in delta cells 
(Jorgensen et al. 2007, Mastracci et al. 2013). Double Nkx2.2-/- Nkx6.1-/- mutant mice have the 
same phenotype as Nkx2.2 simple mutant mice, showing that Nkx2.2 is epistatically before 
Nkx6.2 in the process of pancreatic differentiation (Sander et al. 2000). Nkx2.2 null mice lack 
beta cells, have a 80% reduction in alpha cells number, and a slightly reduced PP cell 
population, with no change in delta cells, but a great increase in ghrelin+ cells at E18.5 as 
compared to control (Sussel et al. 1998, Prado et al. 2004). At E10.5, no insulin+ cells could 
be detected and decreased glucagon+ cell population was evident. The expression of Nkx6.1 is 
totally lost between E12.5 and E18.5, consistent with the absence of insulin+ cells that 
normally express Nkx6.1. In addition, only low-level-Pdx1 or Hlxb9 expressing cells were 
detected at E14.5 (Sussel et al. 1998, Wang et al. 2004). Thus Nkx2.2 appears to be required 
for beta cells differentiation and also for part of alpha cell pool, while repressing the epsilon 
lineage. Interestingly, studies on Nkx2.2 knock-out mice showed that Pax6 expressing cells 
are severely reduced and the expression of Pax4 at mRNA level is not changed (Wang et al. 
2004).  
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Pax6 is first detected at E9.0-E9.5 by immunohistochemistry in the pancreatic 
epithelium (Sander et al. 1997). At E10.5 and E14.5, Pax6 is expressed in all glucagon+ cells 
and some scattered glucagon- cells but the identity of the latter is unknown (but may represent 
insulin+ cells as Pax6 is also expressed in mature islet alpha and beta cells) (Sander et al. 
1997, St-Onge et al. 1997, Heller et al. 2004). Some Ngn3+ cells express Pax6 (Maestro et al. 
2003). Pax6 null mice or mice carrying an inactivating mutation in the Pax6 gene (SeyNeu) 
demonstrate a 4 and 3 fold decrease in glucagon+ and insulin+ cells respectively at E18.5 with 
each population severely reduced at E12.5 (Sander et al. 1997). It was nevertheless recently 
found that ghrelin+ cell population (not proliferating) is greatly enhanced in Pax6 mutant mice 
pancreases suggesting that the epsilon lineage replaces in part alpha and beta differentiation in 
Pax6 mutant mice. Thus, Pax6 may repress the differentiation of this lineage (Heller et al. 
2005). This study highlighted that Pax6 is not required for the endocrine commitment of 
pancreatic progenitors, but important for the differentiation of alpha and beta cells. 
The transcription factor Pax4 gene seems to be a direct target of Ngn3 in vitro (Smith 
et al. 2003). Pax4 mRNA or reporter inserted at Pax4 locus is expressed in the pancreatic 
epithelium at E9.5, becoming scattered in pancreatic epithelium at E11.5 and increases in the 
pancreas from E13.5 to E15.5, then decreases until birth. Pax4 mRNA is detected in some 
clusters of insulin+ cells at birth and is mainly undetectable in adult islets (Sosa-Pineda et al. 
1997, Wang et al. 2004). However, studies with a specific Pax4 antibody (Wang et al. 2008) 
that was used at several times in different recent studies (Collombat et al. 2009, Lu et al. 
2010, Yang et al. 2011, Schaffer et al. 2013), showed that Pax4 protein was expressed in beta 
cells from adult mice (Collombat et al. 2009, Yang et al. 2011), whereas no betagalactosidase 
expression is detected in islet from Pax4+/LacZ mice (Wang et al. 2004) which may reflect low 
mRNA expression but high protein expression. It was described that betagalactosidase 
activity in Pax4+/Lacz mice is detected in Ngn3+ pancreatic endocrine progenitors and most 
betagalactosidase positive cells express Islet1 at this stage (Wang et al. 2004). Later at E15.5, 
the betagalactosidase activity is detected in Ngn3+ cells and also in some insulin+ and 
glucagon+ cells, becoming restricted to insulin+ cells solely at E18.5. Ngn3 expression is not 
altered in the pancreases from Pax4 null mice (Wang et al. 2004). The mutant mice virtually 
do not develop any insulin+ cells (Sosa-Pineda et al. 1997), and delta cells are also absent. 
However there is a strong increase in glucagon and ghrelin expressing cells (Sosa-Pineda et 
al. 1997, Prado et al. 2004, Heller et al. 2005, Wang et al. 2008).  Importantly, a substantial 
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part of glucagon producing cells in Pax4 mutants are also expressing ghrelin and IAPP, which 
is normally expressed in beta cells and only rarely in alpha cells. It was shown that at birth, 
the number of ghrelin+glucagon- cells was unchanged, but the double ghrelin+glucagon+ cell 
population was increased by nearly 25% as compared to control, which led to conclude that 
Pax4 does not regulates the true epsilon cell lineage (Heller et al. 2005). Interestingly, most 
Pax4 deficient ghrelin+ cells express low levels of Pdx1 at E17.5 and at birth which is not the 
case in control mice (Sosa-Pineda et al. 1997, Wang et al. 2008). (Greenwood et al. 2007, 
Wang et al. 2008). It is important to note that truly assessing Pax4 protein expression during 
pancreas development is of crucial importance to better study its role.  
 Transcription factor Arx, localized on the X chromosome, was shown to have an 
opposite role to Pax4. (Collombat et al. 2003). At E9.5, Arx protein is expressed in a small 
subset of Pdx1+ pancreatic progenitors, and in a small fraction of Ngn3+ endocrine progenitors 
at E12.5 (Mastracci et al. 2011). Through pancreatic development, Arx protein is expressed in 
most glucagon+ cells and in both ghrelin+glu- and ghrelin+glu+ cell populations  (within a total 
of 20% ghrelin+ cells at E16.5)  (Kordowich et al. 2011, Mastracci et al. 2011). In adult islet, 
Arx is expressed only in alpha and PP cells (Collombat et al. 2007). It was shown, that Ngn3 
is necessary for Arx expression as Ngn3 null mice do not express Arx anymore (Collombat et 
al. 2003). In Arx hemizygous mice (knock-out), the total endocrine cell number is unchanged 
in 2-day-old pancreas relative to control mice, but no alpha cells are detected, the number of 
epsilon and PP cells remains unchanged and that of beta and delta cells is increased by 1.3 
and 2 folds respectively, indicating a switch of normally alpha cell committed progenitors 
toward beta and delta lineages (Collombat et al. 2003, Heller et al. 2005, Mastracci et al. 
2011). Similar results were obtained in mice with conditional disruption of Arx in Pdx1+ 
pancreatic progenitors(Hancock et al. 2010), with the exception that PP cell population also 
increased. In Arx mutants at early stage of endocrine development, glucagon producing cells 
are detected at E10.5 and also at E12.5, most of them being insulin+ at E12.5, but no 
glucagon+ cells could be detected at E15.5 (Collombat et al. 2003). Thus, Arx may not be 
necessary for first wave alpha cells. Importantly, human boy patients with ARX mutation 
display pancreatic islets containing no alpha or PP cells, whereas insulin and somatostatin 
populations do not increase and a high proportion of ghrelin+ cells is present as in controls 
where ghrelin cells are expressed in all glucagon+ cells (Itoh et al. 2010) (Raghay et al. 2013). 
More detailed analyses are required to better understand the precise role of ARX in human. 
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The compound Arx and Pax4 KO mice present normal total pancreatic endocrine cell mass 
devoid of both alpha and beta cells, but a strong increase in PP and delta cells that is not 
observed in one of the simple mutants (Collombat et al. 2005). In fact, the increase in PP cell 
population was detectable starting at P2 and was dependent on feeding. Most of these cells 
were also coexpressing somatostatin, with cell counting of monohormonal PP+ cells being 
unchanged as compared to control. Therefore, delta lineage replaced alpha and beta lineages 
in double Arx:Pax4 KO mice but this lineage is not stable after birth and feeding because it 
starts to express PP. Other genetic interactions were also described for Arx. The compound 
mutants Nkx2.2 : Arx show loss of both alpha and beta cells but an increase in somatostatin+ 
and ghrelin+ cells and restoration of PP cell number (Mastracci et al. 2011). However, in the 
double null mice, most somatostatin+ cells were coexpressing ghrelin and vice-versa 
(Kordowich et al. 2011, Mastracci et al. 2011) with only one fifth of cells only expressing 
ghrelin and one fifth of cells only expressing somatostatin. Cells expressing both ghrelin and 
somatostatin in compound mutants were attributed to originate from ghrelin cells that would 
ectopically express somatostatin due to loss of Arx (Kordowich et al. 2011). It was observed 
that mice overexpressing Arx in Pdx1 or Pax6 compartments, or specifically in beta cells 
during development shifted beta and delta cell lineage toward either alpha or PP cell lineages 
(Collombat et al. 2007). Interestingly, in these transgenic mice glucagon and PP never 
colocalized showing that it may exist two subtypes of beta cells with different sensitivity to 
convert into alpha or PP lineages upon Arx misexpression. 
 MafB is a member of MAF family of transcription factors. During pancreatic 
development, MafB is expressed in subsets of Ngn3+ cells as early as E13.5 (coexpression 
experiment was not assessed at earlier stage) and in early glucagon producing cells from first 
wave and persists in all glucagon+ cells through the development. MafB is also expressed in 
insulin+ cells at E12.5 until two weeks after birth and is lost from the latter at 3 weeks after 
birth (Artner et al. 2006). In adult mouse islets, MafB is only expressed in alpha cells and 
occasionally in some PP cells. MafB-/- mice that die at birth from apnea, develop an absolute 
number of endocrine cells comparable to control animals (Artner et al. 2007). The quantity of 
PP, delta and ghrelin+ cells is not altered, whereas a twofold decrease in glucagon+ cells and a 
three-fold decrease in insulin+ cells number are observed at E18.5. The hormone negative 
cells that differentiated in the mutant mice seemed to conserve partially their identity in the 
absence of MafB, as it was for example demonstrated that Brn4 was expressed in pseudo 
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glucagon- alpha cells (Brn4 is a alpha cell specific ranscription factor in adult islet). The 
intriguing point is that a half of glucagon+ and less than a half of insulin+ cells remain in Mafb 
null pancreases. The authors attributed the insulin+ population to be cells that had already 
expressed MafA, an important regulator of insulin expression in beta cells that is expressed 
only in late maturation steps of beta cells, whereas the pseudo insulin- beta cells were not 
expressing MafA (Artner et al. 2007, Artner et al. 2010). However, it is not yet clear how 
hormone- pseudo alpha or beta cells are formed. It would be interesting to conditionally 
invalidate MafB expression specifically in developing pancreas at different time points after 
birth, in order to accurately define the precise role of MafB. The functions of MafB pointed 
out the difficulty in some instance to clearly dissociate the role of a factor in the 
differentiation from a progenitor or in the maturation of a specific cell-type. Some crucial 
transcription factors for pancreas development that have no role in pancreatic endocrine 
lineage commitment, such as Foxa2 or Pdx1, are important for the specific functions of 
mature alpha and/or beta cells (Ahlgren et al. 1998, Lee et al. 2005, Gao et al. 2007).  
 
1.1.4.5 MAINTENANCE OF DIFFERENTIATED ENDOCRINE CELL IDENTITY 
 We have discussed about the essential transcription factors mediating endocrine cell 
lineages commitment toward the different pancreatic endocrine cell lineages. Most of the 
phenotypes that we have described were based on the analysis of conventional total knock-out 
mouse models or conditional disruption during pancreas development. However, the role of 
many of these transcription factors and other genes has been studied in differentiated 
endocrine cells (or at least hormone expressing immature endocrine cells), and this led often 
to uncover their role in the maintenance of cell identity. A differentiated cell is defined by its 
ability to assure its specific function in a given organ. Consequently, we could consider that 
each molecular modification altering the defined function of a cell is in fact modifying the 
identity of the cell. Therefore, the following part will treat genes whose alterations lead to a 
modification of the nature of the hormone secreted and/or expressed by a given pancreatic 
endocrine cell.  
 The role of Ptf1a in adult acinar cells has not been much investigated in vivo, 
principally due to the lack of conditional targeted allele for this gene. However, it was 
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recently shown in zebrafish that loss of Ptf1a activity from acinar cells can reprogram the 
cells to pancreatic hormone expressing cells (Hesselson et al. 2011). 
 Pdx1 controls the identity of adult beta cells. Several models of conditional Pdx1 
disruption in beta cells using Rat Insulin Promoter (RIP) driven Cre recombinase mice. These 
studies showed that Pdx1 loss in pancreatic beta cells at 3 weeks after birth results in the 
conversion of beta cells into glucagon expressing cells (Ahlgren et al. 1998) (Gannon et al. 
2008). However, the embryonic deletion of Pdx1 in insulin+ cells showed a decrease in insulin 
expression by immunostaining and an increase in alpha cells and delta cells number that did 
not expressed the reporter in lineage tracing experiment (ghrelin expression was not assessed), 
indicating that cell conversion is not involved (Gannon et al. 2008). Interestingly, this 
differential role of Pdx1 at different stages of endocrine cells development was also 
demonstrated recently in mouse with ectopic overexpression of Pdx1 in either Ngn3 
progenitors or glucagon expressing cells (Yang et al. 2011). Indeed, it was demonstrated in 
this study that Pdx1 irreversible overexpression in Ngn3 progenitors leads to reprogram alpha 
cells into beta cells but mainly occurring 7 to 12 days after birth, resulting in a nearly 
complete loss of glucagon expressing cells in adult. Differently, stable overexpression of 
Pdx1 specifically in glucagon producing cells did not induce alpha-to-beta conversion, or 
other pancreatic hormone expression, but induced loss of glucagon and MafB expression 
without loss of Arx in the pseudo alpha cells.  
 The maintenance of beta cell identity also requires the transcription factor NeuroD1. 
Disruption of NeuroD in immature beta cells (with the RIP-Cre transgene) or in adult islet 
beta cells (inducible Pdx1-CreERTm), induces a loss of Insulin 1 expression, and an increase 
by two folds in the number of beta cells expressing NPY and some beta cells also coexpress 
somatostatin (Gu et al. 2010). 
The role of Nkx6.1 in maintenance of beta cell identity was recently demonstrated 
(Schaffer et al. 2013). Indeed, Nkx6.1 loss in insulin expressing cells converts them into 
somatostatin expressing cells that express Pdx1 but no longer express insulin. On the contrary, 
Nkx6.1 disruption in Ngn3+ cells which lead to a decrease in beta cell lineage cell fate choice, 
display Pdx1- MafA- Pax4+ insulin+ cells with a great proportion of them coexpressing MafB, 
Arx, glucagon or somatostatin. It is still however not clear if these Nkx6.1 deficient insulin+ 
cells in the Ngn3 mediated Nkx6.1 disruption model have a maturation deficiency or if they 
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arise from conversion of glucagon+ and somatostatin+ cells into immature insulin+ cells in 
order to compensate the loss of beta cells. In contrast, Nkx6.1 overexpression in alpha cells do 
not convert them into beta cells (Schaffer et al. 2013). 
 The conversion of beta cells into alpha cells was also reported in mice carrying a 
homozygous Nkx2.2 mutation (Papizan et al. 2011). This effect was attributed to the ectopic 
expression of Arx in Nkx2.2 mutated beta cells. Indeed, they showed that Arx gene expression 
is normally repressed by the repressor complex formed by Nkx2.2, Nkx6.1, Grg3 and Dnmt3a 
in wild-type beta cells. Conversely, Dnmt3a disruption in beta cells also led to a 
transdifferentiation of beta cells into alpha cells(Papizan et al. 2011). 
Arx appears to be crucial in the regulation of islet cell identity. Indeed, in addition to 
the previous work, the repression of Arx expression in beta cells was also shown to be crucial 
for the maintenance of beta cell program by several groups, including mice with specific 
disruption in beta cells of the DNA methyl transferase Dnmt1, a DNA methylation 
maintenance enzyme. These beta cells convert progressively during aging into alpha cells, 
mainly due to Arx ectopic expression (Dhawan et al. 2011), because of progressive loss of 
repressive DNA methylation at Arx locus after normal division of beta cells. Consistent with 
this observation, transgenic ectopic overexpression of Arx specifically in beta cells, converts 
them into glucagon+ and PP+ cells with most converted glucagon+ cells being PP+. The 
increase in conversion into PP+ cells remains somewhat intriguing. Nevertheless, it seems that 
the role of Arx in the conversion of beta cells into alpha cells is conserved in human (Spijker 
et al. 2013). 
  Pax6, was shown to control the maintenance of alpha and beta cell differentiation in 
adult mouse pancreas with induced systemic disruption of Pax6 (Hart et al. 2013). Several 
markers of differentiation are clearly down-regulated in beta cells, a three-fold decrease in 
insulin+ and glucagon+ cells, and an increase of 30 fold in the number of epsilon cells (that did 
not express any other hormones) mainly localized in the periphery of islets, whereas PP 
expression was not assessed. It seems that no transdifferentiation of alpha and beta cells into 
ghrelin+ expressing cells occurred, raising the question of the origin of these ghrelin+ cells that 
probably arise from PP or alpha cells that have already lost glucagon expression. Moreover, it 
seems that not all alpha and beta cells are sensitive to loss of Pax6 four weeks after Pax6 
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disruption, which could reflect different alpha and beta cell subpopulations within islets or 
may only be due to a too early analyze.  
 The maintenance of alpha cell identity is also controlled by the Men1 tumor 
suppressor gene. Indeed, our group revealed that Men1 disruption in alpha cells triggers the 
transdifferentiation of a substantial proportion of alpha cells into insulin expressing cells (Lu 
et al. 2010). The transdifferentiation process occurs only two months after birth. Remarkably, 
a subpopulation of Men1-deficient alpha cells does not transdifferentiate and gives rise to 
alpha cell tumors.  
1.1.4.6 MECHANISMS CONTROLLING ISLET CELLS PROLIFERATION. 
As previously described, adult islet cell mass is formed by massive differentiation 
from a pool of Ngn3 progenitors during development and the proliferation of differentiated 
cells in a narrow time window just before birth until weaning. The endocrine cell mass is then 
maintained, tightly regulated and expands during adulthood by slow-rate of replication of islet 
cells (Rankin and Kushner 2009, Salpeter et al. 2010, Stolovich-Rain et al. 2012, Salpeter et 
al. 2013). Contrary to other organs such as intestine or liver, the maintenance of endocrine 
islet mass in adult is apparently not supported by significant neogenesis from potential adult 
stem cells or progenitors (Teta et al. 2007), while several pathological or physiological 
conditions can influence the proliferation of islets cells such as islet tumorigenesis, obesity 
and pregnancy. Most of the studies in this field are aimed at understanding beta cell mass 
expansion in order to improve therapy for diabetes. Consequently, the mechanisms controlling 
the proliferation of other islet cells are far from being understood with the exception of the 
recent interest on alpha cells. The known molecular mechanisms controlling beta cell 
proliferation are deeply described in the recent review from Kulkarni et al(Kulkarni et al. 
2012). Several genetic evidences demonstrate that islet cell proliferation is differentially 
regulated during the embryonic stage than in adult life. The works based on in vitro 
experiments with cell lines will not be addressed here, even if we totally agree with the 
importance of these works, especially for the ex vivo expansion of islet cells for 
transplantation-based therapies. 
The Men1 gene encoding the protein menin (please refer to Part 1.3) is a critical 
regulator of islet-cell proliferation. Men1 disruption in either alpha, or beta cells specifically 
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using RIP-Cre, Glu-Cre or Pdx1-Cre transgenes, or specifically in adult beta cells using 
inducible Pdx1-CreER induces the proliferation of the target islet cells (Bertolino et al. 2003, 
Crabtree et al. 2003, Shen et al. 2009, Lu et al. 2010, Shen et al. 2010, Yang et al. 2010). It 
has been also described that downregulation of menin is important for the compensatory beta 
cell growth that occurs during pregnancy (Karnik et al. 2007). The effect of Men1 in the 
regulation of proliferation seems to be in part due to its known role in the regulation of insulin 
growth factor pathway (Fontaniere et al. 2006), and cell cycle regulators (reviewed in (Wu 
and Hua 2011)). However it is still not clear whether Men1 regulates proliferation of islet 
cells during development and postnatal period, as this was not studied in these investigations. 
Interestingly, several cell cycle regulators were described to regulate islet cell mass. 
Among CyclinD group (CyclinD1, 2 and 3), it seems that the major regulator of islet cell 
proliferation is CyclinD2 in normal mice. CyclinD2 begins to be expressed in pancreatic 
endocrine cells in postnatal period and is decreasing after two weeks (Georgia and Bhushan 
2004). Analysis of the pancreases from CyclinD2 null animals showed that CyclinD2 is 
necessary for the proliferation of both alpha and beta cells, 4 days after birth, there was no 
proliferation, neither the increase of cell mass in CyclinD2-/- animals in a C57BL/6 
background (Georgia and Bhushan 2004). In a mixed genetic background, Kushner and 
colleagues however revealed that CyclinD2-/- mutants had normal postnatal beta cell 
proliferation at 2 weeks after birth that is due to compensation by CyclinD1, the beta cell 
proliferation being impaired only in adult mice at 3 months of age (Kushner et al. 2005).   
The cyclin dependent kinase 4 (Cdk4) positively regulates beta cell replication after 
birth. Cdk4 null mice have normal islet cell mass at P5, but subsequent proliferation of beta 
cells is impaired in these mice and the beta cell mass is dramatically decreased in adult mice, 
whereas other islet cell-types are not affected (Rane et al. 1999, Martin et al. 2003, Mettus 
and Rane 2003). Conversely, in mice with homozygous Cdk4 mutations disrupting its 
interaction with INK4 family (p16, p15, p18, p19) (therefore Cdk4 is not inhibited anymore 
by these INK4 proteins), the beta cell mass is increased in adult, whereas at P5 the islet cell 
mass is normal (Martin et al. 2003) even if it has been recently shown that beta cells in these 
mutants readily proliferate at P1 (Kim and Rane 2011). Altogether, it seems that Cdk4 may 
regulate beta cell proliferation, except during mid- and late gestation respectively. 
Calcineurin/NFAT signaling through Cnb1 was shown to positively regulate postnatal beta 
cell proliferation at weaning by activating the expression of CyclinD2, Cyclin A2 and FoxM1 
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(Heit et al. 2006) (Goodyer et al. 2012). Prenatal and early postnatal beta cell proliferation 
seems not to be affected by loss of Cnb1. 
p16Ink4 (Cdkn2a) that inhibits Cdk4, is not expressed in the islets of young mice, but 
its expression progressively increases in aging islet (Krishnamurthy et al. 2004, 
Krishnamurthy et al. 2006). It was shown that Bmi1, which is expressed until 1 month after 
birth and then decreases with aging, represses p16 expression (Dhawan et al. 2009). In Bmi1-/- 
mice, islets and exocrine pancreas display a strong expression of p16 at 2 weeks after birth, 
accompanied by a half reduction of beta cell proliferation at 4 weeks. Similar results were 
obtained when Ezh2 was specifically deleted in beta cells (Chen et al. 2009), suggesting the 
role played by Ezh2-Bmi1-p16 axis in controlling beta cell proliferation starting from late 
postnatal period. In addition, upstream factors such as Pdgf signaling were described as 
regulating beta cell mass expansion by regulating Ezh2 expression after birth, mediated by 
Erk and RB-E2F pathways. Pdgfr-α and Pdgfr-β receptors are expressed in neonatal islets but 
highly downregulated in adult islet cells together with their ligands in a similar way as Ezh2 
(Chen et al. 2011). Beta cell proliferation and mass are decreased by 3 and 2 folds 
respectively in 2- to 3-week-old mice with specific disruption of Pdgfr-α in beta cells. 
Interestingly, the expression of a constitutive active form of Pdgfr-α in islet beta cells results 
in 2 fold increase in beta cell proliferation and 4-fold increase in beta cell mass at 3 months. 
The authors also demonstrated that concomitant disruption of the 3 Retinoblastoma family 
members, Rb, p130 and p107 in beta cells in adult islets increased their proliferation 
eventually leading to beta cell tumors (Chen et al. 2011). Also, it was shown that p38MAPK 
regulates p16Ink4a and p19Arf but only in old pancreatic islets. In mice with a dominant 
negative allele of p38MAPK treated with STZ, islet proliferation was hampered only in old 
mice (22-month-old) but not in 4-month-old mice(Wong et al. 2009).  
p18Ink4c an inhibitor of Cdk4, negatively regulates islet cell mass (Pei et al. 2004). The 
role of p18 in the regulation of different islet cell populations is not clearly defined, but as p18 
regulation of islet cell mass is dependent on Cdk4, we may speculate that p18 only regulates 
beta cells proliferation. 
Loss of p27Kip1 (Cdkn1b, a cyclin E/Cdk2 inhibitor) in p27-/- mice results in 
proliferation of newly differentiated alpha and beta cells during embryogenesis which 
normally are quiescent until E16.5-E17.5  (Georgia and Bhushan 2006). However during islet 
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cell mass expansion in peri-natal period, p27 inactivation does not affect the proliferation of 
expanding alpha and beta cells which was attributed to the fact that CyclinD2 expression 
during this period may have a major role which predominates on p27. However, it seems that 
after weaning, in adult beta cells at least, p27 anew represses proliferation. 
FoxM1 was shown to regulate beta cell proliferation only after weaning and during 
pregnancy, by preventing nuclear accumulation of p27 (Zhang et al. 2006). 
 Perk kinase is important for beta cell proliferation during late embryogenesis and 
postnatal periods, since Perk null mice and mice with Pdx1 mediated ablation of Perk  fail to 
expand beta cells even at weaning and display profound maturation defects (Zhang et al. 
2006). However, as beta cell maturation is severely impaired in Perk null mice, it is difficult 
to know if Perk has a direct role on proliferation or if the proliferation is affected because of 
maturation defects. Furthermore, beta cell specific disruption of Perk, which was mainly 
efficient after birth at P4, does not affect their proliferation or their maturation (Zhang et al. 
2006 227). Taken together, it seems that Perk may regulate before birth the expression of a 
critical factor that is necessary for beta cell proliferation.  
It has been shown that critical differentiation and maturation factors such as Islet1, 
Pdx1 and MafA are related to islet cell proliferation. Pdx1-mediated disruption of Islet1, 
results in a decrease in islet-cells proliferation and an increase in apoptosis in islets after birth 
(Du et al. 2009). Pdx1 disruption in beta cells decreases beta cell proliferation at late 
gestation, whereas it seems that proliferation is not impaired after weaning (Gannon et al. 
2008). Ectopic expression of MafA (a beta cell specific transcription factor) in Pdx1+ 
pancreatic epithelium impairs the proliferation of pancreatic progenitors by upregulating p27 
and p57 expression (Nishimura et al. 2009). However, MafA null mice do not display 
significant changes in total islet mass at birth or at 12 weeks but present severe defects in beta 
cell maturation (Zhang et al. 2005). Thus the role of MafA in beta cell proliferation needs to 
be more precisely investigated. MafB that is important for the differentiation of alpha and beta 
cells and restricted to adult alpha cells in the mouse was shown to play a role in beta cell 
proliferation. The data from our lab indeed demonstrated that MafB expression was 
reactivated in mouse Men1 insulinomas and during adaptive beta cell proliferation triggered 
by pregnancy and diet induced obesity (Lu et al. 2012). This MafB reexpression may play an 
important role in beta cell proliferation in these cases. 
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 Several growth factors and hormones were shown to regulate islet cell mass and 
specifically beta cell proliferation (Nielsen et al. 2001, Tarabra et al. 2012). The importance 
of AKT/mTOR signaling pathways in regulating beta cell proliferation was highlighted by 
several mouse models as reviewed in (Blandino-Rosano et al. 2012). It was recently shown 
that insulin increases alpha cell proliferation in a mTOR dependent manner which does not 
involve Foxo1 contrary to beta cells (Liu et al. 2011). This effect was corroborated in mice 
with specific disruption of insulin receptor in alpha cells that have a slight decreased alpha 
cell mass with aging and hyperglucagonemia but also marked beta cell hyperplasia with 
evidence of some low-level alpha cell to beta cell transdifferentiation (Kawamori et al. 2009, 
Kawamori et al. 2011).  
Glucose is indirectly involved in beta cell proliferation through glycolysis and body metabolic 
demand on insulin. The whole is integrated as beta cell “workload” which represents the “net 
insulin secretion per beta cell” (Porat et al. 2011). It was shown that glycolysis through 
membrane depolarization increases beta cell proliferation. 
Recently, it was demonstrated that betatrophin, a protein secreted by the liver, is a strong 
inducer of beta cell proliferation which is highly specific to the latters. Its expression is 
increased during pathophysiological challenges such as pregnancy or obesity but not during 
regeneration after beta ablation (Yi et al. 2013). 
Glucagon signaling appears also as a critical regulator of alpha cell proliferation. Mice 
lacking functional Prohormone convertase 2 (PC2, Pcsk2) leading to deficiency in 
Proglucagon processing, and thus, mature glucagon but not GLP1, display an increased 
alpha-cells proliferation in late embryogenesis and at birth resulting in alpha cell hyperplasia. 
But the proliferation rapidly decreases and is similar to control in adult mice (Furuta et al. 
1997) (Vincent et al. 2003). Nevertheless alpha-cell hyperplasia persists in adult mice lacking 
functional PC2, and an increased delta cell number is also observed along with increased islet 
neogenesis. Similarly, mice deficient for the Proglucagon gene also develop alpha cell 
hyperplasia and have increased islet expression of Somatostatin, PPY and Ghrelin mRNA 
(Hayashi et al. 2009). Interestingly, mice lacking the glucagon receptor (Gcgr) show overt 
alpha cell hyperplasia, with an increase in glucagon, GLP1, and somatostatin levels in 
pancreatic extracts(Gelling et al. 2003), and develop glucagonomas (Yu et al. 2011) (Kedees 
et al. 2009).  Elegantly, it was reported that the specific disruption of Gcgr in the liver induces 
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a phenotype similar to Gcgr null mice, suggesting that increased alpha cell proliferation with 
disrupted glucagon signaling may be due to an unknown factor released by hepatocytes 
(Longuet et al. 2013). It would be interesting to further dissect the role of glucagon, insulin 
and glucose in pancreatic endocrine neogenesis and alpha cell proliferation in vivo in the 
context of alpha-cell deficiency. 
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1.2 PART II GASTROENTEROPANCREATIC ENDOCRINE TUMORS 
1.2.1  GENERALITIES 
 Endocrine tumors are also called neuroendocrine tumors because endocrine cells share 
common markers and similar storage-release organelles with neural cells. Endocrine tumors 
gather all tumors arising from endocrine glands, such as the adrenal and pituitary glands, and 
organs with diffuse endocrine system such as the gastrointestinal tract, the pancreas (islets), 
the lung, the larynx, the thymus and the genital tract. The endocrine tumors are characterized 
by the expression of NeuronSpecificEnolase or the secretory vesicle components such as 
Synaptophysin or ChromograninA. These tumors are rare but their incidence is increasing 
mainly due to better sensitive diagnostic tools. Their prevalence is also increasing, because 
most of endocrine tumors are benign which is reflected by a high survival rate at 5 years. The 
most frequent neuroendocrine tumors are gastroenterpancreatic neuroendocrine tumors (GEP-
NETs), as they represent about 60 percent of all endocrine tumors (Frilling et al. 2012). 
Among GEP-NET, more than 73% have an intestinal origin (including colon and rectum), 9% 
arise from the stomach and 12% have a pancreatic origin or location (Frilling et al. 2012). 
1.2.2  TUMOR CLASSIFICATION (OMS, ENET) 
GEP-NETs are classified in three grades based on WHO classification. The low grade, 
grade1, neuroendocrine neoplasms well-differentiated; the intermediate grade, neuroendocrine 
neoplasms, grade 2; the high grade, neuroendocrine carcinoma grade 3 subdivised into small 
cell carcinoma and large cell neuroendocrine carcinoma. The ENET established its own 
classification based on the WHO classification depending on the KI67 index, tumor size and 
angio invasion. GEP-NETs can arise sporadically or hereditary. Most of inherited GEP-NETs 
arise in the context of Multiple Endocrine Neoplasia in patients with germline mutation of the 
MEN1 gene with predominance for pancreatic and duodenal endocrine tumors, the remaining 
cases develop in patients with von Hippel-Lindau syndrome bearing a germline mutation on 
VHL gene,  more rarely, in patient with germline mutations in NF1 or TSC1-TSC2 (Capurso 
et al. 2012). Most common oncogenes (KRAS, etc) do not seem to have an important role in 
GEP-NET tumorigenesis. 
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1.2.3  GASTROENTEROPANCREATIC FUNCTIONAL NETS 
 GEP-NETs functioning tumors are endocrine tumors associated with a clinical 
syndrome due to the excessive hormonal secretion by the tumor.   
1.2.3.1 FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMORS 
Several subtypes of functioning pancreatic endocrine tumors (functional p-NETs) exist 
(Table 1). However, certain types of duodenal tumors, such as duodenal-gastrinomas, are 
often classified as pancreatic endocrine tumors (Halfdanarson et al. 2008, Jensen et al. 2012). 
The two most common functional p-NETs are insulinomas and gastrinomas. 
 Insulinomas are the most common functional p-NETs with an estimated incidence of 
1–3/million population/year and are characterized by the abnormal expression and secretion 
of insulin resulting in hypoglycaemia. 90% of insulinomas are benign and appear between 30 
to 60 years old of age. In patients with insulinoma, 4% are MEN1. In MEN1 patients, 
insulinomas represent in average 18% of all pancreatic endocrine tumors (Jensen et al. 2008). 
Somatic MEN1 mutations are found in about 10% of sporadic insulinomas (8/81) (Bergman et 
al. 2000, Moore et al. 2001, Corbo et al. 2010). Loss of 11q13 locus (bearing MEN1 gene) 
occurs in 15-20% of insulinomas (Capurso et al. 2012). 
 Gastrinomas are the second most frequent functional p-NETs, however this is due to 
the inclusion of duodenal gastrinomas as "pancreatic" endocrine tumors, which seem to be 
more frequent than their pancreatic counterpart. The incidence of gastrinomas is 0.5–2/million 
population/year. Gastrinomas are characterized by oversecretion of gastrin leading to the 
Zollinger-Ellison syndrome (ZES) characterized by peptic ulcers, gastroesophageal reflux and 
diarreha. Gastrinomas appear between 20 and 70 years old, and are mainly found within the 
gastrinoma triangle comprising the proximal part of the duodenum and the pancreatic head. 
Pancreatic gastrinomas are often malignant at diagnosis, associated with local invasion and/or 
metastasis in proximal lymph nodes and in the liver. MEN1 syndrome is diagnosed in 20 to 
25% of all patients with gastrinomas (Jensen et al. 2012). In MEN1 patients, real pancreatic 
gastrinomas are rare (0 to 15% of MEN1 gastrinomas), most of them occurring in the 
duodenum (Jensen et al. 2008). Gastrinomas (duodenum and pancreatic) account for 54% of 
pancreatic tumors in MEN1 patients (Jensen et al. 2008). The cell origin of pancreatic 
gastrinomas is intriguingly unknown as gastrin is not expressed in adult pancreas. Somatic 
 
 
 
INTRODUCTION.  
PART II Gastroenteropancreatic Endocrine tumors: Gastroenteropancreatic functional NETs 
 
41 
 
MEN1 mutations are found in about 50% of sporadic gastrinomas (16/32)(Moore et al. 2001, 
Jensen et al. 2008, Corbo et al. 2010).  
 VIPomas are rare functional p-NET with an incidence of 0.05 to 0.2 cases/million 
population/year. VIPomas secrete the vasoactive intestinal polypeptide leading to clinical 
symptoms as diarrhea, hypokalemia and dehydratation. These tumors are malignant in 40-
70% of case and appear between 20 and 80 years of age. MEN1 syndrome is associated in 6% 
of VIPomas. These tumors represent about 3% of PET in MEN1 patients. The cell origin of 
these pancreatic tumors is unknown as VIP is not expressed in the pancreas. Sporadic 
VIPomas harbor somatic MEN1 mutation in 36% of cases (4/11) (Moore et al. 2001, Corbo et 
al. 2010). 
 Glucagonomas are also rare pancreatic tumors that represent less than 10% of all p-
NETs with an incidence of 0.01-0.1 /million population/year. The clinical symptoms often 
comprise rashes and glucose intolerance due to the secretion of glucagon by the tumor. 
Glucagonomas are malignant in 40-80% of cases and appear between 40 and 60 years of age. 
MEN1 syndrome is associated in 1 to 20% of glucagonomas (Jensen et al. 2012). About 3% 
of pNETs in MEN1 patients are glucagonomas (Jensen et al. 2008). Few sporadic 
glucagonomas were studied for somatic MEN1 mutations, but the mutations were described in 
60% (3/5) of glucagonomas analyzed (Bergman et al. 2000, Moore et al. 2001, Corbo et al. 
2010). 
 Somatostatinomas are even rarer than VIPomas and glucagonomas, and occur both in 
the duodenum and the pancreas. Somatostatinomas which secrete somatostatin are 
characterized by occurrence of diarrhea cholelithiases and diabetes, appearing between 30 and 
80 years old. More than 70% of somatostatinomas are malignant. MEN1 syndrome is 
associated in 45% of somatostatinomas (Jensen et al. 2012). Somatostatinomas are extremely 
rare tumors in MEN1 patients and account for 0 to 1% of pNETs in these patients (Jensen et 
al. 2008). 
 Several other types of functioning pNETs are also rarely reported, secreting either 
growth hormone, ACTH, serotonin, CCK. Most of these tumors are highly malignant (Jensen 
et al. 2012). 
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1.2.3.2 GASTRIC AND INTESTINAL FUNCTIONAL NETS 
 Most gastric endocrine neoplasms are non-functional and will be treated hereafter.  
 Duodenal functioning endocrine tumors (functional d-NET) comprise mostly duodenal 
gastrinomas (48% of all d-NET). Most lesions are generally solitary, with the exception of 
duodenal gastrinomas in MEN1 patients which are often multiple and small. d-NETs in 
general are found within the submucosa or mucosa (Delle Fave et al. 2012). Sporadic and 
MEN1 gastrinomas are often highly metastatic (50 to 90%) to lymph nodes, the later often 
being bigger than the primary tumor. Liver metastases occur in 7% of MEN patients with 
gastrinomas (Jensen et al. 2008, Kloppel 2011). 
Small bowel (jejunal and illeal) endocrine tumors have an average incidence of 
0.4/100,000/year in the world. However, autopsy studies reveal that these tumors are 
extremely frequent. Most of these tumors are well differentiated serotonin secreting tumors, 
associated with the carcinoid syndrome due to hypersecretion of serotonin. They are generally 
localized in the distal part of the ileum. Metastasis is frequently found at diagnosis. These 
tumors seem not to be related to MEN1 syndrome (Pape et al. 2012). However they are 
multiple in 26 to 30% of cases and some hereditary forms have been reported but the genetic 
basis of these hereditary forms is unknown (Kloppel 2011). Colorectal endocrine tumors 
account for 27% of gastrointestinal endocrine tumors but a high proportion are non-functional 
(Caplin et al. 2012). 
1.2.4  GASTROENTEROPANCREATIC NON-FUNCTIONAL NETS 
 The majority of gastroenteropancreatic neuroendocrine tumors are considered non-
functional, therefore, without being associated with the manifestation of clinical symptoms 
that could be attributed to the secretion of hormones. These tumors are often hormone-
expressing but they either do not secrete it or do not secrete sufficient amount of hormone to 
cause clinical symptoms. Thus, if they express glucagon for example, they are called 
"glucagon-producing tumor" rather than glucagonoma. These tumors are often well-
differentiated in terms of histopathological aspects. Poorly differentiated neuroendocrine 
carcinomas exist and virtually never express any hormone. They are thus often diagnosed on 
the basis of positivity for synaptophysin which is generally the only marker that can classes 
these carcinomas as neuroendocrine (Nilsson et al. 2006). A gap exists between the clinical 
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definition of endocrine tumors and the characterization of cell-types in research. Indeed, as 
explained in the above, the identity of a normal endocrine cell is defined by the different 
transcription factors and hormone(s) that it secretes. Thus, a beta cell for example that loose 
the expression of molecular differentiation marker such as MafA or Pdx1 for example could 
be considered as altered in its differentiation status. Few studies exist concerning the 
molecular characterization of endocrine tumors, in order to distinguish what may be the 
molecular basis of a tumor that make it an insulinoma or a non-functional insulin producing 
tumor. The rarity of endocrine tumors may explain, at least partially, this lack of 
characterization as compared to other more frequent tumors or cancers. 
 
1.2.4.1 NON-FUNCTIONAL PANCREATIC ENDOCRINE TUMORS 
 All endocrine tumors that are not associated with clinical symptoms due to 
hypersecretion of hormone and PPomas (that generally are not associated with specific 
clinical symptoms) are classified as non-functional p-NETs (NF p-NETs) (Table 1). 
 The incidence of NF p-NETs is 1-3/100000/year and 60-90% of the cases are 
malignant. Microscopic NF pNETs are found in most MEN1 patients with p-NETs (80-100% 
of case) and large NF p-NETs represent about 13% of p-NETs in MEN1 patients. Most p-
NET (superior to 98%) in VHL patient are non-functional. The MEN1 genes was found to be 
mutated in 24% of NF p-NETs (32/132) (Moore et al. 2001, Corbo et al. 2010). 
 A high proportion of NF p-NETs is actually secreting hormones or peptides. They, 
secrete the pancreatic polypeptide (60-85% of cases), calcitonin (42% of cases) and 
sometimes ghrelin (5-65%) (Ito et al. 2012). A number of NF p-NETs expresses glucagon, or 
insulin or other hormones, but either are not secreting sufficient amounts or are not secreting 
at all. The precise proportion of the different hormones that can be expressed in NF p-NETs is 
not established as few studies reported the precise immunohistological profile of such tumors. 
Anlauf and colleagues reported that in two tumor banks comprising a total of 300 NF p-NETs, 
3% were expressing gastrin (9/300) (Anlauf et al. 2006). It was found in a study of 114 
patients with NF p-NETs that 23% of the tumors displayed multihormonality, which is a little 
bit lower than 37% found in 86 patients with functional pNETs (Kapran et al. 2006). In a 
study of 9 MEN1 patients, it was demonstrated that 40% of tumors were multihormonals 
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(Kloppel et al. 1986). Among these patients, a high proportion of microlesions expressed 
glucagon or PP or insulin. Similar results were obtained in more recent studies showing that 
in MEN1 patients without insulinomas or glucagonomas associated symptoms, a very high 
proportion of micro and macro lesions expressing glucagon or insulin can be detected (Anlauf 
et al. 2006, Perren et al. 2007). In a French study, among 23 tumors found in 6 asymptomatics 
MEN1 patients, 3 stained for insulin, 12 for glucagon and 8 for PP, but none of these stained 
for gastrin (Le Bodic et al. 1996). However, it was shown that in 10 MEN1 patients, a 
substantial proportion of pancreatic endocrine tumors displayed focal gastrin stainings in 
tumors mostly expressing insulin or PP (5/24) (Thompson et al. 1984). 
 
1.2.4.2 NON-FUNCTIONAL GASTRIC ENDOCRINE TUMORS 
As gastric endocrine tumors (gastric neuroendocrine tumors, gastric NETs) are 
predominantly non-functional, the gastric NET denomination will be kept in this part. Gastric 
NETs can be well or poorly differentiated (called poorly differentiated neuroendocrine 
carcinomas or NECs). Gastric NET represent 5 to 14.6% of GEP-NETs (Fraenkel et al. 2012) 
with an incidence of 0.2/100,000/year (Delle Fave et al. 2012). Gastric well differentiated 
NETs are classes into 3 types.  
 The Type 1 comprises 70-80% of gastric NETs which arise mainly in women from 50 
to 60 years. These NETs occurs in the context of autoimmune or not chronic atrophic gastritis 
(CAG) of the oxyntic mucosa which is more frequent in women. The decreased gastric pH 
during CAG leads to hypergastrinaemia. Gastrin will bind to CCK-2 receptors on 
Enterochromaffin like (ECL) histamine producing cells of the stomach resulting in 
hyperplasia of these cells. Most type 1 gastric NETs are benign and present as multiple 
polypoid tumors in the gastric corpus or fundus (0.3-1cm). Metastases of these type 1 gastric 
NETs are rare (Kloppel 2011, O'Toole et al. 2012). LOH of 11q13 are found in 17 to 73% of 
type 1 gastric NET. 
 The type 2 gastric NETs represent 5 to 6% of gastric NETs. These tumors are ECL 
tumors similar to type 1 gastric NETs but they arise in MEN1 patients with Zollinger-Ellison 
syndrome. Interestingly, patients with sporadic gastrinomas usually do not develop type 2 
gastric NETs reflecting that genetic background may influence type 2 gastric NET 
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development. Type 2 gastric NETs occur in corpus and fundus but also in antrum part of the 
stomach. These tumors are metastatic in 10-30% of cases (Kloppel 2011, O'Toole et al. 2012).  
 The type 3 gastric NETs represent 14 to 25% of gastric NETs, and are sporadic and 
solitary. They do not occur in the clinical course of ZES or gastritis. They are composed of 
cells that secrete 5-HT and not 5-OHT (serotonin) and mostly localized in the gastric antrum. 
They are the most malignant gastric NETs and they metastasize in 50 to 100% of cases. 
Poorly differentiated NECs are classified in this type 3 gastric NETs or sometimes 
denominated as type 4. LOH of 11q13 is detected in 25 to 50% of type 3 gastric NETs 
(O'Toole et al. 2012). 
 
1.2.4.3 NON-FUNCTIONAL DUODENAL ENDOCRINE TUMORS 
Non-functional duodenal endocrine tumors (non-functional d-NETs) are most of time 
well differentiated and not observed in inherited tumor syndromes such as MEN1, or VHL. 
Most of them express gastrin. The second most commonly expressed hormone in non-
functional d-NETs is somatostatin, then serotonin, pancreatic polypeptide and finally 
calcitonin (Kloppel 2011). 
 Gastrin expressing (or also called "producing") NF d-NETs are mainly localized in the 
proximal duodenum mucosa or submucosa as their functioning counterparts. Lymph nodes or 
liver metastases are rare for these tumors. Interestingly, Anlauf and colleagues showed that in 
a collection of sporadic d-NETs, the number of non-functional gastrin expressing tumors was 
equivalent to that of functional gastrinomas (Anlauf et al. 2006). 
 Somatostatin expressing NF d-NETs are sometimes miscalled somatostatinomas, but 
they do not induce diabetes or other clinical symptoms that produce real functional 
somatostatinomas. They represent about 44% of all duodenal NETs. These non-functional 
somatostatin expressing tumors arise mainly in the ampulla of Vater and peri-ampullary 
region and may invade the muscularis propria. These tumors develop in 10% of patients with 
hereditary syndrome NF1 (neurofibromatosis 1). 
 Other NF d-NETs are reported such as non-functional serotonin-containing tumours 
which represent 28% of d-NETs and non-functional calcitonin-containing NETs representing 
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9% of d-NETs. Rare case of NF d-NETs can express, insulin, PP, glucagon or ACTH (Delle 
Fave et al. 2012).  
 Gangliocytic parangliomas, commonly found in periampullary region, are tumors 
composed of endocrine cells that express either PP or somatostatin, ganglion cells and 
Scwhann-like cells. Poorly differentiated NECs are usually found in or near ampullary of 
Vater. They are aggressive and often present with lymph nodes or liver metastases. 
 
1.2.4.4 NON-FUNCTIONAL SMALL INTESTINE AND COLORECTAL ENDOCRINE TUMORS 
In colon, most NETs are actually neuroendocrine carcinomas (NECs) whereas well 
differentiated NETs are mainly found in the rectum. Rectal net often express Glucagon-like 
peptides or PP but are classified as non-functional because of the absence of clinical 
syndrome (Kloppel 2011). 
1.2.4.5 MEN1 AND SPORADIC P-NETS 
It is well established that alteration of the MEN1 gene is an important mechanism in 
pancreatic and duodenal endocrine tumors. Several studies have demonstrated MEN1 
mutations and often LOH of the remaining MEN1 wild-type allele in sporadic pancreatic 
endocrine tumors and duodenal gastrinomas. However, other mechanisms than mutations, 
such as promoter hypermethylation leading to decreased or absent menin expression may also 
occur in some sporadic p-NETs and duodenal gastrinomas (Arnold et al. 2007). Thus the 
importance of menin inactivation in pancreatic endocrine tumors may be underestimated. 
Animal models of Men1-deficient pancreatic tumors demonstrated a relative late onset of 
tumor after Men1 disruption in pancreatic endocrine cells. This suggests that other molecular 
events (genetics, epigenetics or biochemics) may also be required to trigger tumorigenesis. In 
addition, total alteration of MEN1, combining frequency of allelic loss of 11q13 (comprising 
MEN1 gene) and the frequency of MEN1 mutations, may represent 25% to 50% of sporadic 
PETs (Moore et al. 2001, Corbo et al. 2010). Thus it is clear that other factors are important in 
the initiation and the tumorigenesis process of the remaining sporadic PETs. Interestingly, a 
recent study conducted on 68 sporadic p-NETs, showed that 44% of tumors harbored a 
mutation in MEN1, 25% in DAXX, 17.6% in ATRX, 7.3% in PTEN, 8.8% in TSC2 and 1.4% 
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in PIK3CA (Jiao et al. 2011). Even if this study was of great importance to better understand 
the genetic basis of pancreatic endocrine tumors, it is regretfully non-informative. Indeed, 
even if authors state that mainly aggressive tumors were screened for mutations, no 
description was given on the biology and type of the tumors (functional, non-functional, the 
type of hormone expressed by the tumor, etc). 
1.2.5 CELLS OF ORIGIN OF PANCREATICO-DUODENAL ENDOCRINE TUMORS 
1.2.5.1 GENERALITIES 
The majority of tumor studies until recently were aimed at understanding the biology 
of well-established tumors, in order to discover markers of diagnosis and prognosis, and 
targets for therapies. Finding molecular alterations in tumors also allowed to investigate the 
role played by these events in initiating tumorigenesis or contributing to tumor progression. 
Recent advances in technologies allowed demonstrate that each tumor is different for a given 
type of tumor, which can be attributed to the different selection process and random 
alterations that lead to tumor development. In addition, recent studies demonstrate frequently 
seen heterogeneity inside a given tumor, indicating that cancer is not a uniform disease. 
Among different factors causing tumor heterogeneity, more and more concerns are paid to the 
cells of origin (Blanpain 2013).   
Morphological and/or ultrastructural resemblance of tumor cells with their possible 
normal counterpart, the shared expression of peptides/proteins that can be detected by 
immunohistochemistry between a normal cell-type and the tumor cells inside the same organ 
is so far generally used to establish classifications concerning cell type of a given tumor. A 
similar approach was used to classify gastroenteropancreatic endocrine tumors but is mainly 
based on the clinical symptoms due to hormonal secretion, which is a characteristic of 
functional endocrine tumors. However, these criteria have their limits. For example, it was 
recently demonstrated in a murine model that pancreatic ductal adenocarcinoma may arise 
from acinar cells by cell conversion (Kopp et al. 2012). Clearly, cells of origin of a given type 
of tumor play an important role in the heterogeneity of established tumors, as similar tumors, 
depending on their cellular origin, may behave really differently in terms of progression and 
resistance or relapse after treatment. Consequently, deciphering cell of origin of tumors is 
necessary for more comprehensive and complete understanding of tumor biology. Also, it 
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allows to generate adequate in vitro and in vivo models that faithfully recapitulate key events 
of tumor initiation, development and progression of a given tumor-type. Meaningful 
biomarkers can thus be identified to detect neoplasms earlier and appropriate targets be found 
for early therapeutics before the onset of aggressive disease.  
The following approaches are widely used in the study of cells of origin of tumor. 
Firstly, finding the expression of molecular markers that are normally specifically expressed 
in a differentiated cell type or progenitor can be informative. The analyses of early lesions in 
the peritumoral tissues, especially in inherited tumor diseases, provide instrumental clues on 
the cell of origin of a tumor. Indeed, this can often allow appreciating the lesions with 
different characteristics in the different stages of tumor progression, in contrast to sporadic 
cancers (Vortmeyer et al. 2004). The use of genetic lineage tracing of different-cell types in 
mouse models is a powerful tool to decipher cells of origin of a tumor. Lineage tracing 
combined with specific targeting a given differentiated cell type or progenitors to disrupt a 
tumor suppressor or to activate an oncogene in mouse can allow the determination of the 
susceptibility of the cells to tumor formation and the type of tumor derived. 
1.2.5.2 NORMAL DIFFERENTIATED ENDOCRINE CELLS 
In the pancreas, functional tumors were until recently mainly considered as originating 
from their normal differentiated counterpart depending on the main hormone that they secrete 
(van Eeden and Offerhaus 2006, Ehehalt et al. 2009). Pancreatic beta cells that secrete insulin 
are considered as the cells of origin of insulinomas, as alpha cells for glucagonomas. In the 
mouse, several models of GEP-NETs were engineered to date allowing to more precisely 
define the cell of origin of some of GEP-NETs. The development of insulinomas from beta 
cells was first demonstrated in a transgenic mouse model expressing the viral SV40 Large T 
antigen (Tag) under the control of the rat insulin promoter (RIP) (Hanahan 1985). The 
disruption of the Men1 gene specifically in insulin expressing cells induces the formation of 
insulinomas (Bertolino et al. 2003, Crabtree et al. 2003). However, since Men1 disruption or 
Tag expression can occur initially in non-fully differentiated insulin expressing cells during 
development in these models, it is not completely understood if fully differentiated adult beta 
cells are susceptible to insulinoma formation or if only beta cell precursors expressing insulin 
are at the origin of insulinomas. In addition, in RIP-Tag transgenic mice, half of islets display 
beta cell hyperplasia at 6 weeks and tumors develop in all mice at 12 weeks after birth but in 
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relative small number (2 to 10/ animal) compared to the number of hyperplastic beta cells.  
This could be explained by that either only a few subpopulations of beta cells give rise to 
tumors or secondary events are needed to trigger insulinoma development (Hanahan 1988). 
Same experiences targeting glucagon expressing alpha cells demonstrated that alpha cells may 
be at the origin of glucagonomas (Efrat et al. 1988, Lu et al. 2010, Shen et al. 2010). 
Interestingly, the Glucagon promoter driven Tag expression in glucagon expressing cells, 
starting at the first wave of pancreatic endocrine differentiation, induces proliferation of alpha 
cells but only at 5 months after birth, leading to low frequency (less than 1% of islets) of 
glucagonoma development at 9 to 10 months of age (Efrat et al. 1988). 
1.2.5.3 STEM OR PROGENITOR CELLS 
In addition, it was also shown that pancreatic endocrine tumors are often 
multihormonal (Kapran et al. 2006). It is still not known whether the multihormonality is due 
to multiple occurrences of monohormonal lesions with the same site or because there is 
initially a common affected cell of origin that gives rise to different types of cells in the 
tumor.  Thus, it is also hypothesized that the cell of origin of GEP-NETs could be a stem-cell, 
progenitor or precursor. Although such a role of stem or progenitor cells has not been so far 
experimentally demonstrated in GEP-NET, the following works provided hints showing such 
a possibility.  
In the pancreas from patients developing mixed acinar-endocrine carcinomas, the 
lesions generally do not stain for any hormone, suggesting either an early progenitor origin of 
these tumors during embryogenesis or dedifferentiation mechanisms (Klimstra et al. 1994, 
Ohike et al. 2004). Interestingly, these mixed acinar-endocrine carcinomas generally do not 
display common pancreatic ductal cancers genetic alterations such as KRAS activation or 
SMAD4, p16 loss, as same as pancreatic endocrine tumors (Stelow et al. 2010). 
Similarly, a pancreatic ductal origin of PETs was suggested in MEN1 patients based 
on a histopathological study showing the existence of ductal-like early lesions displaying 
MEN1 LOH (Vortmeyer et al. 2004). The work is further supported by the observation of 
single endocrine cell closely localized to ducts in mature normal pancreas, which may suggest 
endocrine neogenesis from adult progenitors from ducts (Yoneda et al. 2013). The 
significance of neogenesis is highly debated in the field. Recently, it was reported, based on 
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the use of a powerful and elegant transgenic mouse model, that neogenesis of beta cells is not 
likely to occur even during endocrine cell regeneration after injuries, at least in the mouse 
(Xiao et al. 2013). This report nevertheless confirmed that Ngn3 is reexpressed during 
pancreatic injuries and colocalize with ductal markers and insulin+ cells. The significance of 
such Ngn3 reactivation is not known but may potentially reflect a dedifferentiation of beta 
cells which may be necessary to improve their proliferation or survival. In human it was 
nevertheless recently reported that neogenesis may occur in patients with impaired glucose 
tolerance and newly diagnosed diabetes (Yoneda et al. 2013). 
On the contrary, in the duodenum or intestine, multipotent stem-cells or progenitors 
may be at the origin of endocrine tumors. Indeed, in these organs, the rapid renewal of 
endocrine cells suggests that endocrine cell tumors may not arise from fully differentiated 
endocrine cells but maybe from long-lived stem-cells. In addition, the submucosa localization 
of endocrine tumors argues for a potential crypt origin of enteroendocrine tumors. However, 
as it was demonstrated that some differentiated endocrine cells can migrate toward the crypt 
and not only toward the villi, we could speculate that these endocrine cells could be at the 
origin of enteroendocrine tumors (Aiken et al. 1994). 
The origin of gastrinomas is maybe among the most intriguing enigma, especially in 
the case of pancreatic gastrinomas. Indeed, in contrast to insulinomas or glucagonomas that 
have a normal fully differentiated counterpart in the pancreas, gastrin-expressing cells are not 
found in the adult pancreas. Considering the high frequency of pancreatic gastrinomas in the 
region derived from ventral bud during development, within the so-called “gastrinoma 
triangle” it has been speculated that they would derive from stem-cells of embryonic ventral 
pancreatic bud (Passaro et al. 1998), partly because of their subserosal or submucosal 
localization. It has not been defined by the authors whether the cell of origin is stem-cells per 
se or endocrine cells that differentiated from these ventral pancreatic stem-cells or 
progenitors. Indeed, even if no gastrin+ cells can be found in the adult pancreas, gastrin 
secreting cells are readily detected within the developing and neonatal pancreas (see Part 
1.1.4). These gastrin+ cells could be subjected to tumorigenesis and subsequent gastrinoma 
development. Indeed, transgenic mice harboring a human Gastrin gene promoter fused to the 
coding sequence of SV40 large T antigen develop islet tumors (Montag et al. 1993). However, 
intriguingly, these tumors are insulinomas and do not express gastrin, whereas the Tag keeps 
being expressed in tumors. Gastrin mRNA expression in hyperplastic islets or tumors was not 
 
 
 
INTRODUCTION.  
PART II Gastroenteropancreatic Endocrine tumors: Cells of origin of pancreatico-duodenal endocrine tumors 
 
51 
 
assessed. It was not assessed whether the transgene has been directly targeted in Gastrin-
expressing islet cells. Tumors do not develop in the duodenum, but interestingly, small G-cell 
hyperplasia or microtumors are found in gastric antrum in this model (Montag et al. 1993). 
One may speculate that duodenal G cells may not be targeted by the transgene; or that 
duodenal G cells are not sensitive to Tag induced tumorigenesis; or that duodenal gastrinomas 
are unlikely to develop in mice. 
1.2.5.4 CELL TRANSDIFFERENTIATION 
Interestingly, α-cell specific Men1 disruption, besides glucagonoma development, also 
leads to the formation of mixed glucagon+/insulin+ tumors and insulinomas by 
transdifferentiation of a subset of menin deficient alpha cells into beta cells (Lu et al. 2010). 
The occurrence of cells co-expressing both insulin and glucagon were also observed in the 
heterozygous Men1+/- mice supporting the idea that insulinomas in a MEN1 context can have 
an alpha cell origin (Lu et al. 2010). This work provided experimental evidence allowing to 
explain the observations made by anatomopathological analysis of pancreas from MEN1 
patients that displayed a high proportion of glucagon+ microadenomas and micro lesions, 
whereas macrotumors from the same patients were in majority insulin+, suggesting a potential 
alpha cell origin of insulinomas in MEN1 patients (Perren et al. 2007).  
In the pancreas, some observations suggest that gastrinomas could originate from other 
islet cells. Indeed, it has been reported by Lodish and colleagues a sporadic pancreatic 
endocrine tumor with characteristics of both insulinoma and gastrinoma. The tumor stained 
for both insulin and gastrin immunohistochemically, and immunogold electron microscopy 
studies revealed cells containing the both hormones. The patient presented with both 
hyperinsulinemia and hypergastrinemia, all along with associated clinical symptoms 
hypoglycaemia and duodenal ulcer. Historically, hypoglycemic episodes began before 
symptoms of ulceration, suggesting that the insulinoma potentially originating from a beta cell 
evolved into a dual gastrin/insulin secreting tumor (Lodish et al. 2008). Another report 
showed the case of an insulinoma that further evolved in gastrinoma (Mizuno et al. 2001). In 
addition, it has been shown in a cohort of patients with pancreatic endocrine tumors that a 
hypergastrinemia with clinical features of a gastrinoma developed after initial PET diagnosis 
in 4% (13/353 patients) of cases (Wynick et al. 1988). Initial PETs diagnosis before 
hypergastrinemia apparition was 8 glucagonomas, 3 VIPomas and 2 insulinomas. It has not 
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been described if patients were MEN1. It is still unclear from these different observations, 
whether a transdifferentiation mechanism led to gastrinoma development in patients with a 
previously diagnosed PET secreting another hormone, or whether gastrin+ cells participated in 
the initial tumor development.  
It is noted that little is known about the mechanisms involved in the development of 
non-functional endocrine tumors, whereas a high proportion of them in the pancreas or 
duodenum are expressing hormones such as glucagon or gastrin (Garbrecht et al. 2008). It is 
still currently unknown if non-functional differentiated endocrine tumors (other than PP 
secreting) could be pre-functional tumors that may evolve into a functional form. 
Table 2. MEN1 pathology (tumors and hyperplasia)  
Tumor localisation Tumor type % of MEN1 
patients 
% of GEP tumors 
in MEN1 
Endocrine    
Parathyroid Multiglandular hyperplasia, adenomas 
(hyperparathyroidism due to PTH 
secretion) 
90-100  
GEP  20-100  
Duodenal - Gastrinomas 40 20-61 
Pancreatic    
 -Non-functional macroscopic PETs 20 0-13 
 -Insulinomas 10 7-31 
 -Glucagonomas  1-6 
 -VIPomas  1-12 
 -GRFomas  <1 
 -Somatostatin secreting tumors  0-1 
 -pancreatic gastrinomas rare  
Stomach -Type II gastric NET (non-functional) 
associated with ZES 
  
Anterior pituitary  10-60  
 -PRLomas 20  
 -GH 5  
 -GH/PRL 5  
 -ACTH 2  
 -TSH rare  
 -Non-functional 17  
Adrenal (adrenocortical)  20-40  
 -Non-functional 20-40  
 -cortisol secreting rare  
 -aldosterone secreting rare  
 -pheochromocytomas <1  
Foregut carcinoids -Thymic carcinoid 2-8  
 -Lung (bronchial) carcinoids 2-8  
Thyroid Thyroid adenomas   
Non-endocrine    
Cutaneous -Skin angiofibromas 85-88  
 -Collagenomas 70-72  
 -Lipomas 30-34  
    
Central Nervous System -Meningiomas 5-8 
 
 
 -Ependydomas 1  
 -Schwannoma ND  
Smooth muscle -leiomyomas 
-leiomyosarcomas 
10  
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1.3 PART III MEN1 SYNDROME 
1.3.1 GENERALITIES 
Multiple Endocrine Neoplasia Type 1 (MEN1) (MIM#131100) is a hereditary 
autosomal dominant syndrome. It is characterized by multiple occurrences in a same patient 
or in several members of the same family of tumors in endocrine organs. The major endocrine 
organs affected in MEN1 comprise the parathyroids, the endocrine pancreas (and the 
duodenum) and the anterior pituitary (Table 2). MEN1 patients can also develop less 
frequently adrenal cortical tumors, foregut carcinoids, and non-endocrine tumors such as 
lipomas, facial angiofibromas, collagenomas and fibromas. 
In MEN1 patients, hyperplasic and tumor lesions of the parathyroids affect virtually 
all patients (90%), pancreatico-duodenal endocrine tumors occur in 40% of patients, followed 
by anterior pituitary lesions (functional prolactinomas in 20% of patients, GH secreting, 
GH/PRL secreting, ACTH secreting, non-functional in 17% of patients) (Falchetti et al. 2009, 
Thakker 2010). Non endocrine cutaneous tumors are frequent in MEN1 patients with 
prevalence at 40 years old of 85% for facial angiofibromas and 70% for collagenomas. 
 
1.3.2 THE MEN1 GENE 
The predisposing gene to MEN1 syndrome is the MEN1 gene, identified by positional 
cloning in 1997 (Chandrasekharappa et al. 1997, Lemmens et al. 1997). It is localized at 
chromosome 11q13. The gene is considered as a tumor suppressor in affected endocrine 
organs. 
1.3.2.1  ORTHOLOGS, EVOLUTION AND CONSERVATION 
The MEN1 gene is conserved in mammals, notably in the mouse (Bassett et al. 1999, 
Guru et al. 1999), and orthologs exist in the Zebrasfish (Khodaei et al. 1999, Manickam et al. 
2000) and Drosophila melanogaster (Guru et al. 2001), but neither in Saccharomyces 
cerevisiae nor in Caenorhabditis elegans. 
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In the mouse, animals with genetic disruption of one allele of the Men1 gene 
(heterozygous Men1 knockout mice) develop a range of endocrine tumors highly similar to 
what is observed in MEN1 patients, reflecting the conservation of MEN1 role in mouse 
(Crabtree et al. 2001, Bertolino et al. 2003, Loffler et al. 2007, Harding et al. 2009). 
1.3.2.2  MEN1 TRANCRIPTS 
The MEN1 gene spanning 9.8 kb is constituted of 10 exons, with the first exon and 
distal part of the exon 10 being non-coding. The human MEN1 coding sequence consists of 
1830 bp. Two MEN1 transcripts were detected by northern-blotting in human tissues, a main 
2.8 kb transcript expressed in most organs, and a 4.2 kb transcript expressed in thymus and 
pancreas (Lemmens et al. 1997). In the mouse, the Men1 gene is localized in the 
pericentromeric region of the chromosome 19, in a region synthenic to human 11q13 locus, 
with at least two reported transcripts, a 2.8 kb and a 3.2kb transcripts that result from 
differential alternative splicing of the noncoding exon 1, containing a coding sequence of 
1833bp, and are expressed in most tissues excepted skeletal muscle (Stewart et al. 1998, 
Bassett et al. 1999).  
1.3.2.3  MEN1 GENE MUTATIONS 
An extensive landscape of MEN1 gene mutations has been described to date. More 
than 1000 germinal mutations and more than 200 somatic mutations (occurring in sporadic 
tumors) have been reported and lie on the entire MEN1 gene. About 41% mutations are 
frameshift deletions or insertions, 23% are nonsense, 20% are missense, 9% affect splice-site 
and 6% are in-frame deletions or insertions. Interestingly, some mutations in MEN1 patients 
are not localized in the coding sequence, but rather in the promoter or other untranslated 
regions. Germline deletions of MEN1 exons have also been reported. Most mutations are 
inactivating mutations consistent with the tumor suppressing functions of the MEN1 gene. No 
phenotype-genotype correlations have been reported so far, excepted the work recently 
reported by the GTE showing that mutations affecting the interaction domain of the protein 
with JunD had a higher risk of death (Thevenon et al. 2013). 
In MEN1 endocrine tumors (90%), the loss of heterozygosity (LOH) of the MEN1 
wild-type allele, leading to completely MEN1 inactivation, can be systematically detected. 
The LOH seems, therefore, to be an essential event to initiate tumorigenesis, even if a report 
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suggest that inactivation of one Men1 allele in the mouse may lead to happloinsufficiency 
(Lejonklou et al. 2012).  
1.3.3 MENIN PROTEIN 
The MEN1 gene encodes the protein called menin with 610 amino acids in human, 
whereas mouse menin protein is constituted of 611 amino acids (Stewart et al. 1998).  
Menin is expressed in all the tested endocrine and non-endocrine tissues and cell lines 
(Guru et al. 1999, Wautot et al. 2000). Menin is mainly a nuclear protein but can also be 
detected in the cytoplasm and membrane in some tissues, cell lines or during cell-cycle 
progression (Guru et al. 1998, Kaji et al. 1999, Wautot et al. 2000, Cao et al. 2009, Wuescher 
et al. 2011, Ren et al. 2012). Consistent with its nuclear localization, menin sequence contains 
in C-terminus two classical nuclear localization signals (NLS), NLS1 and NLS2, which are 
necessary for nuclear menin expression (Guru et al. 1998), and an accessory NLS domain, 
NLSa, also localized in C-terminus of menin protein (La et al. 2006).  Menin is not a 
transcription factor per se but was shown to be able to directly bind DNA in a sequence 
independent fashion (La et al. 2004). It was also shown that menin contains two functional 
Nuclear Export Signal (NES). The NES1 consists of the amino acids 33 to 41 of human and 
mouse menin, and the NES2 comprises amino acids 258 to 267, the latter containing a 
LXXLL motif (Cao et al. 2009). 
Recently, after years of efforts, the crystal structures of a menin homolog from 
Nematostella vectensis (Murai et al. 2011) and of human menin (Huang et al. 2012), were 
reported. These studies demonstrated that menin behaves as a scaffold protein. Importantly, 
the crystal structure of menin in complexes with MLL1 or JUND, the two most studied menin 
partners (see “Menin functions” part) (Huang et al. 2012). MLL1 and JUND compete to 
interact with menin as they bind to the same domain of menin protein. In addition, this study 
demonstrated that menin mutants can still bind target gene Hoxc8 but are unable to recruit the 
histone methyl-transferase MLL1 to this target gene. Menin interaction with JUND inhibits 
JUND activation by JNK and subsequent JUND transcriptional activity, since JUND domains 
required for interaction with menin and JNK are overlapping (Gallo et al. 2002, Huang et al. 
2012). 
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Post-translational modifications of menin protein were reported to occur in vitro 
and/or in vivo. Several menin amino acids residues can be phosphorylated in response or not 
to DNA damage (MacConaill et al. 2006, Francis et al. 2011), but the importance of these 
phosphorylations are elusive. Sumoylation of non-consensus SUMO sites were also detected 
on menin, but to which extent sumoylation affects menin function is not known (Feng et al. 
2013). 
1.3.4 MENIN FUNCTIONS 
The biological roles played by menin in an organism is multiple, even if the major in 
vivo biological functions of menin currently known in human consists in repressing endocrine 
but also non-endocrine tumorigenesis in the organs affected in MEN1 syndrome. Importantly, 
more and more works provided compelling evidence showing that menin plays critical roles 
in a variety of biological processes in non-endocrine tissues, including hematopoiesis, 
osteogenesis, myogenesis, adipogenesis, etc... Many studies demonstrated that multifaceted 
biological roles of menin rely on its molecular function as a transcriptional regulator 
(activator or inhibitor), which participates in the control of two crucial aspects of cellular 
activities:  cell differentiation, and cell proliferation and survival.  Menin apparently exerts its 
molecular actions through its physical or functional interaction with numerous partners (Table 
3), including those specific to a given cell-type and/or tissue. This may result in the distinct 
multiple biological effects in different cells.  
 
1.3.4.1  REGULATION OF DIFFERENTIATION 
 Menin is essential for embryonic development, at least in the mouse, and probably 
also in human, since the living individual with homozygous inactivation of the MEN1 gene 
has never been found so far. Indeed, homozygous Men1-/- embryos die at mid gestation during 
development (Crabtree et al. 2001, Bertolino et al. 2003, Lemos et al. 2009). Men1 null 
embryos show delayed development after E11.5 and they die between E12.5 to E13.5. The 
major defects are hemorrhages, myocardial hypotrophy, pericardial effusion, neural tube 
defects (exancephaly) and liver growth retardation. Different analyses done on different 
mouse genetic background suggested that one possible cause of death in Men1 null embryos 
could be in part attributed to pericardial effusion (Lemos et al. 2009). However, mice with 
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targeted Men1 disruption in myocardial muscle, has no effect on development and mice are 
even viable after birth and fertile (Engleka et al. 2007).Massive apoptosis of hematopoietic 
cells was observed in E12.5 fetal liver (non-published data of our lab). These data may favor 
the occurrence of fetal hematopoiesis failure as the major cause of the embryonic death.  
1.3.4.1.1 REGULATION OF ENDOCRINE CELLS DIFFERENTIATION 
 Our laboratory sought to study menin’s role in the development of the endocrine 
pancreas. Menin is expressed in all pancreatic cells during development and in adult mouse 
pancreas (Fontaniere et al. 2008). Men1 null pancreases at E12.5 have a noticeable decrease in 
endocrine cell number and fail to undergo massive endocrine differentiation in ex vivo 
experiments. Moreover, in chimeric mice, the contribution of Men1 null ES cells to pancreatic 
endocrine cells is substantially low as compared to other organs such as the exocrine pancreas 
or the skin, demonstrating that menin is essential for pancreatic endocrine cell development 
(Fontaniere et al. 2008). As apoptosis is clearly observable in pancreatic endocrine cells from 
E12.5 Men1 null embryos, it seems that menin may be required for the survival of pancreatic 
endocrine cells during embryogenesis. However, the conditional disruption of the Men1 gene 
in Pdx1 progenitors cells, and insulin or glucagon-expressing cells during embryonic 
development using transgenic corresponding Cre mice, demonstrated that the entire 
development of endocrine pancreas may not be affected and the mice survive and develop 
pancreatic endocrine tumors (Bertolino et al. 2003, Crabtree et al. 2003, Biondi et al. 2004, Lu 
et al. 2010, Shen et al. 2010). However, neither the activity and the efficiency of the cre 
recombinases were assessed, nor different stages of embryonic pancreas development studied 
in these conditional models (Bertolino et al. 2003, Crabtree et al. 2003, Biondi et al. 2004, Lu 
et al. 2010, Shen et al. 2010). However, it seems that menin expression is crucial to maintain 
the identity of a subset of alpha cells as Men1 disruption in these cells induces a 
transdifferentiation into beta cells in adult mice (Lu et al. 2010). 
Additionally, menin is involved in the regulation of the expression of several adult 
endocrine cells hormones. Menin was shown to inhibit glucose stimulated insulin secretion 
and the rat Insulin2 gene promoter activity in the INS-1 rat insulinoma cell line (Sayo et al. 
2002). In the GH3 rat pituitary-tumor derived cell-line, menin overexpression was associated 
with a decrease in endogenous Prolactin mRNA expression (Namihira et al. 2002). 
Conversely menin was shown in another rat pituitary cell-line to be necessary for Activin-
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mediated downregulation of Prolactin gene expression, a possible indirect effect that could be 
due to the down-regulation of Pit-1, an important positive regulator of Prolactin expression 
(Lacerte et al. 2004). Moreover, menin can repress basal Parathyroid Hormone (PTH) gene 
expression in human primary parathyroid hyperplastic cells, and is also necessary for Tgf-β 
mediated repression of PTH expression (Sowa et al. 2004). 
Menin inhibits JunD expression and also interacts physically with JunD to repress 
JunD mediated Gastrin gene expression in AGS cell-line (Mensah-Osman et al. 2008, 
Mensah-Osman et al. 2011). The reported role of menin as an inhibitor of Gastrin gene 
expression was validated in vivo (Veniaminova et al. 2012). In addition, menin 
overexpression was shown to repress the expression of the GIP hormone mRNA in 
enteroendocrine cell line STC-1 (Angevine et al. 2012). 
1.3.4.1.2 REGULATION OF NON-ENDOCRINE CELLS DIFFERENTIATION 
 Menin regulates osteogenesis in vivo and in vitro. Indeed, it was shown that menin is 
necessary for the commitment of mesenchymal stem cells into preosteoblasts (Sowa et al. 
2003, Sowa et al. 2004, Naito et al. 2005), menin being crucial for BMP induced 
transcriptional activation of Runx2 by interacting with Smad1 and Smad5 resulting in the 
commitment of progenitors into preosteoblasts. However, once the commitment is engaged, 
menin represses osteoblast maturation by repressing Smad1/5 transcriptional activity and by 
promoting Tgfβ mediated Smad2 induced repression of differentiation, through its physical 
interaction with Smad1, Smad5 and Smad3(Sowa et al. 2003, Sowa et al. 2004). It was also 
shown that, in addition to its Smad dependent regulation of maturation, menin antagonized 
JunD mediated osteoblast maturation (Naito et al. 2005), through its interaction with the AP-1 
member JunD to represses its transcriptional activity (Agarwal et al. 1999, Gobl et al. 1999, 
Huang et al. 2012). Menin interacts physically and functionally with β-catenin in 
mesenchymal and osteoblastic cell lines, by positively regulating β-catenin transcriptional 
activity (Inoue et al. 2011). In addition, menin seems to be necessary for β-catenin-mediated 
enhancement of C2C12 mesenchymal cells differentiation into osteoblasts after BMP-2 
treatment (Inoue et al. 2011). Conditional Men1 disruption in neural crest results in cleft 
palate that may result from defects in osteoblast lineage progression (Engleka et al. 2007). 
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More recently, it was demonstrated that during osteoblast induction of human 
Adipose-tissue Derived Stem Cells (hADSC) menin can indirectly regulate Smad1 expression 
by activating the transcription of mir-26a which represses Smad1 protein expression (Luzi et 
al. 2012). 
 Menin was also shown to regulate myogenic commitment from mesenchymal stem-
cells. Indeed, menin expression decreases during muscle differentiation (Aziz et al. 2009), 
consistent with previous reports showing absence or low menin/Men1 expression in 
differentiated muscles (Stewart et al. 1998, Guru et al. 1999, Wautot et al. 2000). Ectopic 
menin expression impairs myogenesis from mesenchymal stem cells, which is mediated by a 
negative effect of menin/Smad3 complex on differentiation (Aziz et al. 2009). This effect was 
further supported by the fact that mice with conditional Men1 disruption in neural crest have 
an increased number of intercostal muscle fibers, (Aziz et al. 2009). 
 Menin appears to be crucial for adipocytes differentiation. It was shown that menin 
interacts physically and functionally with PPARgamma and that menin loss impairs 
PPARgamma mediated differentiation of 3T3L1 and mouse embryonic fibroblast into 
adipocytes (Dreijerink et al. 2009). It seems that this role is specific to PPARgamma 
dependent adipogenesis, as it was demonstrated that menin does not affect BMP-2 mediated 
adipogenesis from mesenchymal stem cells (Sowa et al. 2003). 
 Men1 disruption in adult mice decreases the number of peripheral white blood cells 
and decreases B lineages progenitors, but mice maintain a normal population of upstream 
hematopoietic progenitors (Chen et al. 2006, Maillard et al. 2009). However, following 
hematopoietic stress, Men1 deficient hematopoietic stem cells are severely affected 
demonstrating the crucial role of menin for hematopoiesis (Maillard et al. 2009). The role of 
menin in hematopoiesis has been highlighted by its reported physical interaction with the 
histone methyltransferase MLL (Mixed Lineage Leukemia), the mammalian homolog of 
Drosophila trithorax. MLL1 forms a complex with several proteins, including LEDGF, 
menin, c-myb, WDR5, Ash2L, RbBP5, which regulates the expression of Hox genes (Thiel et 
al. 2012). Mll1 is critical for the establishment and maintenance of hematopoiesis during 
development and in adult in the mouse, since Mll1 disruption impairs more or less 
hematopoietic stem cells (HSCs) depending on the model used (Hess et al. 1997, Ernst et al. 
2004, Jude et al. 2007, McMahon et al. 2007). MLL1 rearrangements in acute lymphoid and 
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myeloid leukemias lead to an upregulation of HOXA9 and MEIS1 genes expression critical for 
leukemogenesis. Interestingly, menin was shown to interact physically with 
MLL1(Yokoyama et al. 2004) and MLL2 (TRX2) (Hughes et al. 2004) , c-Myb (Jin et al. 
2010), and LEDGF(Yokoyama and Cleary 2008),  positively regulating Hox genes 
transcription in different cell lines. Men1 disruption in HSCs (Maillard et al. 2009) does not 
recapitulate the phenotype observed after Mll disruption, demonstrating that in basal 
conditions, Mll can overcome the absence of menin to preserve relatively normal 
hematopoiesis.  
1.3.4.2  REGULATION OF PROLIFERATION AND CELL SURVIVAL 
Menin regulates the proliferation of several endocrine cell-types as well as non-
endocrine cells.  
1.3.4.2.1 REGULATION OF ENDOCRINE CELLS PROLIFERATION AND SURVIVAL 
 Several murine models aimed at disrupting the Men1 gene specifically in endocrine 
compartments demonstrated the putative role of menin in the regulation of the proliferation 
and tumorigenesis of these cells. The heterozygous Men1+/- mice as already described, 
develop a range of endocrine tumors similar to MEN1 syndrome. Interestingly duodenal or 
pancreatic gastrinomas only rarely develop or even do not develop at all suggesting a possible 
resistance of the murine organism to Men1-related gastrinoma tumorigenesis (Crabtree et al. 
2001, Bertolino et al. 2003, Loffler et al. 2007, Harding et al. 2009). On the contrary, specific 
Men1 disruption using Cre/Lox system in pancreatic beta cells (Bertolino et al. 2003, Crabtree 
et al. 2003, Biondi et al. 2004), pancreatic alpha cells (Lu et al. 2010, Shen et al. 2010), 
pituitary (due to leakage of Cre transgenes) (Crabtree et al. 2001, Biondi et al. 2004, Seigne et 
al. 2013), or parathyroid (Libutti et al. 2003), leads to the development of tumors from the 
targeted cells consistent with a role of menin in regulating proliferation of these endocrine 
cells in vivo. 
 An interesting study carried out by Thakker group showed that intratumoral injection 
of adenoviral vectors allowing the reexpression of Men1 in Men1 deficient pituitary tumors of 
Men1+/- mice considerably decreased their proliferation after 4 weeks (Walls et al. 2012). This 
strongly suggests that menin expression by itself is an important gate-keeper of endocrine cell 
proliferation and that maybe menin loss and subsequent deregulated proliferation is the key 
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event required for Men1 related tumorigenesis. However, more precise and long term studies 
on the effect of Men1 gene therapy rescue are required. 
It has been shown that menin mediates TGF-β-induced growth inhibition by 
interacting with Smad3 in anterior pituitary cell lines (Kaji et al. 2001). 
 Menin positively regulates the expression of the cyclin dependant kinase inhibitors 
p18Ink4c (Cdkn1b) and p27Kip1 (Cdkn2c) in several endocrine cell types in vivo mainly through 
its interaction with Mll (Karnik et al. 2005, Milne et al. 2005, Schnepp et al. 2006). However, 
analysis of Cdkn1b and Cdkn2c mRNA did not reveal significant down-regulation of these 
genes in human MEN1 pancreatic endocrine tumors (Lindberg et al. 2008). In addition, 
change in p27 mRNA expression was not detected in Men1-deficient beta cells in vivo 
(Scacheri et al. 2006) and 23% of insulinomas from mice with beta cell specific Men1 
disruption had normal p27 protein expression (Fontaniere et al. 2006).  
 Menin also regulates cyclin dependent kinases (CDKs) and cyclins expression. Cdk4 
expression is increased in mouse Men1 pancreatic endocrine tumors developed in 
heterozygous Men1+/- mice (Karnik et al. 2005). Men1 disruption in islet cells also increases 
the expression of CyclinA2, CyclinB1, CyclinB2, and factors positively involved in cell cycle 
progression such as Pbk and Mcms genes (Yang et al. 2010). Importantly, menin was shown 
in vitro to directly repress CyclinB2 gene expression by promoting the recruitment of negative 
regulators at Ccnb2 locus (Wu et al. 2010). In addition, specific beta cell disruption of the 
Men1 gene is accompanied with an increase in CyclinA2, CyclinB2 and CyclinD2 expression 
in tumors developed in these mice (Fontaniere et al. 2006). 
 It was shown that menin can interact physically with β-catenin in vitro to mediate 
nuclear export of β–catenin to the cytoplasm (Chen et al. 2008, Cao et al. 2009). β-catenin 
nuclear accumulation is increased upon loss of menin expression in Men1 deficient alpha and 
beta cells in vivo(Cao et al. 2009) at early stage, which may be involved in the proliferation of 
these cells (Dessimoz et al. 2005). In addition, membrane expression of E-cadherin and β-
catenin is decreased in Men1-disupted mouse beta cells (Bertolino et al. 2003, Yan et al. 
2009). Moreover, menin interacts with the scaffold protein IQGAP1 to mediate intercellular 
adhesion by stabilizing E-cadherin and β-catenin at cytoplasmic membrane (Yan et al. 2009). 
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 Menin seems also to play a pivotal role in AKT signaling. It was demonstrated in MEF 
and HEK-293 cells that menin can bind and sequester inactive AKT, to prevent AKT 
activation. Consistently, activated AKTpS473 staining is increased in all pancreatic islet 
adenomas analyzed that developed in Men1+/- mice, but the hormonal profile of adenomas 
was not precised (Wang et al. 2011). Considering the important role of AKT in promoting cell 
proliferation and survival, AKT activation in endocrine cells upon menin loss may play an 
important role in MEN1 tumorigenesis, but more investigations are needed. 
 Recently, menin was involved in the repression of Hedgehog signaling in pancreatic 
beta cells. It was demonstrated that menin interacts with the H4R3me2 methyl transferase 
PRMT5 to promote repression of Gas1 expression, a Sonic Hedgehog co-receptor (Gurung et 
al. 2013). Gas1 is overexpressed in mice with β-cell specific Men1 disruption, and treatment 
of the mice with Hedgehog signaling inhibitors considerably decrease menin deficient beta 
cells proliferation (Gurung et al. 2013). The role of menin on Hedgheog signaling is 
straightened by the recent finding that menin represses the transcription of Gli1, a major 
effector of Hedgehog signaling (Gurung et al. 2013).  
 A role of menin in physiological control of β-cells proliferation was reported by 
studies on the adaptive β-cell proliferation in mouse. It was shown that menin protein 
expression is decreased in islet during pregnancy(Karnik et al. 2007, Zhang et al. 2010, 
Hughes and Huang 2011) and in genetically obese mice (Karnik et al. 2007), thus allowing 
compensatory beta cell proliferation that occurs in these models. It was shown in vitro and in 
vivo, that glucose through Akt signaling (Zhang et al. 2012), and/or prolactin and placental 
lactogen through increase of Bcl6 (Karnik et al. 2007, Zhang et al. 2010, Hughes and Huang 
2011), may play a role in the down-regulation of menin expression during adaptive beta cell 
proliferation. 
 Menin was shown to negatively regulate the protein expression but not mRNA 
expression of Hlxb9 in an insulinoma cell line by an unknown mechanism (Shi et al. 2013). In 
this study Hlxb9 overexpression was shown to induce apoptosis, this effect being rescued 
partially by Men1 knock-down. In addition, increased nuclear and cytoplasmic Hlxb9 is 
observed in tumoral islets from Men1+/- mice. The precise role of Hlxb9 in MEN1 related 
tumorigenesis need to be more precisely investigated. 
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 Menin may regulates proliferation at another level by repressing the expression of 
several growth factors such as IGF2, Igfbp-2 and PTHrP (La et al. 2004, Fontaniere et al. 
2006, Dejeux et al. 2009).  
 Testis leydig cells proliferation and apoptosis is respectively negatively and positively 
regulated by menin (Hussein et al. 2007). Heterozygous male Men1 mutant mice frequently 
develop Leydig cells tumors (Bertolino et al. 2003, Loffler et al. 2007). It was shown that loss 
of menin in these tumors is accompanied by decreased protein expression of TGF-β and BMP 
effectors Smad3 and Smad1/5 respectively and of the common Smad, Smad4, which may play 
a role in the development of these tumors (Hussein et al. 2008). 
Menin was involved in differential regulation of endocrine cell apoptosis between 
development and adult islet cells. As already mentioned above, Men1 null embryonic 
pancreases display apoptosis of endocrine cells, but it is still not clear if it is a direct effect of 
menin absence in endocrine cells or not (Fontaniere et al. 2008). In pancreatic endocrine beta 
cell lines in vitro, menin promotes apoptosis (Sayo et al. 2002, Bazzi et al. 2008). However 
the role of menin-regulated apoptosis in adult endocrine cells in vivo needs further 
investigations. 
Recently, it was demonstrated that menin loss in epithelial cells in the stomach 
antrum, duodenum and the intestine displayed a decrease in p27Kip1 mRNA and a two-fold 
increase in the number of gastrin+ cells in the antrum but not in the proximal duodenum  of 12 
month-old mice(Veniaminova et al. 2012). It is however not clear whether these G cells are 
Men1-deficient and if the increased G cell number results from proliferation or from an 
increased differentiation of progenitors toward G lineage. In parallel, increased proliferation 
of crypt cells is observed in the proximal duodenum after menin loss, suggesting that menin 
may regulates the proliferation of cells of transient amplifying compartment.  
1.3.4.2.2 REGULATION OF NON-ENDOCRINE CELLS PROLIFERATION AND APOPTOSIS 
While menin plays a crucial role in diverse endocrine cells, it also has important 
biological functions and specifically regulates cellular proliferation in several non-endocrine 
cells or tissues which are not part of MEN1 syndrome. 
 MLL fusion proteins formed upon chromosomal translocations (MLL-AF4, MLL-
ENL, MLL-AF9 and others) are important drivers of acute leukemias initiation and 
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maintenance by upregulating HOX genes and MEIS1 expression. Menin is required for MLL 
fusion proteins induced leukemogenesis (Chen et al. 2006, Thiel et al. 2012). This role seems 
to be due to the recruitment of LEDGF to menin/MLL1 complex (Yokoyama and Cleary 
2008). Importantly, inhibitors allowing the loss of menin interaction with MLL and MLL-
fusions proteins decrease the expression of MLL/MLL-fusions proteins target genes resulting 
in a differentiation of leukemic cells and apoptosis, as well as decreased proliferation 
(Grembecka et al. 2012, Shi et al. 2012). Altogether, these observations demonstrate that in 
hematopoietic cells, menin behaves as a pro-oncogenic factor by promoting the activity of 
MLL fusion proteins. 
  Studies from our group and others also showed a role of menin in the development of 
hormono-dependants tumors (prostate, breast) (Bertolino et al. 2003, Loffler et al. 2007, 
Harding et al. 2009, Seigne et al. 2010, Seigne et al. 2013). Menin expression is decreased in 
subsets of human breast cancers, and Men1 disruption in mouse mammary gland luminal 
epithelial cells increases the incidence of mammary intraepithelial neoplasias (Seigne et al. 
2013). Interestingly, it was shown that menin interacts with the estrogen receptor α (ERα) and 
that menin is required for ligand dependant ERα transcriptional activity (Dreijerink et al. 
2006, Imachi et al. 2010). Importantly Erα is an important proproliferative factor in ER+ 
breast cancers that can be treated by antiestrogens therapy such as tamoxifen. It was shown 
that in ER+ breast cancers treated by tamoxifen, menin positive expression was correlated 
with a decrease in relapse free survival, likely because of menin’s competitive binding to ER 
with tamoxifen (Imachi et al. 2010). More studies are needed to precisely define the role of 
menin in breast tumorigenesis. 
 More and more evidences indicate the importance of menin in suppressing lung 
tumorigenesis. Indeed, it was shown in lung cancer cell lines that menin positively regulates 
Pleiotropin gene silencing mediated by the Polycomb group protein H3K27 methyl 
transferase EZH2 by an unknown mechanism (Feng et al. 2010). Menin depletion results in 
enhanced Pleiotropin (PTN) expression, promoting lung cancer cell proliferation. Several 
lines of evidence suggest that menin could enhance EZH2 expression. In MLL-MA9 leukemic 
cells, menin is necessary for MLL-MA9 fusion protein to bind to EZH2 promoter and 
subsequent EZH2 transcription (Thiel et al. 2013). However, it was shown that in Men1 null 
MEF cells, Ezh2 expression is similar to wild-type MEFs, and menin loss also leads to 
decrease in the binding of Ezh2 to a target promoter (Pax2) (Xu et al. 2011), likely due to 
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decreased expression of Wilms tumor suppressor protein (WT1) protein necessary for Ezh2 
binding and subsequent H3K27 trimethylation of the Pax2 promoter. Altogether, these 
observations demonstrate the indirect but important role of menin in EZH2 mediated gene 
silencing. It would be crucial to investigate if this role is conserved in endocrine cells and in 
MEN1 related tumors. 
In addition it was demonstrated that Men1 disruption facilitates KrasG12D mediated 
lung tumorigenesis in the mouse (Wu et al. 2012). These results are in accordance with 
previously demonstrated role of menin as a suppressor of RAS-mediated transformation in 
vitro (Kim et al. 1999). Thus, it would be interesting to determine if menin has a role in the 
initiation or progression of others cancers driven by KRAS mutations, especially in pancreatic 
ductal adenocarcinomas, since menin expression was shown to be down-regulated in these 
cancers (Cavallari et al. 2009).  
Menin expression is lost in a subset of human melanomas (Gao et al. 2011, Fang et al. 
2013), and a study reported possible MEN1 LOH in 4/19 sporadic melanomas (Nord et al. 
2000). It has been shown in vitro that menin overexpression represses proliferation of 
melanoma cell lines mainly through repressing gene expression of PTN and its receptor RPTP 
β/ζ in this cell type and subsequent decreased activation of PI3K and ERK1/2 (Gao et al. 
2011).  
 Menin loss triggered apoptosis during liver development but mainly in liver 
hematopoietic compartment (Bertolino et al. 2003) (unpublished data of our laboratory). 
Intriguingly, only a few proportion of Men1-/- ES cells contribute to liver cell mass in 
chimeric mice (Fontaniere et al. 2008), suggesting that menin may have some unknown 
functions in developing hepatocytes. Men1 disruption in hepatocytes using Albumin-Cre 
transgene which is active since E19 during mouse embryonic development has no effect on 
hepatocyte proliferation or death (Scacheri et al. 2004). However menin was shown to have 
an important metabolic role in hepatocytes (Cheng et al. 2011, Wuescher et al. 2011, 
Wuescher et al. 2012).  
 A role of menin in DNA repair and maintenance of genome integrity has been 
suggested by the description of high rate of chromosomal abnormalities in lymphocytes and 
skin fibroblast from MEN1 patients (Scappaticci et al. 1991). However such role has been 
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demonstrated in vivo only in Drosophila melanogaster (Busygina et al. 2004, Busygina et al. 
2006, Papaconstantinou et al. 2010) and still needs to be confirmed in mammals. Some in 
vitro evidences support a probable role of menin in DNA repair and maintenance of genome 
integrity by interacting with proteins involved in DNA repair mechanisms (Tomassetti et al. 
1995, Ohkura et al. 2001, Yaguchi et al. 2002, Jin et al. 2003, Sukhodolets et al. 2003, 
Kottemann and Bale 2009, Gallo et al. 2010). In addition, it was shown that in cell lines 
menin never co-localizes with sites of DNA damage, excluding a direct role of menin in DNA 
repair. It was suggested that menin’s role in DNA repair may be only at transcriptional level 
(Francis et al. 2011). This was further consolidated recently in melanocytes where menin/Mll 
complex could be recruited by ERα to upregulate the transcription of Brca1 and Rad51, thus 
promoting efficient DNA repair (Fang et al. 2013). 
1.3.4.3  OTHER MENIN FUNCTIONS.  
Several studies involved menin in several function, principally based on its interaction 
with numerous partners as described in Table 3. 
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2 RESULTS 
 
2.1.1 CONTEXT OF THESIS WORK AND QUESTIONS RAISED  
As described in the literature review chapter, clinical features of both sporadic and 
hereditary pancreatic endocrine tumors are extremely varying and complex. The first level of 
their complexity resides in the occurrence of well differentiated and poorly differentiated islet 
tumors, two categories of the tumors giving rise to markedly distinct clinical outcomes. 
Moreover, well differentiated PNETs can either be functional or non-functional, depending on 
whether they secrete or not an excess of hormone causing clinical symptoms. Furthermore, 
functional PNETs are subdivided into different subtypes according to the major hormone they 
secrete or express. Finally, multihormonality of PNETs is far from rare, contributing largely 
to the heterogeneity of PNETs. The latter is further amplified, intriguingly, by the occurrence 
of tumors expressing and/or secreting non pancreatic hormones, such as Gastrin or VIP. 
Consequently, several questions may arise concerning such diversity of the clinical features of 
islet tumors: 
- What are the biological bases of such tumor diversity?  
- Does it reside in different cells of origin for each type of tumors, or can it be due to 
alternative ways of evolution during tumor progression, or both? 
- Are there common or specific molecular and cellular mechanisms contributing to each 
PNET type? 
2.1.2 AIMS OF THESIS WORK 
 In the context of MEN1 disease, PNET initiation is triggered by the loss of function 
of the remaining wild-type allele of the MEN1 gene. This event may virtually occur at any 
time during pancreatic embryogenesis or adult life, and in any cell-type belonging to the 
endocrine pancreas. Classical and conditional Men1 KO mouse models have been engineered 
to date and have proven their usefulness in the understanding of PNETs related to MEN1 
inactivation. However, it is impossible to control and determine the timing of Men1 disruption 
in the classical Men1+/- model.  Furthermore, although the use of conditional Men1 disruption 
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in the mouse allows to precisely define the cell type(s) and the timing of Men1 inactivation, 
virtually nothing was known about the tumorigenic potential of Men1-disruption before the 
appearance of differentiated pancreatic endocrine cells. Considering the above mentioned 
issue concerning the diversity of PNETs, the major aim of this thesis was to investigate the 
consequences of Men1 disruption specifically in pancreatic endocrine progenitors. Indeed, we 
made the assumption that menin loss in pancreatic endocrine progenitors may trigger a more 
diverse range of PNETs types, as compared to alpha or beta-cell specific Men1 disruption 
models. 
In addition, it is well known that menin has an important role in maintaining the 
identity or in controlling the differentiation of several cell-types. Also, as already 
hypothesized in the literature, PNETs expressing non pancreatic gut hormones (such as 
gastrinomas) may have a stem/progenitor cell of origin. It is, therefore, relevant for the field 
to provide concrete experimental clues to better understand tempo-spatial effects of Men1 
disruption in islet cells, including in particular the progenitors. 
 
2.1.3 STRATEGY 
In order to specifically disrupt the Men1 gene in pancreatic endocrine progenitors, we 
used a novel mouse model based on Cre/Lox system, allowing specific expression of Cre 
recombinase in Ngn3 expressing pancreatic endocrine progenitors. 
 
2.1.4 RESULTS 
The analyses of tumors developed in this model combined with other conditional 
Men1 KO models, led to the interesting observation that endogenous Ngn3-derived pancreatic 
endocrine cells are at the origin of pancreatic gastrin-expressing tumors. The results were 
reported in the manuscript #1 that is currently in the final stage of preparation.  
In parallel, we demonstrated that targeted ablation of Men1 in pancreatic progenitors 
in the mouse led to the development of a tumoral phenotype displaying larger features than 
that described in other Men1 mouse models. The molecular analyses of these tumors allowed 
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to obtain evidence showing that menin deficient insulinomas and glucagonomas display 
differential abnormalities in signaling pathways. These investigations are included in the 
Manuscript #2 that needs further experiments before its submission.  
 
2.1.5 RELEVANCE 
Our results may open the way for the better understanding of the pathophysiology of 
pancreatic gastrinomas. In addition, our data concerning the heterogeneity of 
survival/proliferating pathways among mouse Men1 PNETs, may help in the better 
management of PNETs, if they can be validated in patients.  
 
2.1.6 ADDENDUM 
In addition to the works presented hereafter, during my thesis, I have had the 
opportunity to carry out or participate in several other projects related to the study of islet cell 
biology in normal or pathological conditions. In particular, in an attempt to validate the 
observations acquired in our mouse models, I observed notable distinct expression of PAX4 
and MAFA, both of them being well-known beta-cell markers, in human islets (please refer to 
the publication 1 in the annexes). Since these works are relatively distant to the main theme of 
my thesis, or that my contribution was only minor, I decided not to include the data from 
these works in the Result. Nevertheless, the corresponding published papers can be found in 
the Annexes. 
2.2 MANUSCRIPT #1: INTRA-ISLET PERINATAL GASTRIN-EXPRESSING CELLS SERVE AS 
THE CELL OF ORIGIN OF PANCREATIC GASTRIN-EXPRESSING TUMORS. 
 
2.3 MANUSCRIPT #2: MEN1-DISRUPTION IN NGN3+-PROGENITORS REVEALS ISLET 
TUMOR HETEROGENEITY BOTH IN TUMOR TYPES AND MOLECULAR ALTERATIONS  
 
 
 
 
 
SHORT COMMUNICATION 
 
Intra-islet perinatal gastrin-expressing cells serve as the cell of origin of  
pancreatic gastrin-expressing tumors 
 
AUTHORS: Rémy BONNAVION1,2,3, Rami JAAFAR1,2,3, Doriane RIPOCHE1,2,3, Philippe 
BERTOLINO1,2,3, Chang Xian ZHANG1,2,3 
1Inserm U1052, Lyon, France; 
2CNRS UMR5286, Lyon, France; 
3Université de Lyon, Lyon, F-69008, France; 
GRANT SUPPORT : 
ABBREVIATIONS: NPG, neonatal pancreatic gastrin.  
CORRESPONDING AUTHOR 
Chang Xian Zhang, PhD 
Lyon Cancer Research Center (CRCL) 
Inserm U1052- CNRS 5286 
28 Rue Laennec, 69008 Lyon, France 
Tel : (33)4 69 16 66 63   Fax: (33)4 69 16 66 60   
Email: chang.zhang@lyon.unicancer.fr 
 
 
 
ABSTRACT 
Pancreatic gastrinomas develop either hereditarily in patients with Multiple Endocrine 
Neoplasia type 1 or sporadically, although, intriguingly, no gastrin expressing cells are found 
in normal adult pancreas. Previous studies described the existence of Gastrin expressing cells 
in developing and neonatal mammal pancreases that disappear rapidly after birth. However, 
neither their origin, nor their relation with other islet-cells was clearly defined. By using cell 
lineage-specific gene ablation approach, we provided compelling evidence showing that 
gastrin-expressing cells in the pancreas, found from E12.5 till P7 days, are derived from 
pancreatic Ngn3+-progenitors. More importantly, the majority of them co-express glucagon, 
with 1/25th co-expressing insulin, indicating that they are a temporary subpopulation of both 
alpha and beta cells. Consistent with their ontogeny, Men1-disruption in both Ngn3-
progenitors, and beta and alpha cells led to the development of pancreatic Gastrin-expressing 
tumors. Our data provide insight into histogenesis of MEN1 pancreatic gastrin-expressing 
tumors. 
 
 
 
 
 
INTRODUCTION  
 Gastrinomas are endocrine tumors secreting peptide hormone gastrin, usually 
associated with Zollinger-Ellison syndrome (ZES) characterized by recurrent peptic ulcers 
and gastroesophageal reflux due to gastrin-induced gastric acid hyper-secretion (Zollinger 
1987). Most adult gastrin-producing cells are found within gastric antrum and, to a much 
lesser extent, in the proximal duodenum in mammals. Intriguingly, the majority of primary 
gastrinomas, about 70%, is found located in the duodenal submucosa, the remaining third 
within the pancreas, and only rarely in stomach (Tartaglia et al. 2005). These tumors can 
develop either sporadically or hereditary in patients with Multiple Endocrine Neoplasia type 1 
(MEN1, OMIM131100). MEN1 patients develop multiple tumors in endocrine organs 
principally affecting parathyroids, pituitary and gastroenteropancreatic tract. Gastrinomas are 
the most common functioning tumors of the gastroenteropancreatic axis in MEN1 patients 
(Halfdanarson et al. 2008),  displaying as multiple small lesions in the duodenum and, in rare 
case, in the pancreas. Sporadic gastrinomas are often solitary tumors originating both in the 
duodenum and pancreas, with the etiology of these tumors being poorly understood. 
Interestingly, somatic MEN1 mutations and LOH at MEN1 locus on 11q13 have been detected 
in a substantial proportion, approximately 30%, of both sporadic duodenal and pancreatic 
gastrinomas (Debelenko et al. 1997, Zhuang et al. 1997). In addition, we reported previously 
the occurrence of gastrin expressing pancreatic tumors in about 15% of heterozygous Men1 
mutant mice (Bertolino et al. 2003), further confirming that  MEN1 inactivation plays a 
crucial role in gastrinoma pathogenesis.  
 Deciphering the cell of origin of cancers and tumors is currently a highly active field 
(Blanpain 2013), due to its importance not only for better understanding tumor biology but 
also for tumor treatment with targeted therapy. The histogenesis of gastrinomas is a 
longstanding intriguing question (Passaro et al. 1998) that is still unanswered especially for 
 
 
 
pancreatic gastrinomas. To determine the cells of origin of the latter, being the most 
aggressive form as compared to their duodenal counterparts, is of special interest, since 
gastrin expressing cells are not found in human and rodent adult pancreas. Nevertheless, 
several studies described Gastrin expression, both at mRNA and protein levels, in developing 
and neonatal mammal pancreases, which decreases rapidly after birth (Brand and Fuller 1988, 
Bardram et al. 1990, Gittes et al. 1993, Furukawa et al. 2001). Analyses of the lysates from 
rodent neonatal pancreas established that gastrin was fully processed and active in the 
pancreas at this stage (Bardram et al. 1990). Consistently, Takaishi and colleagues 
demonstrated, by the use of transgenic mice harboring the GFP gene whose expression is 
driven by the mouse gastrin promoter, that GFP expression could be targeted to pancreatic 
cells in embryonic and neonatal pancreases until 2 days after birth (Takaishi et al. 2011). 
Passaro et al. postulated that stem cells formed in ventral pancreatic bud could be the cell 
origin of pancreatic gastrinomas found in the triangle area, based on the clinical features of 
the tumors (Passaro et al. 1998). Indeed, pancreatic endocrine cells derive from the 
differentiation of Ngn3 expressing progenitors, while gastric and duodenal Gastrin-expressing 
cells also derive from endocrine progenitors expressing Ngn3 situating at the corresponding 
tissue (Jenny et al. 2002). This may argue for that pancreatic gastrin-expressing cells may also 
arise from Ngn3+ pancreatic endocrine progenitors. However, the existence of the transient 
pancreatic Gastrin-expressing cells remains so far poorly defined, and the evidence showing 
their cell origin is totally lacking. Altogether, the above mentioned observations prompted us 
to better define gastrin-expressing cells in the pancreas and determine the cells of origin of 
MEN1 pancreatic gastrinomas.  
 
METHODS 
-Animal study approval 
 
 
 
All animal maintenance and experiments were performed in accordance with the animal care 
guidelines of the European Union and French laws and were validated by the local Animal 
Ethic Evaluation Committee (Protocol CLB 2010/016). 
-Mouse studies 
Ngn3tTA knock-in mice were generously provided by Dr Jan.N. Jensen (Wang et al. 2009). 
The tetO-cre mouse line (B6.Cg-Tg(tetO-cre)1Jaw/J MGI:2679524) was purchased from 
Charles River France. Men1F/F-RIPCre+ (βMen1 KO) (Bertolino et al. 2003), Men1F/F-
GluCre+ (αMen1 KO) mice (Lu et al. 2010) and R26eYFP mouse line were already described 
(Srinivas et al. 2001). Ptf1aCre knock-in mice (Kawaguchi et al. 2002), were generously 
provided by Dr Christopher V.E. Wright.  
-Immunohistochemistry and immunofluorescence 
Neonate and adult pancreases were fixed in Neutral buffered formalin (Lilly’s fixative) for 2 
hours at room-temperature or 18 hours at 4°C respectively, and then were embedded in 
paraffin. Serial section of 3μM were prepared, mounted on Superfrost Plus glass slides, and 
subjected to deparaffinization and rehydration. Endogenous peroxydases were quenched in 
3% H2O2 solution for 30 minutes at room-temperature. Heat-induced epitope retrieval was 
performed by immersion in Antigen Unmasking Solution (H-3300, Vector) in a microwave 
oven. After blocking with antibody diluent (DAKO) sections were incubated overnight with a 
primary antibody. For immunofluorescence, stainings were revealed with Cy-3 or Cy-5 
Tyramide amplification kit (PerkinElmer) according to the manufacturer’s instructions with 
prior incubation with appropriate biotinylated secondary antibody, or incubated with 
appropriate Alexa488-555-or-647 coupled secondary antibodies (Life Technologies) for 1 
hour. For immunohistochemistry (IHC), after 1st antibody incubation, biotinylated secondary 
antibody was applied for 1 hour and revealed using ABC-DAB system (Vector Lab). Images 
were captured on a TCS-SP5 confocal microscope (Leica-Microsystems) or a Zeiss 780 
 
 
 
confocal microscope. Cell counting was manually performed with ImageJ cell counter module 
(U. S. National Institutes of Health, Bethesda, Maryland, USA) on multiple channel pictures. 
Graphs and results of counting are represented as mean+S.E.M. 
-Antibodies. 
Antibodies used in the study were, anti-glucagon (G2654, Sigma), anti-insulin (A056401, 
DAKO), anti-somatostatin (sc-7819, Santa Cruz), anti-PP (IMG-3835, Imgenex), anti-Ghrelin 
(Kind Gift from Dr Catherine Tomasetto), anti GFP recognizing eYFP (A-6455, Life 
Technologies), anti-Chromogranin A SP (20085-Immuno, Immuno Star), anti-Gastrin (NCL-
GASp, Novocastra), anti-gastrin antibody (serum 2717, Dr. Jens F. Rehfeld), anti-CCK 
antibody (Dr J. Chayvialle), anti-CCK antibody (detects proCCK, sc-20937, Santa Cruz), 
anti-Menin (A300-105A, A300-106A, Bethyl), anti-Ngn3 (BCBC AntibodyCore AB2774), 
anti-Ki-67 (sc-7846, Santa Cruz), anti-MAFA (ab26405, Abcam), anti-PDX1 (ab47383, 
Abcam), anti-MafB (IHC-00351,Bethyl) and anti-Pax4 antibody (Kind gift from Dr Beatriz 
Sosa-Pineda (Wang et al. 2008)). Donkey secondary antibodies coupled with either Alexa 
488, 555, or 647 were used (Life technologies, Jackson Immunoresearch). For 
Immunohistochemistry or immunofluorescence with TSA, biotinylated secondary antibodies 
from horse or donkey were used (Vector Lab). 
 
RESULTS 
Pancreatic gastrin+ cells represent subpopulations of alpha and beta cells at birth. 
We first tried to better characterize the population of mouse neonatal pancreatic gastrin-
expressing (NPG) cells, since very little is known about this transient cell population. 
Immunofluorescence (IF) analyses with an anti-gastrin antibody demonstrated that scattered 
cells with positive cytoplasmic staining could be detected in the pancreas of mouse neonates 
(Figure1A). We quantified the proportion of these NPG cells relative to the total endocrine 
 
 
 
population at birth by performing double IF staining for gastrin and ChromograninA, a 
marker of endocrine cells (Figure1A). NPG population represented 4.3% of total endocrine 
cell number (Figure 1D) at P0, but became undetectable at P7 (data not shown), consistent 
with what was reported in the literature. Then, we further checked the existence of Gastrin+ 
cells in mouse developing pancreas. Gastrin+ cells were readily detected but rare at E12.5 and 
the population was markedly increased at E14.5 in the wild-type mouse developing pancreas 
(Figure 1F). The related peptide hormone CCK was not expressed at P0 in the pancreas but 
was detectable in the duodenum at birth as was Gastrin (Supplemental Figure 1), supporting 
the specificity of the above detected NGP cells. 
 Furukawa and colleagues observed previously that some gastrin+ cells were also 
positive for insulin staining by restaining method (Furukawa et al, 2001). By double-IF 
staining, indeed, we could detect in rare case cells expressing both gastrin and insulin 
(Figure1B and 1E), accounting for 4.4% ± 1.8 of total NPG cells, while most of NPG cells 
were negative for insulin. Since we observed that most NPG cells localized to the periphery of 
the developing endocrine islets, where most of alpha cells resides in mouse pancreas, we 
sought to determine if these NPG cells could express glucagon. To our surprise, a very high 
proportion, 85.5% ± 7.3, of NPG cells was found to also express glucagon (Figure1C and 1E). 
Thus it appears that NPG cells represent subpopulation of both developing alpha and beta 
cells. We performed double staining of gastrin with other pancreatic hormones and we 
detected that somatostatin+ cells did not express gastrin at P0 (Supplemental Figure 2). In 
order to identify if cells only expressing Gastrin and none of other pancreatic hormones, we 
performed double staining with gastrin antibody and a cocktail of pancreatic hormones 
(insulin, glucagon, somatostatin, PP and ghrelin).  A small proportion (3.3% ± 1.3) of gastrin 
expressing cells was indeed negative for the hormonal cocktail (Figure1E). Analyses of 
transcription factors expressed by NPG cells showed that they displayed high MafB 
 
 
 
expression and some also expressed low-level of Pdx1 at P0 (Figure 1G), whereas the 
expression of neither MafA nor Pax4 was detected. These data argue for the fact that NPG 
cells are immature pancreatic endocrine cells. 
Taken together, our data allowed defining embryonic and neonatal pancreatic gastrin-
expressing cells as the subpopulations of both insulin- and glucagon-expressing cells.  
 
Pancreatic gastrin+ cells originate from pancreatic-progenitors within the developing 
pancreas 
Considering that all alpha and beta cells are derived from Ngn3+ endocrine progenitors, we 
suspected that NPG might also be derived from the differentiation of pancreatic progenitors, 
as virtually all NPG cell expressed either glucagon or insulin. In order to determine if NPG 
derive effectively from pancreatic progenitors, instead of resulting from the migration of gut 
progenitors or gut differentiated cells as hypothesized previously (Passaro et al. 1998), we 
performed lineage tracing experiments with Ptf1aCre+-R26eYFP mice, since Ptf1a-expressing 
cells during development only give rise to pancreatic acinar, ductal and endocrine cells 
(Kawaguchi et al, nature genetics 2002). Using double IF staining, NPG cells were found to 
also express the YFP reporter in Ptf1aCre+-R26eYFP mice (Figure 2A), confirming thus our 
hypothesis. Then, we further checked whether Men1-disruption specifically in pancreatic 
progenitors can target pancreatic Gastrin+ cells.  Using Men1F/F-Ptf1aCre+ mice (PancMen1 
KO), we found that indeed, the expression of menin, the protein encoded by the Men1 gene, 
was lost in a substantial proportion of NPG cells (Figure 2B and E). We next genetically 
traced the progeny of Ngn3+ pancreatic endocrine progenitors using Ngn3wt/tTA-tet-Ocre-
R26eYFP mice. As demonstrated in figure 2C, YFP expression could be detected in NPG cells. 
In addition, as in control neonatal mouse pancreases, gastrin+ cells could be detected in 
pancreas of Men1F/F-Ngn3wt/tTA-tet-Ocre mice (PancEndoMen1 KO) as shown on Figure 2D. 
 
 
 
Analysis of these gastrin+ cells showed that the expression of menin was lost in about 20% of 
NPG cells from PancEndoMen1 KO  mice (Figure 2C and E). Taken together, our results 
indicate that NPG cells are derived from the pan-pancreatic (Ptf1a+) and pancreatic endocrine 
(Ngn3+) progenitors.  
 
Pancreatic gastrinomas development upon Men1-disruption in both Ngn3+ pancreatic 
progenitors and insulin- or glucagon-expressing cells (Figure 3) 
Having identified that NPG cells were derived from pancreatic progenitors, we hypothesized 
that the Ngn3+ endocrine progenitors could be cells of origin of pancreatic gastrinomas. To 
test this hypothesis, we carried out Men1-disruption in Ngn3+ progenitors. Histological 
analyses of pancreas dissected from aged PancEndoMen1 KO mice showed that 12-month-
old mutant mice displayed a high proportion of endocrine lesions. Tumor lesions exhibited a 
complete loss of menin expression as expected (Figure 3), and most of them were positive for 
insulin staining by IHC (the detailed data concerning the analysis of other islet tumors will be 
published elsewhere). Interestingly, by using gastrin antibody, several tumors were positively 
stained (Figure 3), whereas CCK was not detected with two different antibodies in these 
gastrin immunoreactive tumor cells (Data not shown). The frequency of gastrin+ lesions in 
PancEndoMen1 KO mouse model is reported in Table1. Unexpectedly, we found that gastrin+ 
tumors were also insulin+ with a much lower intensity as compared with other insulin+ tumors 
negative for gastrin and other hormones (Figure 3). 
 Since NPG cells co-express insulin or glucagon at birth, we next sought to determine 
whether perinatal Men1-disruption specifically in insulin+ or glucagon+ cells led to gastrin+ 
tumor development. Careful analysis of menin deficient lesions from Men1F/F- RipCre mice 
(βMen1KO) at 12 months of age revealed the occurrence of gastrin+ lesions (Figure 4A). The 
cells expressing gastrin in tumors were also expressing insulin, but not glucagon, as 
 
 
 
demonstrated by triple IF staining (Figure 4B). Three of four analyzed mice developed at least 
1 gastrin+ tumor with a total of 5 gastrin+ lesions on 106 lesions analyzed (see Table 1). 
Molecular characterization of gastrin+ tumors from PancEndoMen1 KO and βMen1 KO 
demonstrated that gastrin expressing tumors were Pdx1+, consistent with a beta cell-gastrin+ 
origin of these tumors. Nevertheless, Ki67 analyses did not revealed any difference in 
proliferation as compared to other insulin expressing tumors (Figure 4D). In parallel, the 
analyses of tumors developed in the mutant mice where the Men1 gene was specifically 
disrupted in glucagon+ cells (αMen1 KO mice) demonstrated a low occurrence of gastrin+ 
lesions in 12-18 month-old αMen1 KO mice (Table 1).  
 
DISCUSSION 
By better defining the pancreatic gastrin-expressing cells, and direct cell-specific 
Men1 ablation, our study provides the evidence showing that both embryonic and neonatal 
gastrin-expressing cells and their progenitors can serve as the cells of origin of pancreatic 
gastrin-producing tumors. The data documented in this study provide insight into our 
knowledge on islet biology and a better understanding of histogenesis of pancreatic 
gastrinomas. 
NPG cells are derived from pancreatic Ngn3+-progenitors and disappear before weaning 
The cells of origin of pancreatic gastrinomas remained so far elusive. Moreover, 
although pancreatic gastrinomas are described in general as monohormonal tumors, clinical 
observations often reported them displaying co-expression of other islet-hormones (Kapran et 
al. 2006). Furthermore, the attempt to generate Men1-deficient mouse gastrinoma has been 
unsuccessful, hampering detailed experimental analyses. The latter situation is at least 
partially due to our poor understanding of gastrin-expressing cells in the pancreas. Albeit the 
reported existence of Gastrin expressing cells, it has been unknown where they are derived 
 
 
 
from and what their relation with other islet cell populations is. In our current study using 
several mouse models combined with different analyses, we found that 1) the neonatal 
pancreatic Gastrin-expressing (NPG) cells are derived from pancreatic Ngn3+-progenitors; 2) 
they can be found at E12.5 till P7 days; 3) the majority of them co-expressing glucagon, and 
the remaining 1/25th co-expressing insulin, with only about 3.3 % Gastrin+ cells without 
coexpressing other islet hormones. Therefore, we defined, for the first time, the NPG cells as 
temporal sub-populations of islet cells, with pancreatic Ngn3+-progenitors as their common 
cell origin.  
During the preparation of the current manuscript, we saw the publication of the work 
by Suissa and colleagues (Suissa et al. 2013). Using different mouse models and cell lineage 
tracing, they detected the existence of embryonic and perinatal gastrin-expressing cell 
population in the pancreas and determined these cells a distinct cell lineage derived from 
pancreatic Ngn3+ progenitors. Indeed, our data are in consistency with the cell origin and the 
appearance, as well as the disappearance of this cell population described by their study. The 
discrepancy between our work and theirs resides in whether they belong to a subpopulation of 
alpha or beta-cells, or rather than an independent lineage. We believe that the finding of the 
presence of only a few Gastrin+ cells without co-expressing other islet hormones at perinatal 
stage, the period, unfortunately, not having been analyzed in Suissa’s study, and of the 
occurrence of Gastrin+ lesions in both αMen1 KO and  KO mice support our 
definition of NGP cells. It remains unknown how these cells evolve, once they no longer 
express Gastrin, and whether they die or they entirely differentiate into alpha or beta-cells. If 
it is the latter case, do they keep on being, even without expressing gastrin, as or potentially as 
a subpopulation respectively in alpha and beta cells. It would be interesting in the future to 
identify the mechanisms, intrinsic or environmental, controlling their formation, relation with 
their counter part and their disappearance. It may be worth mentioning that recent studies 
 
 
 
using human islet cells revealed that there are distinct subpopulations in both alpha and beta 
cells.  
The newly defined NPG cells are reminiscent of another islet-cell lineage, Ghrelin-
expressing cells. The latter also starts to appear at the developmental stage and disappear at 
neonatal period. Moreover, they more frequently co-express glucagon. Although our data do 
not support that they belong to the same subpopulation, their co-existence during the same 
period in the pancreatic islet, more often in alpha-cells, may suggest that both may play some 
relevant biological roles during the neonatal period. Several groups reported that Gastrin-
disruption in the mouse did not result in any overt defect in endocrine pancreas development 
(Boushey et al. 2003, Cowey et al. 2005). Nevertheless, considering the known growth 
promoting of Gastrin in adult tissues and crucial developmental and maturation events in 
islets at the late embryonic and neonatal period, we cannot exclude that Gastrin-expressing 
subpopulation may somehow participate in the regulation of islet cell proliferation or 
maturation.  
 
Men1-disruption in Ngn3+-progenitors and perinatal Gastrin+ cells led to pancreatic 
gastrinoma development  
 
Interestingly, targeting distinct islet cell lineages, including in particular Ngn3+-progenitors, 
alpha and beta cells, triggered gastrinoma development in all used different mouse Men1 
models. This is in total consistency with the ontogeny nature of the above mentioned newly 
defined NPG cells: a Ngn3-derived temporal subpopulation in both alpha- and beta-cell 
lineages. Remarkably, the frequency of gastrinomas found in each of the above mentioned 
models approaches closely to the proportion of gastrin-positive cells found during the late 
embryonic and neonatal period. Interestingly, the similar situation may occur in human, since 
 
 
 
Anlauf and colleagues reported that in two tumor banks comprising a total of 300 NF pNETs, 
3% were stained positive for gastrin (9/300).  
 The Men1 gene is reported being mutated in about from one fourth to one thirds of 
sporadic gastrinomas. Our works using mouse models confirmed more specifically the 
oncosupressive role of the Men1 gene in NPG cells. Obviously, other genetic and epigenetic 
factors may also be involved in the tumorigenesis of these cells. Up to date, there are no 
reports specifically addressing this issue. Recently, using exome sequencing, the study by Jiao 
and colleagues identified several factors, including the MEN1 gene, which were found 
mutated in a substantial proportion of analysed islet tumors (Jiao et al. 2011). The finding of 
the ontogeny nature of NPG cells and their relation with other islet cell lineages led us to 
speculate that the same genes may also play a role in the tumorigenesis of these cells. 
Interestingly, several studies previously highlighted the difference in molecular markers and 
altered gene expression between gastrinomas developed in the pancreatic and those in the 
duodenum, suggesting that distinct molecular mechanisms could be involved in gastrinomas 
developed in these two different but close anatomical sites. Further studies using mouse 
models could be of help to gain more experimental evidence on this issue.    
 
Better ontogeny knowledge of islet cells could be of help for understanding clinical islet 
tumor features 
 
The finding of gastrinomas in Ngn3+-progenitors derived tumors demonstrate that, apparently, 
Men1-disruption in these progenitors does not impair the fate decision made for Gastrin+ 
subpopulations. At the same time, importantly, we noticed that islet Gastrin-expressing 
lesions found in our models displayed only feeble gastrin expression compared with the 
neonatal pancreatic gastrin-expressing cells. Considering the low frequency of their 
 
 
 
occurrence and the lack of pathological lesions in the stomach in mutant mice, 
hypergastrineamia was even not suspected. Consequently, the lesions could be considered 
non-functional. Mensah-Osman and colleagues reported that menin negatively regulates the 
Gastrin gene, by using mainly MEN1 overexpression (Mensah-Osman et al. 2011). Their 
description is consistent with other studies reporting that menin exerts negative regulation of 
other hormones, such as insulin and prolactin. Intriguingly, we noticed that Men1-disruption 
has never been reported to lead to hormone overexpression in every single Men1-deficient 
cell, even mutant mice have in general the increase in blood hormone levels because of 
massively increased number of tumor cells. Taken together, our data suggest that Men1 
inactivation in pancreatic Gastrin-expressing cells should promote their proliferation, whereas 
it does not favor their endocrine functions. However, the role of menin in regulating Gastrin 
gene expression needs to be further clarified. 
Intriguingly, we noticed that the majority of the gastrin+ islet-lesions observed in our 
PancEndoMen1 mutant mice co-express insulin, although 80% of gastrin+ cells co-expressing 
rather glucagon. It is worth mentioning that in this mouse model, although a similar 
proportion of alpha and beta-cells had the Men1 gene disrupted at 1 month of age, only few 
glucagonomas were detected in 12-month-old mutant mice (data not shown). Thus, it is likely 
that Gastrin+Glucagon+ subpopulation may be less sensitive to Men1-disruption, compared 
with Gastrin+Insulin+ subpopulation. Indeed, although rare, several clinical reports described 
the cases where gastrinomas occurred simultaneously or right after an insulinoma 
development (Mizuno et al. 2001). However, we found a substantial proportion of human 
Glucagonomas having Gastrin-expressing cells dispersed within the tumors (data not shown), 
suggesting that islet-tumors co-expressing gastrin and glucagon may be more frequently 
occurring. They could be neglected because of the lack of clinical symptom and of specific 
but sensitive antibodies for Gastrin detection.  
 
 
 
 In conclusion, the current study provides meaningful insights into ontogeny of islet NPG 
cells and histogenesis of pancreatic gastrinomas. Our data pave the way for further dissect the 
molecular mechanisms controlling the development and the tumorigenesis of the pancreatic 
gastrin-expressing cells. They would be also of help for the conception of new strategies for 
diagnosis and treatment of the disease.    
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Table 1 Recapitulation of Gastrin expressing lesions in different models of Men1 disruption 
Model n mouse with gastrin 
lesion/ n total mice  
n Gastrin+ lesion 
/ n Total lesions (%) 
Men1
+/- 1/5 1/17 (5,9%) 
PancEndoMen1 KO 2/4 2/70 (2,9%) 
βMen1 KO 3/4 5/106 (4,7%) 
αMen1 KO 1/6 1/34 (2,9%) 
 
 
 
FIGURE LEGENDS 
Figure 1. Neonatal gastrin expressing cells represent subsets of alpha and beta cells. 
(A) Immunofluorescence (IF) colocalisation of gastrin and ChromograninA in the pancreas of 
newborn wild-type mice. Scale bar = 20μM (B) Graph representing the proportion of gastrin 
expressing cells among endocrine cells at birth. (C) Double IF stainings with antibodies 
directed against Gastrin and Insulin in pancreas of newborn wild-type mice. Scale bars = 
20μM (D) Double immunostaining by immunofluorescence with antibodies against gastrin 
and glucagon in pancreas of newborn wild-type mice. Scale bar = 20μM (E) Graph 
representing the percentage of glucagon, insulin, or any of the pancreatic hormones (cocktail, 
see results part) expressing cells among the gastrin expressing cells at birth in wild-type 
mouse pancreas. (F) Representative IHC stainings for gastrin in wild-type mouse pancreas at 
E12.5 and E14.5. Scale bar = 50μM. (G) Double immunostaining by immunofluorescence 
with antibodies against gastrin and the indicated transcription factor in pancreas of newborn 
wild-type mice. Scale bars = 10μM. 
 
Figure 2. Pancreatic progenitors targeted Men1 disruption results in loss of menin expression 
in NPG cells. (A, C) Representative IF staining for gastrin and eYFP in the neonatal pancreas 
of control R26eYFP mice and Ptf1aCre+-Rosa26eYFP mice (A) or Ngn3wt/tTA-tet-Ocre-R26eYFP 
mice (C). Gastrin expressing cells express the genetic tracer eYFP. Immunofluorescence 
stainings for menin, gastrin and glucagon in the neonatal pancreas of (B) PancMen1 KO. (D) 
PancEndoMen1 KO. Scale bars = 20μM. (E) Graph representing the percentage of gastrin+ 
cells which have lost menin expression at birth in the models analyzed. Scale bars= 20μM 
 
 
 
 
Figure 3. PancEndoMen1 KO mice develop tumors expressing gastrin. IHC stainings for the 
indicated factors in 12-month-old Control and PancEndoMen1 KO mice. Note that the tumor 
located on the right express gastrin whereas the tumor on the left does not. Scale bar = 50μM 
 
Figure 4. βMen1 KO mice develop tumors expressing Gastrin. (A) Immunohistochemical 
detection of gastrin in 12-month-old control and βMen1 KO mice. Gastrin is not expressed in 
normal islets of control mice. Most lesions in βMen1 KO mice do not express gastrin (left), 
whereas subsets of tumors express Gastrin at high (middle) or low levels (right). Scale bars = 
50 μM. (B) Triple IF stainings for insulin, glucagon and gastrin in 12-month-old mice of the 
indicated genotype. Gastrin expressing cells in tumors from βMen1 KO mice also express 
insulin. (C) IF staining for Pdx1, Gastrin and DAPI. The right-handed lesion do not express 
gastrin but express Pdx1 whereas the left-handed lesion express gastrin and Pdx1. (D) Graph 
representing the percentage of Ki67+ tumoral cells in insulin+gastrin- and insulin+gastrin+ 
tumors counted from both 12-month-old βMen1 KO and PancEndoMen1 KO mice. n ≥ 5 
tumors. 
 
Supplemental Figure 1. Representative IHC stainings for gastrin and CCK in wild-type mouse 
pancreas and duodenum at birth. Scale-bar = 50μM 
 
Supplemental Figure 2. Gastrin is not expressed in somatostatin+ cells at P0. Representative 
IF stainings for gastrin and somatostatin at birth in wild-type mouse pancreas. Scale-bar = 
25μM 
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ABSTRACT limit 260 words 
Background & Aims: Pancreatic neuroendocrine tumors (panNETs) are clinically complex 
tumors, with slow evolution but frequent metastasis at the time of diagnosis because of their 
often silent development. The endocrine tumor suppressor MEN1 gene, encoding menin 
protein, is involved in several sporadic panNETs and those in patients with hereditary 
Multiple Endocrine Neoplasia syndrome Type I. To learn more about the complex nature of 
these tumors, especially concerning the occurrence of non-functional and multihormonal 
panNETs, we sought to investigate the consequences of MEN1 inactivation in pancreatic 
progenitors and different derived pancreatic endocrine lineages. 
Methods: We generated and studied new conditional Knock-Out (KO) mouse models where 
the Men1 gene was disrupted in all pancreatic endocrine cells by targeting the pancreatic 
endocrine progenitors expressing Ngn3 and the pan-pancreatic progenitors expressing Ptf1a. 
Results: Our results demonstrated that the mutant mice having Men1-deficient Ngn3+-
progenitors resulted in differential cell proliferation alterations in different pancreatic 
endocrine cells. Importantly, Men1-disruption in either pancreatic endocrine or pan-pancreatic 
progenitors displayed tumors with impaired differentiation features. Moreover, distinct 
signaling pathways, including in particular ERK, were activated in a cell lineage-specific way 
among different islet cell tumors. 
Conclusions: Targeting the Men1 gene in pancreatic progenitors led to the development of 
heterogeneous islet tumors both at cellular and molecular levels. The data obtained from fine 
analyses of the models may afford useful insight into better understanding of tumor 
heterogeneity and finding new strategies of target therapy for islet tumors. 
   
Keywords: neuroendocrine tumors, MEN, menin, proliferation, islet cells, ERK 
 
 
 
 
INTRODUCTION 
Pancreatic neuroendocrine tumors (panNETs) are seemingly simple but clinically complex 
tumors, with slow evolution but frequent metastasis at the time of diagnosis, because of their 
often silent development. The endocrine tumor suppressor MEN1 gene, encoding menin 
protein, is involved in several sporadic panNETs and those in patients with hereditary 
Multiple Endocrine Neoplasia syndrome Type I bearing a germinal mutation on one allele of 
the gene. The second MEN1 allele is almost always found inactivated by LOH in the tumors. 
In MEN1 patients with panNETs, most frequent tumors are so-called non-functional, meaning 
that they are not characterized by the clinical symptoms due to hormone hypersecretion, even 
though they often produce pancreatic polypeptide (PP) or glucagon. Insulinomas represent the 
second most frequent panNETs in MEN1 patients. On the contrary, it has been reported that 
the systematic analysis of whole pancreas from MEN1 patients showed characteristic 
microadenomatosis, with a high frequency of glucagon expressing and multi-hormonal lesions 
(Anlauf, Schlenger et al. 2006). The cell and molecular bases of islet heterogeneity leading to 
non-functional and multi-hormonal tumor development are largely unknown, except cell 
transdifferentiation demonstrated in the context of alpha-cell specific Men1-inactivation (Lu, 
Herrera et al. 2010). The latter may explain at least partially some of the feature of these 
tumors.  
Pancreatic islet-cells biology is a widely investigated field nowadays, with most studies 
dedicated to the understanding of beta cell functions and pathology. In contrast, little is 
known about the biology of alpha, delta and PP cells. This is also true for MEN1-related 
panNETs affecting the latter cell-types, because the majority of basic research studies were 
devoted to the study of insulinoma biology and mechanisms involved, using mouse model 
with disruption of the Men1 gene specifically in beta cells. The only exception would be 
heterozygous Men1 knock-out (KO) model engineered by several laboratories that develops a 
 
 
 
tumor spectrum mimicking the human disease (Crabtree, Scacheri et al. 2001, Bertolino, Tong 
et al. 2003, Loffler, Biondi et al. 2007). These mice develop whole range of panNETs 
including both insulinomas and glucagonomas. However, since panNETs develop randomly 
both in cell-type and timing in these mice, it renders this model difficult to work with, 
especially for dissecting the early event involved in tumor development following menin loss 
of expression.  
To learn more about the complex nature of panNETs, especially concerning the occurrence of 
non-functional and multihormonal panNETs, it would be interesting to investigate the 
consequences of MEN1 inactivation in pancreatic progenitors, combined with the comparison 
among different pancreatic endocrine lineages. Thus, we decided to generate and study new 
conditional Knock-Out (KO) mouse model where the Men1 gene was disrupted in all 
pancreatic endocrine cells by targeting either the pan-pancreatic progenitors expressing Ptf1a 
or the pancreatic endocrine progenitors expressing Ngn3. These models allowed us to 
specifically study the effects of menin loss in pancreatic progenitors affecting simultaneously 
all pancreatic endocrine cells. Our results demonstrated that the mutant mice having Men1-
deficient pancreatic progenitors displayed heterogeneous tumor phenotypes including islet 
tumors with dedifferentiation features. Our data also suggest a differential role of menin in 
different pancreatic endocrine cells in terms of cell proliferation and signaling pathways 
activated upon menin loss. 
METHODS 
-Animal study approval 
All animal maintenance and experiments were performed in accordance with the animal care 
guidelines of the European Union and French laws and were validated by the local Animal 
Ethic Evaluation Committee (Protocol CLB 2010/016). 
 
 
 
-Mouse studies 
Men1F/F-RIPCre+ (βMen1 KO) mice {Bertolino, 2003 #45} and Men1F/F-GluCre+ 
(αMen1 KO) mice were already described (Lu, Herrera et al. 2010).  Ngn3wt/tTA knock-in mice 
were generously provided by Dr Jan.N Jensen (Wang, Jensen et al. 2009). The tetO-cre 
mouse line (B6.Cg-Tg(tetO-cre)1Jaw/J MGI:2679524) was purchased from Charles River 
France.  These two last mouse lines were crossed with Men1F/F mice to generate Men1F/F-
Ngn3tTA-tetO-cre+ (PancEndoMen1 KO) mice. For lineage tracing, Rosa26eYFP mice 
{Srinivas, 2001 #44}, were crossed with previous mouse lines. Control mice used when 
comparing with PancEndoMen1 KO mice were comprised of age-matched Men1F/F-
Ngn3wt/tTA, Men1+/+-Ngn3wt/tTA, and Men1+/+-Ngn3wt/tTA-tet-Ocre mice. Ptf1aCre knock-in 
mice were generously provided by Dr Christopher V.E. Wright. All mouse lines were 
maintained in a mixed genetic background. 
-Immunohistochemistry and immunofluorescence 
Neonate and adult pancreases were fixed in Neutral buffered formalin (Lilly’s fixative) for 2 
hours at room-temperature or 18 hours at 4°C respectively, and then were embedded in 
paraffin. Serial section of 3μM were prepared, mounted on Superfrost Plus glass slides, and 
subjected to deparaffinization and rehydration. Endogenous peroxydases were quenched in 
3% H2O2 solution for 30 minutes at room-temperature. Heat-induced epitope retrieval was 
performed by immersion in Antigen Unmasking Solution (H-3300, Vector) in a microwave 
oven. After blocking with antibody diluent (DAKO) sections were incubated overnight with a 
primary antibody. For immunofluorescence, stainings were revealed with Cy-3 or Cy-5 
Tyramide amplification kit (PerkinElmer) according to the manufacturer’s instructions with 
prior incubation with appropriate biotinylated secondary antibody, or incubated with 
appropriate Alexa488-555-or-647 coupled secondary antibodies (Life Technologies) for 1 
 
 
 
hour. For immunohistochemistry (IHC), after 1st antibody incubation, biotinylated secondary 
antibody was applied for 1 hour and revealed using ABC-DAB system (Vector Lab). 
-Antibodies. 
Antibodies used in the study were, anti-glucagon (G2654, Sigma), anti-insulin 
(A056401, DAKO), anti-somatostatin (sc-7819, Santa Cruz), anti GFP recognizing eYFP (A-
6455, Life Technologies), anti-Menin (A300-105A, A300-106A, Bethyl), anti-Ki-67 (sc-
7846, Santa Cruz), and anti Erk1/2 phosphorylated on Thr202/Tyr204 (#4370, Cell 
Signaling). Donkey secondary antibodies coupled with either Alexa 488, 555, or 647 were 
used (Life technologies, Jackson Immunoresearch). For Immunohistochemistry or 
immunofluorescence with TSA, biotinylated secondary antibodies from horse or donkey were 
used (Vector Lab). 
-Immunofluorescence analyses 
Images were captured on a TCS-SP5 confocal microscope (Leica-Microsystems) or a 
Zeiss 780 confocal microscope. Cell counting was manually performed with ImageJ cell 
counter module (U. S. National Institutes of Health, Bethesda, Maryland, USA) on multiple 
channel pictures. Graphs and results of counting are represented as mean+S.E.M. 
-Statistical analyses 
Unpaired two-tailed Student’s t test was applied to compare means. 
 
RESULTS 
Targeted Men1-disruption in Ngn3+-pancreatic endocrine progenitors. 
The early effects of Men1-disruption in pancreatic endocrine cells has been only studied in 
beta cells. In order to study the effect of menin loss in Ngn3+-progenitors and simultaneously 
 
 
 
in all pancreatic endocrine cell-types, we used a mouse model allowing targeted Men1-
disruption in Ngn3+ pancreatic endocrine progenitors. To generate this model, we crossed 
Men1F/F mice with mice carrying a tetO-cre transgene and a recombined Ngn3 allele where 
the endogenous Ngn3 coding sequence was replaced by the tTA coding sequence (Figure1A).  
Men1F/F-Ngn3wt/tTA-tetO-cre+ mice will be thereafter denominated as PancEndoMen1 KO 
mice. We first ensured the specificity of the model by crossing Ngn3wt/tTA-tetO-cre+ mice with 
Rosa26eYFP mice allowing genetic lineage tracing of Cre recombinase activity. We looked at 
the expression pattern of eYFP at birth in the progeny of Ngn3 cells by immunofluorescence 
(IF) using an antibody directed against eYFp protein. As demonstrated in Figure 1B, eYFP 
was detected in islet like structures at birth, and colocalized with cells expressing either 
insulin, glucagon, or somatostatin. At birth, 25.9%±4.4 of insulin+ cells, 20.0%±6.0 of 
glucagon+ cells and 19.8%±4.3 of somatostatin+ cells expressed eYFP (Figure1D). We next 
verified that the transgenic system allowed disrupting specifically the Men1 gene in the 
pancreatic endocrine cells. To this end, menin expression was studied along with different 
pancreatic hormones in the pancreases of PancEndoMen1 KO neonates. As shown in Figure 
1C, menin expression was found lost in subsets of alpha, beta and delta cells. The 
quantifications revealed that 15.8%±3.3, 11.2%±3.0 and 13.2%±4.7 of insulin+, glucagon+ 
and somatostatin+ respectively had lost menin expression at birth (Figure 1E). Thus, the 
PancEndoMen1 KO model allowed Men1-disruption in pancreatic endocrine cells with 
detectable menin loss at least at P0. We observed that the percentage of menin-negative cells 
in different pancreatic endocrine lineages is noticeably low compared with the percentage of 
eYFP-positive cells in the same cell populations (compare figure 1D and 1E).   
 After birth, in contrast to during embryogenesis, the formation of new endocrine cells 
from pancreatic endocrine progenitors Ngn3+ no longer contributes significantly to islet mass, 
consistent with a rapid decrease in the number of Ngn3 expressing cells in the pancreas after 
 
 
 
birth. However, pancreatic endocrine cells undergo a massive wave of postnatal proliferation, 
in order to generate a sufficient pool of endocrine cells necessary to the function of the 
endocrine pancreas in adult. Interestingly, at 6 weeks after birth, the proportion of menin 
deficient islet cells increased as compared to P0 (Figure2). 67.4%±3.2 beta cells, 43%±2.1 
alpha cells and 33.4±3.0 somatostatin cells displayed an absence of menin expression in 6- 
week-old PancEndoMen1 KO mice (Figure 2B). Indeed, menin negative cell population over 
total islet cells increased by 4.2 times among beta cells, nearly 4 folds among alpha cells and 
by 2.5 fold among delta cells as compare to P0. The data demonstrated that in the absence of 
menin, the three major endocrine cell populations are able to expand during the period from 
P0 to 6 weeks after birth. 
Pancreatic endocrine cell proliferation in the absence of menin. 
Considering that neogenesis is not significant after birth, and that all endocrine cells of a 
given subtype (eg, beta (Brennand, Huangfu et al. 2007, Teta, Rankin et al. 2007), alpha or 
delta) are supposed to equally undergo cell proliferation to expand the endocrine cell mass 
after birth, the increased proportion of menin negative cells at 6 weeks of age suggests that 
menin deficient pancreatic endocrine cells may be already prone to a higher proliferation rate 
than their menin+ counterpart. Thus, we assessed the proliferation rate of menin+ and menin- 
endocrine cells at P0 and at 6 weeks after birth, by performing co-staining of hormones, 
menin and Ki67, a proliferation marker. At P0, 9.4%±2.0 and 17.4%±4.9 of menin+ and 
menin- beta cells respectively were stained for Ki67 (Figure 3 D). This twice increase was 
nevertheless not significant due to high heterogeneity between the mice. The proliferation of 
somatostatin+ cells at birth was null in most mice analyzed both in menin+ and menin- cells. 
In contrast, menin- alpha cells displayed a significant three-fold increased in Ki67+ as 
compared to menin+ alpha cells (Figure 3D; 18.1%±3.5 vs 5.8%±0.3). 
 
 
 
At 6 weeks of age, however, the percentage of proliferative alpha and beta cells decreased in 
both menin+ and menin- cell-populations as compared to P0 (Figure 3A, B, and E), consistent 
with the end of  postnatal proliferation. We noticed that control mice displayed the same 
percentage of Ki67+ staining between the alpha, beta and delta cell populations. Interestingly, 
menin- beta cells sustained a 4-fold higher proliferative rate as compared to menin+ cells in 
the same mice and to control mice in which menin expression is not altered (Figure 3A and 
E). As at birth, glucagon+menin- cells displayed a statistically significantly higher percentage 
of Ki67+cells (3 fold) as compared to their menin+ counterparts in PancEndoMen1 KO mice. 
However, there was no significant change when comparing with the percentage of alpha cells 
Ki67+ in control mice (Figure 3B and 3D). In addition, mean percentage of proliferative alpha 
cells in the control mice (1.9%±0.4) was identical to that of combined menin+ and menin- 
cells in PancEndo Men1 KO mice (1.5%±0.6). Similarly, despite a tendency of menin 
deficient delta cell to be more proliferative, there was no significant change in delta cell 
proliferation in the absence of menin as compared to menin+ delta cells from PancEndoMen1 
KO mice or delta cells in control mice.  
Pancreatic endocrine tumor lesions in aged PancEndoMen1 KO mice. 
We next analyzed the pancreas of 12-month-old PancEndo Men1 KO and control mice for 
tumor development. Control mice did not develop any islet lesions and staining for all four 
major hormones could be observed in islet by IHC as shown on Figure 4. On the contrary, 
PancEndoMen1 KO mice developed numerous islet hyperplasia and tumor lesions that were 
negative for menin staining (see Figure 4 and Table 1). Of seven mice analyzed, all displayed 
islet adenomas. Consistent with the high percentage of menin deficient beta cells at 1 month 
and their increased proliferative rate as compared to control, most lesions in PancEndoMen1 
KO mice were insulin+ (Table 1). Indeed, 78% of hyperplastic/dysplastic islets were insulin+, 
whereas 15% were glucagon+, 5% somatosatin+ and only rare PP hyperplasia were observed 
 
 
 
in PancEndo Men1 KO mice pancreas at 12 months. Most adenomas were insulinomas and 
occurred in all mutant mice analyzed. Of 27 adenomas observed, only 3 were alpha cell 
tumors, and no mice developed delta or PP cell tumor. As shown in Figure 4, alpha cell 
lesions were often associated with beta cell lesions and thus formed mixed tumors.  
Importantly, it is noted that beta cell lesions showed a strongly reduced insulin staining as 
compared to normal islet (Figure 4), consistent with previous reports (Bertolino, Tong et al. 
2003). In addition, by 13 months, PancEndoMen1 KO mice had insulin expressing tumors 
displaying a strong heterogeneous loss of insulin staining that was not positive for the other 
hormone tested (Figure 5A). Consistently, when observing early lesions developed by 4.5 
month-old mutant micewith specific Men1-disruption in pancreatic Ptf1a+ progenitors 
(PancMen1 KO mice), we could observe that insulin expression was markedly decreased as 
compared to their control littermates (Figure 5B). 
Differential activation of proliferative pathways in postnatal menin deficient islet cells. 
Postnatal islet cell proliferation is regulated by several pathways, including ERK signaling 
pathway (Chen, Gu et al. 2011). It was shown that ERK is essential for beta cell mass 
expansion after birth and that activation of ERK dramatically decrease after weaning and is 
mostly absent in adult islets. In addition, it has been described that menin represses ERK 
activation and activity in non-endocrine cell lines in vitro (Gallo, Cuozzo et al. 2002, Gao, 
Feng et al. 2011). Thus, we sought to determine if mechanisms controlling postnatal islet 
mass expansion could be reactivated in mouse Men1 islet-tumors in our PancEndoMen1 KO 
mice. To this end, we examined the activation of ERK signaling using antibodies directed 
against phosphorylated Thr202/Tyr204 ERK1/2 which reflect ERK activation. In control 
mice, most islets did not show any IF staining for phospho-ERK1/2, as shown on Figure 5. 
Interestingly, the majority of beta cell hyperplasia/dysplasia and beta cell tumors did not show 
 
 
 
obvious ERK activation (Figure 5), except that some insulinomas displayed focally strong 
phosphor-ERK staining, always in restricted areas in periphery of tumors. Remarkably, alpha 
cell lesions consistently showed activation of ERK that could be detected both in the 
cytoplasm and nucleus (Figure 5). Interestingly, by analyzing pancreas from βMen1 KO mice 
of the same age (12 months), tumoral cells never showed ERK activation, the latter being 
restricted to endothelial cells (Figure 5). We next sought to confirm if ERK pathway was 
already expressed in early alpha cell lesions that develop in αMen1 KO mice. As shown on 
Figure 6, phospho-ERK was not detected in islets from 3.5 months old control mice, 
consistent with the previous report from Chen and colleagues. In contrast, alpha cells from 
3.5-month-old αMen1 KO islets displayed strong activation of ERK in the absence of menin 
(see Figure 6). Interestingly, some alpha cells that had not yet loss menin expression 
occasionally expressed phospho-ERK. 
DISCUSSION 
By targeting the Men1 gene in Ngn3+-progenitors, we were able to study the biological 
consequences of Men1-disruption both in pancreatic endocrine progenitors and in all derived 
endocrine lineages. Our data demonstrate that Men1-disruption in Ngn3+-progenitors resulted 
in the development of a range of islet tumors having various features, recapitulating complex 
clinical tumor heterogeneity of panNETs. Importantly, different islet tumors displayed distinct 
altered molecular signaling pathways, which could be the molecular basis of tumor 
heterogeneity.   
Men1-disruption in Ngn3+-progenitors gives rise to the development of a range of islet 
tumors  
PancEndoMen1 KO mice develop several types of pancreatic endocrine tumors, with the 
majority being insulinomas. We found that adenomas producing glucagon were quite rare as 
 
 
 
compared to beta cell adenomas, whereas substantial alpha cell hyperplasias could be 
detected, a feature that has been described in pancreas from MEN1 patients (Perren, Anlauf et 
al. 2007). The difference in the proportion between alpha and beta cells in the pancreas and 
different proliferative rate may explain the low number of alpha cell tumors as compared to 
beta cell tumors. However, we described that alpha cell transdifferentiation upon menin loss 
can participate in the development of insulin expressing tumors in mice when alpha-cells are 
specifically targeted (Lu, Herrera et al. 2010). Such a mechanism may also occur in the 
present PancEndo Men1 KO model, and may perhaps not be restricted to alpha cell, and 
potentially affect delta cells. Further analyses, including in particular co-immunostainings for 
somatostatin and insulin or glucagon and insulin, should be performed, in order to better 
appreciate the importance of such mechanisms in islet tumorigenesis in different contexts.  
 The most marked different tumor features observed in PancEndo Men1 KO mice is 
the low and non-homogenous insulin-expression pattern of islet tumors, suggesting altered 
differentiation status of islet tumors. The mechanism involved has not been addressed in the 
current study. We recently demonstrated that MafB, normally absent from adult beta cells but 
necessary for beta cell differentiation during embryogenesis, is reexpressed in early Men1-
deficient beta cells in Men1F/F-RipCre+ (βMen1 KO) mice (Lu, Hamze et al. 2012). Thus, it 
seems that menin loss in pancreatic progenitors may possibly affect pancreatic endocrine cell 
differentiation, in particular the maturation of beta cells, due to altered expression of 
transcription factors involved in the differentiation and/or maturation of beta cells, such as 
MafB and or MafA. It is still not known if insulin down regulation in tumors is a direct 
consequence of Men1 disruption in pancreatic endocrine progenitors or if it is indirectly due 
to tumor progression. More early detailed analysis and comparison with the βMen1 KO mice 
may be helpful to decipher the exact role of menin in regulating the maintenance of the 
differentiation status of beta cells. 
 
 
 
 We did not observe tumors with more than 2 to 5% somatostatin expressing cells, 
which is in accordance with the rare occurrence of somatostatinomas or non functional tumors 
producing somatostatin in pancreas of MEN1 patients. This phenomenon may possibly be 
explained by a low proliferation capacity of delta cells upon menin loss. We noticed that this 
is not in accordance with what has been reported by a recent paper, describing which 
demonstrated that scarce delta cells in tumors developed in heterozygous Men1+/- mice have a 
proliferative rate similar to tumoral beta cells within the same mutant mice (Walls, Reed et al. 
2012).  
Men1-disruption in Ngn3+-progenitors results in differential effects in postnatal cell 
proliferation among islets cell lineages   
Only limited studies addressed the early effects of Men1 disruption in pancreatic 
endocrine cells. It has been demonstrated that Men1 disruption in adult islet cells acutely 
enhance their proliferation at least 7 days after conditional ablation (Schnepp, Chen et al. 
2006, Yang, Gurung et al. 2010). However, we still do not know what the consequences of an 
early loss of Men1 during islet cell development would be. Our study demonstrates that 
pancreatic Ngn3+-progenitors are sensitive to tumor development upon menin loss. We 
studied more specifically the early effects of Men1-disruption by analyzing cell proliferation 
at birth during final maturation of islet cells and at the beginning of the normal massive wave 
of islet cell proliferation. Consistent with previous report (Zhang, Feng et al. 2006), we 
observed that nearly 9% of insulin+ menin+ cells stained for Ki67. However, in menin 
deficient beta cells, we only observed a non-statistically significant twice increase in Ki67 
staining as compared to their menin+ counterpart. The absence of a significant increase in 
menin-deficient beta cell proliferation at birth could be explained by a differential role of 
menin in beta cells during development, postnatal period and in adult. Such differential role 
has been documented for other factors such as p27. Indeed, p27 null mice display a strong 
 
 
 
proliferation of endocrine cells during development before birth, whereas p27 loss does not 
affect post-natal proliferation (Georgia and Bhushan 2006). Men1 disruption thus, may not 
affect proliferation of beta cells during postnatal period, since proliferative mechanisms 
normally repressed by menin may have already been activated during this period.  
 In parallel, the fact that only alpha cells are more proliferative in the absence of menin 
may also be explained by the model used. Indeed, it has been shown that differentiation of the 
different pancreatic endocrine cell-types from Ngn3 progenitors relies on different sequential 
competence windows during development (Johansson, Dursun et al. 2007). Ngn3 expressing 
progenitors first give rise to alpha cells, whereas most beta cells develop later during 
development with delta cells being the last lineage appearing from Ngn3 progenitors during 
development. Thus, considering that after recombination of the Men1 locus, the wild-type 
Men1 mRNA and protein have to be completely degraded in order to affect the cell, alpha 
cells menin deficient are more likely to have lost menin expression for a longer time than 
other cell-types. In this case, the effect on the proliferation of beta and delta cells may appear 
later after P0. More precise conclusion may be drawn by analyzing mice older such as P7 or 
P15 or by using other models allowing earlier and more efficient Men1 disruption in 
pancreatic progenitors using Ptf1a-Cre or Pdx1-Cre mice. 
 In contrast to what seen at P0, alpha and beta cells from both control and mutant 6-
weeks-old aged mice had a strong decreased proliferation, whereas delta cell proliferation was 
increased (compare Figure 3D and 3E).  It has to be noted that at this age, the three endocrine 
cell types analyzed (alpha beta and delta) had the same rate of proliferation in control mice, 
indicating that they have the same proliferative potential at least at 6 weeks. The fact that total 
alpha cell proliferation from PancEndo Men1 KO mice (comprising menin deficient and 
menin expressing cells) is similar to that of control mice suggest that the mechanism of 
negative control may be activated to restrict the expansion of alpha cell mass. However, 
 
 
 
menin deficient alpha cells, significantly more proliferative than menin-expressing alpha-cells 
in the same mice showed that the former is capable of escaping such a negative control, 
leading to alpha cell lesions in old mice.  
The development of pancreatic endocrine cells is potentially impaired by Men1-
disruption in Ngn3-progenitors 
Our data showed that the proportion of menin-negative cells within each islet cell lineage is 
somehow low in the mutant mice at P0, when compared with the targeting efficiency shown 
by eYFP expression. Markedly, this proportion increased 2.5 – 4 folds at 1 month of age. 
Considering the increased cell proliferation rate observed in menin-deficient cells at P0, 
which is the most prominent in alpha-cells (3-fold increase), one would expect an increased, 
or at least equal proportion of menin-negative islet-cells when compared with targeting 
efficiency. The low proportion of menin-negative islet-cells seen in the mutant mice may 
reflect, therefore, a growth disadvantage of menin-deficient cells during the development. 
Indeed, we have previously reported that Men1-null cells had developmental defects. 
Although the current work addressed the effects of Men1-disruption in the rather later stages 
of development, it provides novel clues suggesting that menin is potentially required for the 
normal development of pancreatic endocrine cells from Ngn3-progenitors. However, much 
more detailed analysis of embryonic phenotype of PancEndoMen1 KO mice are required to 
exactly determine if menin loss could trigger differentiation defect from Ngn3+ progenitors or 
apoptosis, or decreased proliferation of differentiating endocrine cells.  
Islet cell lineage-specific alteration of cell signaling pathways upon Men1 inactivation  
 Many studies suggest that menin possesses various molecular and biological functions, 
including in particular its interaction with several transcriptional factors and regulators 
indicating its role in gene expression regulation. As a tumor suppressor, menin regulates the 
 
 
 
proliferation of endocrine cells both in vitro and in vivo. However, the specific pathways and 
mechanism deregulated in affected cells in the absence of menin were mainly studied in beta 
cells, and remain poorly understood. Our results uncovered for the first time the activation of 
ERK1/2 in Men1-deficient alpha cells, whereas such activation did not occur in a model 
targeting specifically the Men1 gene in beta cells (βMen1 KO). Interestingly, in the PancEndo 
Men1 KO model, even though most of insulin expressing tumors did not show ERK 
activation, both alpha-cell lesions and some clusters of insulin+ cells within beta cell tumors 
displayed increased phosphor-ERK1/2. The latter was also observed in some beta cell tumors 
from heterozygous Men1+/- mice (data not shown). Such a differential activation between 
alpha cell and beta cell tumors suggest that distinctt mechanism of proliferation/survival may 
be involved in the tumor development among different cell-types. It is still not known whether 
beta cell tumors with focal ERK activation are due to the earlier loss of menin during beta cell 
differentiation as compared to the betaMen1 KO model. Since alpha cell neoplastic lesions 
displayed ERK activation in alphaMen1 KO model, one could ask whether beta cell tumors 
displaying ERK activation may represent tumors that developed from transdifferentiation of 
alpha cells into beta cells. Further work is needed to clarify the issue.  
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Table 1. Tumoral lesions developed in PancEndoMen1 KO mice. 
 Hyperplasia/Dysplasia Adenoma ADK TOTAL 
Insulin 160 (7/7) 24(7/7) 1(1/7) 185 
Glucagon 32(7/7) 3 (2/7) 0 (0/7) 35 
Somatostatin 11(3/7) 0 (0/7) 0 (0/7) 11 
PP 3(1/7) 0 (0/7) 0 (0/7) 3 
TOTAL 206 27 1 234 
(Numbers in brackets represent the number of mice with lesions/total mice analyzed.  
ADK: adenocarcinoma) 
 
 
 
FIGURE LEGENDS 
Figure 1. Targeted disruption of the Men1 gene in pancreatic endocrine progenitors. (A) 
Schematic representation of the Men1F/F-Ngn3wt/tTA-tetO-cre model allowing recombination of 
the Men1 floxed alleles specifically in Ngn3 expressing cells. (B) Representative images of IF 
analysis of eYFP expression for lineage tracing of Cre activity in wild-type Men1 Ngn3wt/tTA-
tetO-cre-R26eYFP mice. Pancreas of neonate (P0) mice were analyzed. Triple IF were 
performed to analysis the colocalisation of eYFP and DAPI with either insulin, glucagon or 
somatostatin. Scale bars 25μM. (C) Representative images of IF analysis of menin expression 
in hormone expressing cells in the pancreas of control and PancEndoMen1 KO neonate at 
birth. Scale bars 25μM. (D) Graph representing the average proportion ±S.E.M of eYFP 
expressing cells in the indicated hormone expressing cells from wild-type Men1 Ngn3wt/tTA-
tetO-cre-R26eYFP mice. n ≥ 3 mice. (E) Graph representing the average proportion ±S.E.M of 
menin loss in the indicated hormone expressing cells in the pancreas from PancEndoMen1 
KO at P0. n ≥ 3 mice. 
Figure 2. Increased proportion of menin deficient pancreatic endocrine cells in 6 week-old 
PancEndoMen1 KO mice. (A) Representative images of IF analysis of menin expression in 
insulin and somatostatin expressing cells in the pancreas of 6-week-old control and 
PancEndoMen1 KO mice. Middle and left panels represent a magnified view of the 
corresponding insets. (B) Representative images of IF analysis of menin expression in 
glucagon expressing cells in the pancreas of 6-week-old control and PancEndoMen1 KO 
mice. Middle and left images represent a magnified view of the corresponding insets. (C) 
Graph representing the average proportion ±S.E.M of menin loss in the indicate hormone 
expressing cells in the pancreas from 6 week-old PancEndoMen1 KO mice. n ≥ 3 mice. 
 
 
 
Figure 3. Differential proliferation triggered by menin loss in alpha, beta and delta cells at 
birth and young adults. Representative images of IF analysis of menin and Ki67 with insulin 
(A), glucagon (B), or somatostatin (C), expression in the pancreas of 6-week-old control and 
PancEndoMen1 KO mice. The three right hand panels images are a magnified view of the 
corresponding inset. Scale bars 25μM. (D) Graph representing the average proportion ±S.E.M 
of Ki67+ cells among the indicated hormone+ menin+ or hormone+ menin- cell populations in 
the pancreas from PancEndoMen1 KO at P0. n ≥ 3 mice. *, p≤0.05 using unpaired Student’s t 
test. (E) Graph representing the average proportion ±S.E.M of Ki67+ cells among the 
indicated hormone+ cell populations in controls and Ki67+ cells among the indicated 
hormone+ menin+ or hormone+ menin- cell populations in the pancreas from PancEndoMen1 
KO at 6 weeks of age. n ≥ 3 mice. *, p≤0.05; **, p≤0.01 using unpaired Student’s t test. 
Figure 4. Pancreatic endocrine lesions in aged PancEndoMen1 KO mice. Representative IHC 
stainings for menin, insulin, glucagon, somatostatin and PP in the pancreas of 12-month-old 
control or PancEndoMen1 KO mice. For PancEndoMen1 KO mice, several different lesions 
are displayed.  
Figure 5. (A) Representative IHC stainings for menin, insulin, and glucagon in the pancreas of 
13-month-old control or PancEndoMen1 KO mice. Inserted panels are a magnified view of 
insulin stainings showing decreased insulin expression in subsets of tumoral cells in 
PancEndoMen1 KO mice. (B) Representative IHC stainings for menin, insulin, and glucagon 
in the pancreas of 4.5month-old control or PancMen1 KO mice. Inserted panels are a 
magnified view of menin stainings. Scale bars 50μM. 
Figure 6. Differential ERK activation in menin deficient tumoral lesions. Representative IF 
staining for glucagon, insulin and phospho-ERK1/2 in control (A), mixte alpha-beta cells 
tumor (B), and insulinoma (C), from 12-month-old PancEndo Men1 KO mice, or insulinoma 
 
 
 
from 12-month-old βMen1 KO mice (D). Scale bars 25μM. (E) Representative IF staining for 
menin, glucagon, and phospho-ERK1/2 in pancreas from 3.5-month-old control or αMen1 KO 
mice. Lower panels are the magnified view of the corresponding insets. pERK = ERK 
phosphorylated. 
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3 DISCUSSION 
3.1 PANCREATIC GASTRIN EXPRESSING CELLS: WHERE DO THEY COME AND WHERE 
THEY MAY GO? 
3.1.1 GASTRIN EXPRESSION IN THE MOUSE DEVELOPING PANCREAS 
During this thesis, we confirmed and further detailed the presence of gastrin 
expressing cells in the developing and neonate mouse pancreas, their existence having been 
already described in several mammalian species including human. We demonstrated that 
gastrin expressing cells are in fact subsets of both glucagon and insulin producing cells. This 
observation is reminiscent of what has been described for ghrelin expressing cells that mostly 
colocalize with glucagon expressing cells during development and postnatal period. However, 
it has also been demonstrated that a unique endocrine population called Epsilon cells exist in 
the pancreas, and these cells do not express common pancreatic endocrine hormones. Our 
current study did not allow determining whether mono-hormonal gastrin-expressing cells also 
exist in developing and neonate, besides the double gastrin/glucagon or gastrin/insulin 
expressing cell populations. This could be achieved by performing colocalization experiment 
with anti-gastrin antibodies and a cocktail of anti-4 majors pancreatic hormones (eg:insulin, 
glucagon, somatostatin, and PP).  
Furthermore, the Epsilon cell population and ghrelin expression in alpha cells 
disappear shortly after birth in the mouse, just like what we and other demonstrated for 
gastrin. However, in human, it has been reported that ghrelin could keep on being expressed 
in alpha cells in adult pancreas (Raghay et al. 2013), even though different results were 
obtained in a previous study (Andralojc et al. 2009). The data from the literature and our lab 
failed to identify gastrin expression in normal post-weaning or adult human pancreas, though 
we cannot absolutely exclude the presence of a really rare scattered gastrin-expressing  cell 
population that may persist during the adult life. However, we are not certain whether some 
alpha cells that express ghrelin during development and postnatal period could also express 
gastrin. Indeed, our analyses were hampered by the fact that our antibodies against gastrin and 
ghrelin were all raised in rabbit preventing us to perform co-immunostainings.  
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In addition, we still don’t know if all alpha cells express gastrin at one time or another 
during their differentiation or if only a subset of alpha cells is capable of such expression. 
Indeed, all alpha cells do not appear at the same time during pancreas development. 
Consequently, when studying alpha cells at birth for example, they don’t all have the same 
“age” and may not be in the exactly same differentiation state. Answering this question may 
greatly enhance our understanding of alpha cell and specifically their differentiation. This is 
of crucial importance in the field of diabetes research as alpha cells emerge as possible source 
of beta cell by transdifferentiation mechanism. Such a question may not be applicable to the 
gastrin expressing beta cells, as only really few insulin+ cells co-express gastrin (at E14.5 
(personal communication) and at P0). Thus, the double hormone+ beta cells are likely to 
represent an extremely discrete subpopulation of beta cells during development and postnatal 
period. Considering the rarity of these cells, one may even ask if these cells are truly 
programmed to exist or if they are only the result of mere coincidence resulting from 
differential threshold of transcription factors expression or other mechanisms, such as 
differential exposition to growth factors. 
The fact that the majority of gastrin expressing cells and ghrelin expressing cells 
coexpress glucagon suggests that alpha cells are a metastable and heterogeneous endocrine 
cell population before their final differentiation. In addition, it has been shown, using lineage 
tracing with Cre recombinase inserted in the coding sequence of the Ghrelin locus, that nearly 
15% of adult alpha cells expressed the genetic reporter demonstrating that cells that have 
expressed Ghrelin are contributing to adult alpha cell mass. Thus it would be interesting to 
demonstrate if pancreatic gastrin expressing cells contribute to alpha and beta cell population 
in adult. If yes, are they, once become gastrin- cells, entirely the same as other alpha and beta 
cells, or do they keep some “gastrin cell memory” with them? More direct evidence is still 
needed to clarify the issue. This could be done by generating mice expressing Cre 
recombinase under the control of the endogenous Gastrin gene locus, combined with 
subpopulation isolation and fine molecular analyses. Indeed, the data from our tumor analyses 
in the first paper favor the hypothesis that gastrinomas are derived from embryonic and/or 
neonatal gastrin+ cells (coexpressing either insulin or glucagon), and they remain at such a 
“immature” state during tumorigenesis. However, we cannot totally exclude the possibility 
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that they can come from alpha and/or beta-cells having “gastrin cell memory” because of 
Men1-disruption. 
3.1.2 MECHANISMS OF PANCREATIC GASTRIN EXPRESSION 
The mechanisms controlling gastrin expression in the pancreas during development 
and after birth are completely elusive. Many transcription factors necessary for islet cell 
development and maturation are also common to gastric and duodenal endocrine cells 
development. Indeed, transcription factors such as Nkx2.2, Pax4 and Pdx1 are necessary for 
duodenal gastrin+ cells development (Desai et al. 2008, Wang et al. 2009, Beucher et al. 
2012). In addition to Gastrin transcriptional expression, it is well known that Gastrin mRNA 
have to be translated and further processed by different cleavages including the enzyme 
activity of both PC1/3 and PC2 (Rehfeld 2006, Rehfeld et al. 2008). Interestingly, it has been 
shown that in adult islets, PC1/3 expression is restricted to beta cells, whereas PC2 is 
expressed in both alpha and beta cell populations (Neerman-Arbez et al. 1994, Kilimnik et al. 
2010). PC1/3 and PC2 are necessary for the maturation of Proinsulin to active C-peptide, 
whereas Proglucagon is cleaved by PC2 to release glucagon in alpha cells, or by PC1/3 to 
release peptide such as GLP-1 which is expressed in the intestinal L cells. Interestingly, it was 
shown that during development and more specifically in neonates, glucagon expressing cells 
also express PC1/3 protein (Kilimnik et al. 2010). In this case, Progastrin may be fully 
processed to its bioactive form. This processing is important as most antibodies available in 
diagnostic only recognize fully processed gastrin and are well far too specific (Rehfeld et al. 
2012), probably leading to unappreciated expression of Progastrin peptide in different organs. 
Development of antibodies recognizing Progastrin and not only fully processed gastrin are 
emerging as an urgent need, because the putative role of Progastrin (and not forcedly fully 
processed amidated Gastrin-17) in the proliferation of colorectal cells has been described 
(Wang et al. 1996). It would be, therefore, interesting to assess the expression of Progastrin by 
immunohistochemistry in adult human and murine pancreas to ensure that islet cells do not 
effectively express gastrin precursor protein. Interestingly, it has been demonstrated that some 
subsets of alpha cells in normal human adult islets coexpress Glucagon and PC1/3 leading to 
the production of GLP-1 peptides in the latter (Marchetti et al. 2012). 
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At this time, it is difficult to know what molecular mechanism is responsible for the 
progressive loss of gastrin expression in the pancreas after birth. As most gastrin expressing 
cells are coexpressing glucagon at least in the mouse, does the loss of PC1/3 expression in 
these cells combined with a decrease in Progastrin expression account for the loss of gastrin in 
the pancreas after birth? It has been shown that Progastrin level is decreased after birth in rat 
(Bardram et al. 1990), suggesting that at least a decrease in Progastrin expression may explain 
the progressive loss. On the contrary few data are available on Progastrin mRNA expression 
in islets and more specifically in the different types of islet-cells. In situ hybridization 
performed on adult rat pancreas failed to reveal Progastrin mRNA expression in islets 
(Shimizu et al. 1999). However, considering the great differences that exist between ghrelin 
expression in human and rat pancreas (Raghay et al. 2013), it would be urgent to perform 
better analyses on isolated human islets or isolated alpha and beta cells, using more sensitive 
techniques such as PCR.  
3.1.3 BIOLOGICAL ROLE OF NORMAL PANCREATIC GASTRIN EXPRESSING CELLS 
Several hypotheses have been put forward concerning the biological significance of 
the cells expressing gastrin in developing and neonate pancreas. Gastrin null mice present 
with slight fasting hypoglycemia and improved glucose tolerance in oral and intraperitoneal 
challenge at three months of age, which could be explained by a decreased glucagon secretion 
after glucose stimulation (Boushey et al. 2003). In contrast, another group reported that 
Gastrin null mice develop insulin resistance and increased fasting glycemia at 5 months of 
age (Cowey et al. 2005). These data are not informative as to whether the defects observed 
result from eventual islet development defects or due to the absence of gastrin in adult mice.  
Indeed, Boushey and colleagues performed glucagon and insulin pancreas content analysis in 
newborn Gastrin null mice and did not notice any difference. Regretfully, they did not 
perform histological analysis to study if there were some defects in endocrine cell 
differentiation. Interestingly it has been shown that Gastrin receptor (CCK-BR, CCKR2) is 
expressed in developing and adult human alpha cells (Saillan-Barreau et al. 1999). Thus, 
Gastrin may possibly affect the proliferation, differentiation or physiology of alpha cells. In 
addition, CCK can also signal through the gastrin receptor, thus it still has to be demonstrated 
if compensation by CCK expression may occur in Gastrin null mice. However Cck-BR null 
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mice do not show particular phenotype in the pancreas (Langhans et al. 1997), but analyses on 
the development and function of pancreatic endocrine cells in these mice need to be assessed. 
In addition, it may remain possible that gastrin expression in the pancreas may not have 
any biological role. Indeed it may just be the result of the differentiation process of pancreatic 
endocrine cells during which the combination of protein expression and chromatin aperture 
would result in non-specific gastrin expression. 
3.2 GASTRINOMAS IN MICE: WHAT WE MAY LEARN?  
3.2.1 ORIGIN OF PANCREATIC GASTRINOMAS 
The current works provide compelling evidence showing the crucial role played by 
pancreatic endocrine cells themselves in the development of pancreatic gastrin expressing 
tumors, following Men1 gene disruption. Our data demonstrate that subsets of alpha and beta 
cells that express gastrin during the development or the postnatal period should represent the 
cells of origin of pancreatic gastrinomas. Our work also further confirmed the role of the 
Men1 gene in the pathogenesis of pancreatic gastrinomas in the mouse, that our team and 
others previously described in heterozygous Men1 mutant mice (Bertolino et al. 2003, Loffler 
et al. 2007). 
However, several points remain to be elucidated. Our analyses, did not address the 
functionality of gastrin producing tumors in our different mouse models. The analyses of 
Gastrin levels in the serum withdrawn from mutant mice and more precocious histological 
analysis of gastric mucosa may tell us more about the functionality of such tumors. Indeed, if 
gastrin producing tumors effectively secrete high amount of gastrin, this should lead to 
pseudo ZES in mice, with hyperplasia of ECL cells in the gastric corpus, fundus or antrum. In 
addition, it remains surprising that gastrin producing tumors that we reported also express 
insulin even at lower levels than other insulin expressing tumors. However, all human 
pancreatic gastrinomas do not systematically express insulin. It has, nevertheless already been 
indeed reported the case of a sporadic pancreatic tumor leading to clinical manifestation of 
both gastrinoma and insulinoma (Lodish et al. 2008). More importantly, this tumor displayed 
a coexpression of both insulin and gastrin inside same cells (Lodish et al. 2008). Interestingly, 
data from our lab demonstrated a substantial number of human glucagonomas containing 
dispersed gastrin-expressing cells (unpublished data). We suspect that many of the case could 
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be neglected because of the lack of clinical symptom and specific antibodies. In addition, it 
has already been reported the development of gastrinoma subsequently to an insulinoma in 
some patients (Mizuno et al. 2001). Thus, one may ask if pancreatic gastrinomas could 
originate from insulin expressing lesions that would loss insulin expression. Indeed, 
gastrinomas are often lately detected during the tumor development which could explain why 
generally no insulin is found in pancreatic gastrinomas. In addition, a high proportion of 
pancreatic endocrine tumors are non-functional, which could explain why pancreatic 
gastrinomas are generally not associated or do not occurs after an initial diagnostic of 
insulinoma in patients. 
In this thesis, we suggested that the origin of pancreatic gastrinomas may possibly in 
part reside in the pre and neonatal gastrin expressing alpha and/or beta cells. However, we 
could not directly address this issue because mice expressing Cre recombinase specifically in 
gastrin expressing cells have not been engineered so far. Such genetic tool may be used to 
disrupt the Men1 gene specifically in pancreatic gastrin expressing cells during development 
to address the precise contribution of these cells to pancreatic gastrinoma development. 
Intriguingly, mice expressing the SV40 large T antigen under the control of the human gastrin 
promoter develop insulin expressing tumors that surprisingly do not express gastrin, 
demonstrating a potential role of pancreatic gastrin expressing cells in tumor development 
(Montag et al. 1993). Unfortunately, the precise pattern of transgene expression has not been 
assessed to validate that the human promoter used can effectively and only target gastrin 
expressing cells. The fact that this model does not develop gastrinomas may suggest that 
SV40 T antigen is not sufficient to drive gastrinoma development and that other events are 
needed to trigger gastrinoma development. In our model, we were neither able to detect 
cluster of gastrin expressing cells at early time points (i.e. at 1 and 2 months of age, personal 
communication), nor to trace what happens right after Men1-disruption in gastrin expressing 
cells. It would be possible that these cells may lose gastrin expression as their wild-type 
counterpart but are able to reactivate this expression later in life, leading to gastrin producing 
tumors. Another explanation may reside in a transdifferentiation mechanism that may arise 
randomly from insulin expressing tumors leading to spontaneous development of gastrin 
expressing tumors. Considering the low frequency of gastrin expressing tumors arising in our 
different mouse models, and there is no increased frequency of gastrin-expressing tumors with 
age, this is unlikely to be the case, but we are aware that it is worth considering. Remarkably, 
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the low number of gastrinomas is in total accordance with both the low proportion of 
pancreatic gastrinomas in MEN1 patients, and the low proportion of gastrin expressing cells 
in the developing pancreas. 
3.2.1 DUODENAL GASTRINOMAS IN MICE 
Works from my hosting team described the occurrence of gastrinomas in the duodenum 
and the glandular stomach of aged Men1+/- mice (16%) (Bertolino et al. 2003). However, the 
frequency seems to be much lower than what reported in MEN1 patients. It seems that mice, 
on the contrary to human, are not prone to duodenal gastrinoma development. Indeed, the 
models that we generated allow specific Men1-disruption in endocrine Ngn3+ progenitors, 
also target the duodenal endocrine progenitors expressing Ngn3. Our analyses of the 
duodenum of 12 month-old mutant mice did not evidence any development of tumors. This is 
in agreement with a recently published study where the Men1 gene was disrupted in the entire 
intestinal epithelium (including the duodenum) but did not trigger gastrinoma development 
(Veniaminova et al. 2012). Interestingly, it was demonstrated that a high proportion of gastrin 
expressing cells still kept menin expression at protein level. This suggests that in these cells, 
menin protein half-life is higher than the epithelial renewing or that in the mouse, menin is 
important for gastrin cell development leading to a specific positive selection of gastrin 
expressing cells that have not recombined Men1 locus. The absence of duodenal gastrinoma 
development in several Men1 models is reminiscent of the phenotype observed in mice with 
Apc mutations that do not develop colon tumors as opposed to humans with such mutations. 
The differences between epithelial turnover between species, or difference in 
microenvironnement in the mouse and human along the intestinal tract may explain the lack 
of duodenal gastrinomas in the mouse as recently suggested for colorectal cancer (Leedham et 
al. 2013). The microenvironnement may indeed play an important role and may also explain 
the nearly absence of gastrinomas development in human stomach whereas more than 95% of 
gastrin expressing cells are located in the stomach.  
3.3 MENIN AND PANCREATIC ENDOCRINE PROGENITORS: AN ISSUE REMAINS OPEN? 
 
3.3.1 ROLE OF MENIN IN ENDOCRINE PANCREAS DEVELOPMENT 
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Menin’s role in development and more particularly in the endocrine pancreas 
development had been previously highlighted by several studies on Men1 KO embryos 
(Bertolino et al. 2003, Fontaniere et al. 2008, Lemos et al. 2009). Pancreatic explants culture 
and chimeric mice formed from both Wild-type ES cells and Men1 KO ES cells demonstrated 
that menin was required for pancreatic islet cells differentiation (Fontaniere et al. 2008). One 
group reported the generation of Pdx1-Cre-Men1F/F mice allowing the disruption of the Men1 
gene in pancreatic progenitors expressing Pdx1 but also in beta cells (Shen et al. 2009). The 
mice seemed to develop normally and developed pancreatic endocrine tumors, though only 
insulinomas were found in this model. However, the authors did not checked if menin 
expression was lost during development and if any changes in islet cell composition were 
observable at birth. This is of great importance as it was described that some Pdx1-Cre 
transgenic mice are active only in beta cells and not in pancreatic progenitors (Heiser et al. 
2006). Thus, the exact role of menin in pancreatic endocrine cells development remained 
unaddressed. One aspect of our works with the PancEndoMen1 KO model was to further 
dissect the potential role of Men1 in the differentiation of Ngn3+ pancreatic endocrine 
progenitors. Interestingly we could not directly evidence obvious developmental defects 
occurring after Men1 disruption in Ngn3+ progenitors. However, if menin loss would have 
been detrimental for islet cells development, we should be able to find only a relatively small 
percentage of cells with absence of menin expression at P0. The percentage of menin loss in 
alpha, beta and delta cells at birth were slightly lower, when compared with the number of 
eYFP expressing cells in lineage traced control mice Ngn3wt/tTA-tet-Ocre R26eYFP mice. 
Nevertheless, the lower presence of menin-negative cells may also be explained by other 
factors, such as relatively long lasting stability of menin protein or decreased proliferation of 
menin-deficient endocrine cells during late embryogenesis. More detailed analysis, in 
particular those during embryonic stage, are needed to confirm the observation. 
Moreover, using different models targeting Men1 in maturing endocrine cells, we do not 
observe any impact of Men1 inactivation on their development. Considering that menin play 
important role in epigenetic regulation, we could speculate that menin absence may have 
earlier effects, such as inducing nuclear reprogramming in endoderm progenitors for example, 
preventing the differentiation specifically of pancreatic endocrine cells. This remains to be 
investigated using strategies allowing earlier disruption of Men1. 
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3.4 BIOLOGICAL EFFECTS OF MENIN LOSS IN PANCREATIC ENDOCRINE CELLS: FINDING 
THE COMMON MECHANISMS FROM THE DIVERSITY? 
3.4.1 MENIN AND PANCREATIC ENDOCRINE CELL PROLIFERATION DURING 
DEVELOPMENT 
One major enigma in the study of menin’s biological role is to decipher the 
consequences of menin loss at different stages during pancreatic development, as compared 
with its loss in adult differentiated endocrine cells. Indeed, in human MEN1 patients and 
Men1+/- mice, pancreatic endocrine tumorigenesis is dependent on the loss of function of the 
remaining wild-type functional allele of Men1, mainly by LOH. However, LOH is susceptible 
to happen at any time during the life, including during embryogenesis. When analyzing the 
frequency of menin loss and proliferation in different endocrine cell-types in PancEndoMen1 
KO mice, we were surprised to find that the percentage of Men1 disrupted cells was at the 
most equivalent to the percentage of cells expressing the genetic reporter in control Ngn3wt/tTA-
tetOCre+-R26eYFP mice. This observation seems to indicate that loss of menin during 
embryogenesis did not trigger their proliferation. Indeed, it would have been expected that the 
percentage of menin negative cells would have been superior to the percentage of cells 
labeled with the genetic reporter in Ngn3wt/tTA -tetOCre+-R26eYFPif menin deficient cells had 
proliferated. However, this is only an indirect deduction and we need to study the 
proliferation of menin deficient cells in PancEndoMen1 KO mice during embryogenesis in 
order to get further insight. In the case where we could confirm such absence of effect of 
menin loss on the proliferation of endocrine cells during embryogenesis, it would be essential 
to understand the molecular basis of such absence, as it may help in elaboration of strategies 
to inhibit the development and progression of endocrine tumors in MEN1 patients. 
Even if we consider that the effect of menin loss in the pancreatic progenitors is 
unsettled by the current study, one may ask if such loss may trigger different tumor 
development as compared with menin loss in fully differentiated cells. The histological 
analyze of aged PancEndoMen1 KO mice at 13 months demonstrated a generalized but 
uneven decrease in insulin expression. Such phenomenon was not observable in the βMen1 
KO mice. In addition, 4.5-month-old Ptf1aCre+-Men1F/F mice pancreases also displayed such 
generalized diminished insulin expression in the lesions. We may wonder if this is the result 
of menin loss during embryogenesis leading to an alteration of beta cell maturation or if it is 
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indirectly related to factors secreted by other types of menin-deficient islet-cells which are not 
present in the βMen1 KO model. Our data strongly suggest that Men1-disruption in pancreatic 
progenitors may lead to the development of less differentiated and functional tumors. Thus, 
this may indicate that the heterogeneity of islet tumors observed in MEN1 syndrome may be 
at least partially due to the cells of origin of these tumors. Cohorts of 18 month-old 
PancEndoMen1 KO mice and 12 months old Ptf1aCre+-Men1F/F mice will soon be 
thoroughly analyzed both on histological and biological levels in order to better investigate 
the evolution and outcome of derived islet tumors. 
3.4.1 DIFFERENTIAL EFFECT OF MENIN LOSS IN DIFFERENT ISLET-CELL TYPES 
Anatomopathological analyses of aged PancEndoMen1 KO mice confirmed the 
essential role of menin in repressing alpha and beta cell proliferation, even when disrupted 
before and/or during their differentiation. This is in contrast with other previous models of 
Men1 inactivation, which mainly studied the role of menin loss in differentiated islet cells, or 
models that did not allow to discriminate between effect of menin loss in adult differentiated 
or early developing differentiated islet cells. Analyses of the proliferation of menin deficient 
cells at 6 weeks, and the relative low number of alpha cell lesions in aged PancEndoMen1 KO 
mice confirmed that Men1 disrupted beta cells have an increased proliferation as compared to 
menin-deficient alpha cells, as it has been described in tumors from Men1+/- mice (Walls et al. 
2012). This, combined with the fact that beta cells are more numerous than alpha cells in 
normal pancreas, may explain why macrotumors secreting insulin are more frequent than 
those secreting glucagon in MEN1 patients. However, our group also suggested that 
transdifferentiation of alpha cells into insulin secreting cells may be a mechanism of 
insulinoma development following menin loss in alpha cells (Lu et al. 2010). However, to 
date, we could not evaluate in detail the contribution of such mechanism in PancEndoMen1 
KO mice. Lineage tracing of alpha cells would be of help, but it needs a Flip Recombinase 
system to target alpha cells, which is still not available. 
In contrast to alpha or beta cells lesions, somatostatin or PP expressing lesions were 
largely rarer in 12-month-old mice. Results obtained for somatostatin are not surprising 
considering that 1) at 6 weeks, menin deficient delta cells only demonstrate a tendency for an 
increased proliferation as compared to normal delta cells; and 2) that somatostatin expressing 
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tumors are rare in MEN1 patients. However, analyses of the proliferation of delta cells in 
mixed tumors from Men1+/- mice have clearly demonstrated that these delta cells have 
proliferation rate at least equivalent to tumoral beta cells (Walls et al. 2012). Thus, we still 
need to perform proliferation analyses in different pancreatic endocrine cell-types of aged 
PancEndoMen1 KO mice to refine these analyses. In addition, somatostatin analogs and 
therefore somatostatin, have proven their effects in decreasing proliferation of 
gastroenteropancreatic endocrine tumor cells in human (Strosberg and Kvols 2010). Autocrine 
action of somatostatin may act as an intrinsic inhibitor of delta cell tumor development. 
Conversely, other tumorigenic cells such as menin-deficient alpha and beta cells may directly 
or indirectly repress delta cell amplification, in order to avoid such repressive action of 
somatostatin on alpha and beta cell tumorigenic growth. As discussed in the manuscript n°2, 
the absence of somatostatin expressing tumors may also reflect a potential transdifferentiation 
or dedifferentiation-redifferentiation mechanisms converting menin-deficient into insulin 
secreting cells. This process could be even more prevalent than alpha-to-beta 
transdifferentiation as beta cells share very common differentiation program with delta cells. 
We did not observe the appearance of PP expressing tumors in PancEndoMen1 KO mice at 
12 months of age. This is reminiscent of the nearly absence of such tumors in heterozygous 
Men1+/- mice (Crabtree et al. 2001, Bertolino et al. 2003, Loffler et al. 2007, Harding et al. 
2009). These observations highly contrast with the tumor types found in MEN1 patients,  
which have frequently non-functional prelesions and tumors expressing PP. Interestingly, 
Thakker’s group reported that PP+ cells in mouse Men1+/- tumors had high proliferation rate 
comparable to tumoral beta cells and significantly increased by more than 10 fold as 
compared to control PP cells (Walls et al. 2012). Unfortunately, we were not able to assess the 
proliferation rate of menin-deficient PP cells in our model due to the inadequacy of the 
antibody used. Herrera’s group already described that several antibodies against PP cross-
react with alpha cells (Desgraz and Herrera 2009). We used a different antibody than theirs, 
but all these observations raise the possibility that indeed, alpha cells may potentially also 
express PP. Validations of PP antibodies are currently ongoing in the lab, and more analyses 
on the role of menin in the regulation of PP cell proliferation and or biology may be further 
addressed. 
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3.4.2 CELL SIGNALING PATHWAYS HETEROGENEITY IN MEN1 TUMORIGENESIS 
When trying to understand if postnatal proliferation pathways were sustained after 
menin loss in islet-cells, we were surprised to detect an increased ERK1/2 activation 
principally in alpha cells lesions. We could not find any insulin+ tumors that showed a 
homogeneous ERK activation in contrast to what is observed in alpha cells. Indeed, only 
subsets of beta cells tumors had clustered areas with phosphor-ERK1/2 staining that 
comprised only 5 to 10 percent of the tumor area in PancEndoMen1 KO mice but also in 
Men1+/- mice. Tumors and lesions of age matched βMen1 KO mice did not have such 
activation. Considering the known positive role of ERK signalization on tumorigenesis in 
several cancers (Chappell et al. 2011), we suspected that such activation may contribute to the 
proliferation of menin deficient alpha cells and subsets of beta cells. This is the first 
observation, to our knowledge, demonstrating differential mechanism of proliferation between 
different endocrine cell types and perhaps even between different subtypes of beta cells in 
Men1-related tumorigenesis. However, we need to further explore the potential role of ERK 
signaling in the proliferation of pancreatic endocrine cells.  
In addition, it would be relevant to analyze the activation of AKT/mTOR pathway in the 
different types of lesions developed in PancEndoMen1 KO mice, in order to decipher if this 
pathway may be differentially activated. Several studies of human pancreatic endocrine 
tumors showed that this pathway is frequently altered (Shida et al. 2010, Jiao et al. 2011), and 
it was demonstrated that AKT was activated in mouse Men1+/- pancreatic endocrine adenomas 
(Wang et al. 2011). Moreover, substantial progress has been achieved in treating these tumors 
with the inhibitors of this pathway, in particular, those of mTOR (Yao et al. 2011). We 
believe that further studying the role of AKT/mTOR pathway in MEN1-related tumors would 
be of help for refine the therapeutic strategy and finding the new targets. Indeed, our 
preliminary study using cultured cells found distinct effects in mTOR activation triggered by 
MEN1 inactivation, suggesting the potential importance of cells of origin of individual tumors 
in response to targeted therapies. 
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4 CONCLUSIONS AND PERSPECTIVES 
The aim of this work was to investigate the biological and oncosuppressive role of Men1 
in pancreatic endocrine progenitors. The overall project was articulated on the study of a new 
generated model allowing specific Men1 inactivation in Ngn3+ pancreatic endocrine 
progenitors and the comparison with other models disrupting Men1 in pan-pancreatic 
progenitors and more differentiated endocrine cells. 
We first addressed the potential role of Men1 disruption in pancreatic endocrine 
progenitors in the development of pancreatic gastrinomas or gastrin expressing pancreatic 
tumors. The results obtained demonstrated that specific menin loss in Ngn3+ progenitors, 
leading to the loss of menin in perinatal pancreatic-gastrin expressing cells, triggered the 
development of tumors expressing gastrin. Our data also showed that subsets of alpha and 
beta cells during development and postnatal period express gastrin. Consistently, the 
disruption of Men1 in either alpha or beta cells also triggered the development of a low 
frequency of gastrin expressing tumors. Altogether our results suggest the important role 
played by perinatal pancreatic gastrin expressing endocrine cells in the pathogenesis of 
pancreatic gastrinomas. Data obtained may be further investigated to better characterize these 
gastrin expressing lesions and compare them with human pancreatic gastrinomas. In addition, 
our observations may be of help to better understand this pathology and improve the treatment 
of these tumors that are often malignant. 
In the second part, we investigated the early effects and tumorigenic potential of Men1 
disruption in pan-pancreatic progenitors and pancreatic endocrine progenitors during 
embryogenesis. The analyses demonstrated a differential proliferative effect of menin loss 
depending on the stage and endocrine-cell type. It seems that Men1 disruption may not affect 
proliferation or even slightly decrease the proliferation of pancreatic endocrine cells at the end 
of embryogenesis, in contrast with the postnatal period. In addition, Men1 disruption before 
the commitment of pancreatic beta cells, may affect the maturation and or maintenance of the 
differentiation status of beta cells. The current work also highlighted that proproliferative 
signaling pathway, ERK, was differentially activated in menin deficient pancreatic tumors 
depending on the lineage affected. Thus, our results may suggest that signaling pathways 
involved in pro-proliferative and/or pro-survival roles in islet tumors may vary depending on 
the cell of origin of a given pancreatic endocrine tumor. The validation of these results in 
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human pancreatic endocrine tumors is crucially needed. But if confirmed, they may shed light 
onto the development of better targeted-therapeutic strategies. This particularly necessary in 
the field of pancreatic endocrine tumor where different kinds of tumors 
(gastrinoma/insulinoma/glucagonoma/non-functional, etc..) are often not separately 
considered in research studies due to their rarity. An aspect of the project that was not 
addressed in the current thesis was the role played by menin in the intestinal and more 
particularly duodenal-endocrine progenitors. Indeed, the Ngn3wt/tTA-tet-Ocre mouse model 
used in the studies conducted during this thesis also targets the gastric and intestinal Ngn3+ 
endocrine progenitors. This part of the project was unfortunately not studied in detail, mainly 
because of the lack of macroscopic tumor development in the duodenum of aged Men1F/F-
Ngn3wt/tTA-tet-Ocre mice. Consequently, we preferred to focus our analyses on the pancreatic 
lesions developed by these mice. However, sporadic duodenal gastrinomas or those 
developing in MEN1 patients can be of small size but already metastatic at diagnosis. Thus, 
small gastrin lesions may possibly develop in Men1F/F-Ngn3wt/tTA-tet-Ocre mice and better 
investigations are required to better appreciate the role played by menin in gastro-entero 
endocrine progenitors and differentiated enteroendocrine cells. 
Finally, we are persuaded that more detailed analysis of events that follow menin 
disruption in developing pancreas may help to better understand the biology of islet cells and 
the mechanisms of tumor development of islet-cells. 
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Abstract
Pax4 and MafA (v-maf musculoaponeurotic fibrosarcoma oncogene homolog A) are two transcription factors crucial for
normal functions of islet beta cells in the mouse. Intriguingly, recent studies indicate the existence of notable difference
between human and rodent islet in terms of gene expression and functions. To better understand the biological role of
human PAX4 and MAFA, we investigated their expression in normal and diseased human islets, using validated antibodies.
PAX4 was detected in 43.065.0% and 39.164.0% of normal human alpha and beta cells respectively. We found that MAFA,
detected in 88.366.3% insulin+cells as in the mouse, turned out to be also expressed in 61.266.4% of human glucagons+
cells with less intensity than in insulin+ cells, whereas MAFB expression was found not only in the majority of glucagon+ cells
(67.267.6%), but also in 53.6610.5% of human insulin+ cells. Interestingly, MAFA nuclear expression in both alpha and beta
cells, and the percentage of alpha cells expressing PAX4 were found altered in a substantial proportion of patients with type
2 diabetes. Both MAFA and PAX4 display, therefore, a distinct expression pattern in human islet cells, suggesting more
potential plasticity of human islets as compared with rodent islets.
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Introduction
The development and functions of different types of islet cells
are controlled, to a large extent, by essential cell-lineage-specific
transcription factors. Among them, the transcriptional regulators
Pax4 and Maf are of crucial importance for both cell differenti-
ation and normal functions of islet beta cells in the mouse [1,2].
Pax4 is mandatory for the development and maturation of mouse
beta cells [1]. The evidence from the recent studies suggest that
PAX4 is also crucial for mature beta cell expansion and survival,
and that PAX4 mutations or polymorphisms are associated with
both type 1 and type 2 diabetes [3]. Importantly, Pax4
overexpression in mouse pancreatic progenitors resulted in beta
cell conversion [4]. MafB is involved in embryonic development of
both mouse pancreatic alpha and beta cells [5,6], whereas MafA
participates mainly in the maturation of mouse beta cells [2].
During adult life in the mouse, MafB is specifically expressed in
alpha cells [6] and MafA in beta cells [2]. Interestingly, we and
others have recently demonstrated that MafB expression can be
reactivated in mouse beta cells undergoing adaptive proliferation
[7,8] and during tumorigenesis [7], indicating that the dynamic
modulation of Maf expression could be involved in the control of
beta cell proliferation and their endocrine functions. Based largely
on the knowledge acquired from the above mentioned studies in
the mouse, several strategies to cure diabetes are aimed at
replenishing the pool of beta cells, by overexpressing beta cell
specific transcription factors, including Pax4, MafA and Pdx1 in
different cell-types.
Although the expression pattern and biological functions of
these islet transcription factors have been substantially explored in
rodent models and cell lines, little was known in human islets until
recently. PAX4 mRNA was undetectable [9] and PAX4 protein
expression has been barely studied in normal adult human islets,
mainly because of the lack of specific tools. Intriguingly, Dorrell
et al. recently reported that MAFB was detected at equal levels in
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FACS purified adult human alpha and beta cells by RT-qPCR
analysis, suggesting that MAFB expression in human islets may be
different from that in mouse [9]. Consistent with this work, Dai
et al. subsequently reported MAFB protein expression by immu-
nohistochemistry in a rather small proportion of beta cells in
normal adult human islets [10]. Considering the marked difference
reported between MAFB expression in human and murine islets,
the goal of this study was to find out detailed protein expression
patterns of PAX4 and MAFA in human adult alpha and beta cells.
Materials and Methods
Ethics statement
Human paraffin embedded pancreatic tissues from the collec-
tion (CHRU Lille, France) conserved for traceability in the context
of our clinical islet transplant program [11] were obtained from
healthy subjects (n = 9), Type 2 Diabetics (n = 7), and non-diabetic
subjects with obesity (n = 4, Table 1). Verbal consents from the
donor were obtained for use of the samples in research. The study
was conducted in accordance with the guidelines in the
Declaration of Helsinki. Ethical review board (« Comite´ d’Ethique
du Centre Hospitialier Re´gional et Universitaire de Lille »)
approved the use of human pancreatic cells in vitro, and their
associated paraffin sections. Authorization to access research grade
pancreases is granted by Agence de la BioMedecine, France. The
Agence de la BioMedecine has standardized procedures for
Coordinators to assure that the informed consent procedure is
identical throughout France.
Cell transfection and western-blotting
aTC1-9 were transfected with the empty vector pCI-neo, pCI-
mPax4 or pCI-hPAX4 expressing mouse or human PAX4
respectively and were analysed as previously described [7]. MEF
cells were transfected with pcDNA-MAFA and pcDNA-MAFB
expressing human MAFA and MAFB, respectively, and analysed
as previously described [7].
Pax4 vectors cloning
Mouse Pax4 expressing vector was constructed by subcloning of
a PCR fragment obtained from bTC3-cell line cDNA into the
pCI-neo mammalian expression vector and was verified by
sequencing. The following primers containing SalI and NotI
restriction sites were used: 59-ATAAGTCGACATGCAGCAG-
GACGGACTCAGC-39 and 59ATAAGCGGCCGCTTATGG
CCAGTTTGAGCAATG-39. Human PAX4 expressing vector
was constructed by subcloning of a PCR fragment obtained from a
human insulinoma cDNA into the pCI-neo mammalian expres-
sion vector and was verified by sequencing. The following primers
containing SalI and NotI restriction sites were used: 59-
ATAAGTCGACATGCATCAGGACGGGATCAGC-39 and 59-
ATAAGCGGCCGCTTAAGGCCAGTGTGAGAAGTG -39.
Antibodies used
The anti-MAFA antibody (ab26405, Abcam) and a panel of
anti-MAFB antibodies were subjected to different tests to assess
their specificity toward MAFA and MAFB proteins both in mouse
and in human tissues. The anti-MAFA (ab26405, Abcam) and the
Table 1. Human patient samples.
Patient# Sex Age (year) BMI (kg/m2) HbA1c (%) Clinical features
1 M 64 39.2 10.3% T2D
2 M 58 32.8 7.0% T2D
3 M 62 32.7 7.4% T2D
4 M 49 29.9 7.7% T2D
5 M 57 36.5 8.2% T2D
6 F 55 22.4 7.7% T2D
7 M 59 37.7 7.0% T2D
Mean ± S.E.M T2D – 57.7±1.8 33.0±2.2 7.9±0.4% –
8 M 66 36.9 5.3% Control obese
9 F 50 33.3 6.2% Control obese
10 F 46 33 5.7% Control obese
11 M 55 39 5.8% Contol obese
Mean ± S.E.M Control obese – 54.3±4.3 35.6±1.5 5.8±0.2% –
12 M 18 21.6 5.6% Control
13 M 17 23.7 5.6% Control
14 M 18 23.3 ND Control
15 M 41 22.2 5.5% Control
16 M 36 24.2 ND Control
17 M 43 22.5 5.6% Control
18 F 47 25.7 ND Control
19 F 47 20.8 5.7% Control
20 H 48 24,7 ND Control
Mean ± S.E.M Control – 35.0±4.5 23.2±0.5 – –
BMI: Body Mass Index; HbA1c: Glycated Hemoglobin; ND: Not Determined.
doi:10.1371/journal.pone.0072194.t001
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noncommercial anti-MAFB2 (mouse monoclonal antibodies, clone
1F4 [12]) antibodies were validated and used for the current study.
Anti-glucagon (G2654, Sigma), the anti-insulin (A056401,
DAKO), the anti-PDX1 (ab47383, Abcam) and anti-ARX
(noncommercial, [13]), mMafB1 (anti mouse MafB, IHC-00351,
Bethyl), and hMAFB3 (Anti human MAFB, HPA005653, Sigma)
were also used in the study.
Immunofluoresence analyses
Briefly, serial sections (4 mm) mounted on glass slides were de-
waxed and rehydrated through a series of ethanol dilutions then
distilled H2O. Heat-induced epitope retrieval was performed by
immersion in Antigen Unmasking Solution (H-3300, Vector) in a
microwave oven. After blocking with antibody diluent (DAKO)
sections were incubated with a primary antibody, and treated with
Cy-3 or Cy-5 Tyramide amplification kit (PerkinElmer) according
to the manufacturer9s instructions or incubated with appropriate
Alexa488–555–or–647 coupled secondary antibodies (Life Tech-
nologies). For PAX4 detection in human pancreas, heat-induced
epitope retrieval was not performed but sections were incubated in
PBS-Triton X100 0.2% for 5 min at room-temperature. However
this prevented us from performing ARX and PAX4 co-expression
because ARX could not be detected with this protocol. All nuclear
co-localization experiments were performed and controlled to
ensure that no non-specific crossreaction occurred. Images were
captured and analyzed on a TCS-SP5 confocal microscope (Leica-
Microsystems) or a Zeiss 780 confocal microscope. Cell counting
was manually performed with ImageJ cell counter module (U. S.
National Institutes of Health, Bethesda, Maryland, USA) on
multiple channel pictures. Graphs and results of counting are
represented as mean 6 S.E.M.
Results
Endogenous PAX4 nuclear expression can be detected
both in human pancreatic alpha and beta cells
First, we sought to validate the capacity of a widely used anti-
Pax4 antibody [4,14,15] to recognize human PAX4 (Figure 1A)
expressed in aTC1-9 cells, since the antibody has not been
reportedly used in human pancreatic tissues. As illustrated in
Figure 1A, the antibody recognized properly ectopically expressed
human PAX4 and its mouse counterpart. Using triple IF staining
of PAX4, glucagon, and insulin, we found that surprisingly, PAX4
was expressed with an equivalent intensity in 43.065.0% and
39.164.0% of normal human alpha and beta cells respectively
(Figure 1B, C). The relative expression intensity was much less in
human islets than in mouse islet beta cells (data not shown).
Importantly, this unexpected result is consistent with reported
Figure 1. PAX4 is detected in both human pancreatic alpha and beta cells. (A) Detection of ectopically expressed mouse and human PAX4
by western blotting. The capacity of the anti-Pax4 antibody to recognize human PAX4 was assessed using aTC1-9 cells transfected respectively with
the pCI-neo empty vector or constructs expressing mouse Pax4 (mPax4) or human PAX4 (hPAX4) protein by western-blotting analysis. Protein
extracts from transfected cells were used for the detection, using antibody against Pax4. (B) Representative images of triple IF staining with
antibodies against PAX4 together with glucagon and insulin. Right panels are the amplified view of the insets in the left panel. Red arrowheads,
PAX4+ INS+ cells. Yellow arrowheads, PAX42INS+ cells, Green arrowheads, PAX4+GLU+. White arrowheads, PAX42GLU+ cells. (C) Percentages of
insulin+ cells and glucagon+ cells expressing PAX4 represented as the averaged counting results 6S.E.M from n=5 control individuals (A total of 164
GLU+ cells and 904 INS+ cells were analyzed). Scale bars = 25 mm.
doi:10.1371/journal.pone.0072194.g001
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weak PAX4 mRNA expression found in both human adult alpha
and beta cells [9].
Expression patterns of MAFA and MAFB are largely
distinct in human endocrine pancreas than those in the
mouse
Then, to better investigate endogenous expression of MAFA
and MAFB in human islets, we validated the specificity of anti-
MAFA and MAFB antibodies used in the current study. We found
that the anti-MAFA antibody (Abcam) and the non-commercial
anti-hMAFB2 (mouse monoclonal antibodies, clone 1F4 [12])
reacted specifically without cross-reaction both to their corre-
sponding human counterpart ectopically expressed in mouse
embryonic fibroblasts (Figure 2A) and their corresponding protein
in mouse pancreas (Figure 3A). These antibodies were then further
validated for the detection of endogenous human MAFA and
MAFB expression in fixed human pancreatic sections by IHC
(data not shown).
As expected, the validated antibodies recognized human MAFA
in the nucleus of most insulin+ cells (88.366.3%) on sections of
adult human pancreas from healthy individuals (Figure 2B and C).
Surprisingly, as opposed to what was observed in mouse alpha
cells, MAFA was also detected in more than half of human
glucagon+ cells (61.266.4%, Figure 2B and C). MAFA expression
in alpha cells was confirmed by colocalisation with an alpha cell-
specific transcription factor, ARX (Figure 2D and 2E). In parallel,
using an antibody recognizing specifically both mouse and human
MAFB (Figure 2A and 3A), we found that 67.267.6% of human
Figure 2. MAFA is detected in both human pancreatic alpha and beta cells. (A) Detection of ectopically expressed human MAFA and MAFB
by western blotting. The specificity of selected antibodies against human MAFA and MAFB were evaluated using mouse embryonic fibroblasts (MEF),
which do not express endogenous murine MafA and MafB proteins, transfected respectively with constructs expressing human MAFA or MAFB
protein by western-blotting analysis. Protein extracts from MEF transfected with empty pcDNA and pcDNA expressing respectively human MAFA and
MAFB were used for the detection, using antibodies against MAFA (Abcam) or MAFB (anti hMAFB2, mouse monoclonal antibodies, clone 1F4). Note
that the anti-MAFA antibody and the noncommercial anti-hMAFB2 reacted specifically without cross-reaction, whereas the other tested commercially
available anti-MAFB antibodies failed (data not shown) (B) Triple immunofluorescent (IF) staining showing MAFA expression in human islets from
healthy donors. (C) The percentages of cells expressing MAFA were 88.366.3% MAFA+ beta cells and 61.266.4% MAFA+ alpha cells. Results are the
averaged expression 6S.E.M of counting results from n= 4 control individuals (1058 INS+ cells and 345 GLU+ cells were counted in total). (D) ARX
expression was detected in human pancreatic alpha cells but not human pancreatic beta cells. Representative images of triple IF-staining showing
ARX expression in human islets from healthy donors. ARX was detected only in nuclei of alpha cells. (E) Co-localisation of MAFA with ARX in human
islets. Right panels are the amplified view of the inset in the left panel. Red arrowheads, MAFA+ARX2GLU2cells. Green arrowheads, MAFA2ARX+GLU+.
White arrowheads, MAFA+ARX+GLU+ cells. Scale bar = 25 mM.
doi:10.1371/journal.pone.0072194.g002
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Figure 3. MAFB is expressed in both human alpha and beta cells. (A) Different antibodies were tested for their specificity toward mouse MafB
by triple immunofluorescent (IF) staining of mouse pancreatic sections. Representative images of triple IF staining with anti-glucagon, insulin, and
hMAFA, mMafB1, hMAFB2 and hMAFB3 antibodies. Note that hMAFB3 did not show an alpha cell specific pattern as did mMafB1 and hMAFB2
antibodies. (B) MAFB expression was detected in both human pancreatic alpha and beta cells. Representative images of triple IF-staining showing
MAFB expression in human islets from healthy individuals. The percentages of positive cells for MAFB in glucagon+ (green) and insulin+ (red) cells
were 67.267.6% MAFB+ alpha cells and 53.6610.5% MAFB+ beta cells. Results are the averaged expression 6 S.E.M of counting results from n=4
PAX4 and MAFA in Human Pancreatic Alpha Cells
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glucagon+ cells displayed an overt MAFB staining, yet MAFB was
also detected in a large number of insulin+ cells (53.6610.5%,
Figure 3B), and double insulin+ PDX1+ cells (30.265.8%,
Figure 3C), similar to what was reported in a recent study but
to a larger extent [16].
MAFA and PAX4 expression is found deregulated in
patients with type 2 diabetes
Recently, Butler and colleagues reported that nuclear localiza-
tion of MAFA was abolished in beta cells of type 2 diabetes
patients [17]. We analysed MAFA expression in pancreatic
sections from 9 control nonobese, nondiabetic individuals, 4 obese
non-diabetic individuals and 7 type 2 diabetic (T2D) patients. We
found that MAFA expression was unaltered in islets from subjects
control individuals (463 GLU+ cells and 797 INS+ cells were counted in total). Scale bar = 25 mM. (C) MAFB expression in insulin+ PDX1+ cells. The
percentage of double insulin+ PDX1+ cells positive for MAFB was 30.265.8% (858 INS+ PDX1+ counted cells in total). The above percentages of
expression are the averaged counting results 6S.E.M from n= 3 control individuals. Scale bar = 25 mM.
doi:10.1371/journal.pone.0072194.g003
Figure 4. MAFA expression in islets from subjects with obesity or T2D diabetes. (A) Representative images of triple IF staining of MAFA
together with insulin and glucagon in subjects with obesity and T2D patients showing a MAFA-negative (upper panels), a MAFA-cytoplasmic (middle)
and a nuclear MAFA staining (lower panels) were respectively shown. (B) Percentage of T2D patients displaying each category of prominent MAFA
expression in islets. Scale bars = 25 mm.
doi:10.1371/journal.pone.0072194.g004
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with obesity as compared to normal individuals. On the contrary,
among tested T2D patients, MAFA expression was completely lost
in 2 patients, and shifted to a predominant cytoplasmic localisation
in 3 patients (Figure 4A and B). More importantly, this
deregulated MAFA nuclear expression was not only detected in
beta cells, consistent with what has been reported by Butler et al
[17], but also concurrently observed in alpha cells in the same
samples. It was noticed that islet MAFA expression was not altered
in the remaining two T2D patients, suggesting heterogeneity in
molecular pathway alterations among the patients. We did not
detect any significant change in PAX4 nuclear expression in alpha
or beta cell from T2D patients, when compared with the subjects
with obesity or control individuals (Figure 5A). However when
analyzing the overall distribution of PAX4 expression, we
observed a statistically significant decrease in the percentage of
PAX4+ alpha cells per islet from the T2D cohort compared to
individuals with obesity (respectively 37.263.7% vs 52.864.8%)
(Figure 5B), whereas there was no significant change in the
percentage of beta cells expressing PAX4 per islet in the same
patients (Figure 5C).
Discussion
Our present study revealed significantly different PAX4 and
MAFA protein expression patterns in human islets compared to
what was previously established in rodents. For the first time, our
data uncover the expression of PAX4 and MAFA in approxi-
mately half of human adult alpha cells, while the expression of
both factors is known to be exclusively present in beta cells during
adult life in the mouse. Consequently, in humans, one might
conclude that PAX4 and MAFA proteins are apparently neither
specific markers nor specific transcriptional factors in beta cells.
It is noted that our data are consistent with the previous results
from transcriptomic analysis of purified human islets, which
indicate that PAX4 and MAFA expression at low transcription
levels was indeed perceptible in alpha cell population [9]. The
weak expression of both transcription factors in alpha cells and the
lack of specific and sensitive tools for protein expression detection
may explain at least partially the failure to detect them so far in
human alpha cells. The current work confirmed the recent
publication by Dai et al [10], who used a different anti-human
MAFB antibody. Furthermore, by examining nuclear co-localiza-
tion of PDX1/MAFB, we showed that MAFB is expressed in a
Figure 5. PAX4 expression in islets from subjects with obesity or T2D diabetes. (A) Representative triple IF of PAX4 together with insulin
and glucagon showing PAX4-positive islet from control subject with obesity and T2D patients. The lower panel represents a magnified view of the
insets in the upper panel. Scale bars = 25 mm. (B) Overall distribution of PAX4+GLU+ cells per islet from control subjects with obesity and T2D patients
(52.864.8% with n = total of 21 islets from 4 control subjects with obesity vs 37.263.7% with n = total of 23 islets from 5 T2D patients, p = 0.0133
using unpaired two-tailed Student’s t test. (C) Overall distribution of PAX4+INS+ cells per islet from control subjects with obesity and T2D patients
(31.764.5%, n = total of 22 islets from 4 control subjects with obesity vs 34.862.5% with n = total of 23 islets from 5 T2D patients). Differences in
average expression were analyzed using unpaired two tailed Student’s t test, and p values were represented on the graphs.
doi:10.1371/journal.pone.0072194.g005
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fairly large population of PDX1-expressing cells. The discrepancy
between the MAFB positivity in insulin+ cells found in our work
(42% being the average of percentages of INS+MAFB+ and
PDX1+MAFB+ staining combined) and that (9%) reported by Dai
et al. [10] may mainly result from detection and counting methods.
In particular, co-nuclear IF immunostaining used in the current
study may facilitate a more accurate evaluation. How MAFB
works and interacts with other transcriptional factors, MAFA in
particular, within beta cells to exert its biological functions remains
to be shown.
The data obtained from our study provide compelling evidence
demonstrating the existence of subpopulations, in terms of protein
expression, among human alpha and beta cells. It would,
therefore, be relevant to investigate whether GLU+PAX4+ cells
represent a functionally, and even developmentally, different
population than the GLU+PAX42 cells that are similar to alpha
cells in rodent islets. Similarly, the same question could be applied
to GLU+MAFA+ cells versus GLU+MAFA2 cells. It would be
worth mentioning that, a recent study in rat islets indicated that
functionally distinct beta cell sub-populations do exist [18]. Our
data, therefore, may provide further molecular basis supporting
the presence of these subpopulations and unknown cell plasticity in
both alpha and beta cells of the adult human endocrine pancreas.
The current finding may also urge further investigations on the
capacity of these distinct subpopulations to transdifferentiate into
insulin-secreting cells, a phenomenon recently discovered in
rodents [15,19]. To this end, it would be critical in the future,
material permitting, to isolate and characterize these subpopula-
tions.
The expression pattern of PAX4 and MAFA in human islet cells
described in the current study urges one to reconsider their
biological roles, as well as the possible impact of such distinct
PAX4 and MAFA expression pattern in human pathology, since
their deregulation could be involved in cell plasticity change in the
diseases affecting islets, as suggested by the recent works [20].
Further studying PAX4, MAFA and MAFB expression, as well as
their activities in human islet cells in different pathophysiological
contexts, may provide useful clues to address these issues in the
future. Lastly this work adds to a growing number of articles
enforcing the imperative nature of research on human pancreatic
islet cells.
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Abstract
Mutations of the MEN1 tumour suppressor gene predispose patients to the development of multiple endocrine
neoplasia type 1 (MEN1) syndrome, which is characterized by multiple endocrine tumours, including prolactinomas.
The recent ﬁndings of the interaction between menin, encoded by the MEN1 gene, and the oestrogen receptor, as
well as the observation of rare cases of mammary carcinomas in our heterozygous Men1 mutant mice, led us to
investigate a putative tumour suppressor function of the Men1 gene in mouse mammary cells by disrupting the
gene in luminal epithelial cells. A signiﬁcantly higher incidence of mammary intraepithelial neoplasia (MIN) was
observed in mutant WapCre-Men1F/F mice (51.5%) than in WapCre-Men1+/+ (0%) or Men1F/F (7.1%) control
mice. The majority of MIN observed in the mutant mice displayed complete menin inactivation. Because of the
leakage of WapCre transgene expression, prolactinomas were observed in 83.3% of mutant mice, leading to
premature death. As there was no correlation between MIN development and elevated serum prolactin levels, and
phospho-STAT5 expression was decreased in mammary lesions, the increased incidence of MIN lesions was most
likely due to Men1 disruption rather than to prolactinoma development. Interestingly, in MIN lesions, we found a
decrease in membrane-associated E-cadherin and beta-catenin expression, the latter of which is a menin partner.
Finally, reduced menin expression was found in a large proportion of two independent cohorts of patients with
breast carcinomas. Taken together, the current work indicates a role of Men1 inactivation in the development of
mammary pre-cancerous lesions in mice and a potential role in human mammary cancer.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
Breast cancer is the most common malignancy world-
wide and remains the leading cause of cancer-related
mortality in women [1]. Only a relatively small pro-
portion of breast cancers (1–2%) arise in individu-
als who inherit mutations in breast cancer suscepti-
bility genes, such as the BRCA1 and BRCA2 genes
[2]. Mouse modelling of human breast cancer mim-
ics many essential features of the various types of
human breast disease [3]. Over the past 10 years,
such modelling has advanced rapidly and become a
useful tool for identifying new genes involved in
tumour susceptibility. The MEN1 gene is a tumour
suppressor in a wide range of endocrine and non-
endocrine tissues. MEN1 mutations predispose patients
to multiple endocrine neoplasia type 1 (MEN1) syn-
drome, characterized by the occurrence of multiple
endocrine tumours mainly affecting the parathyroid
glands, endocrine pancreas, and anterior pituitary gland
[4]. Shortly after the identiﬁcation of the MEN1 gene,
several non-endocrine tumours such as lipomas and
angiomas were also reported in MEN1 patients [5,6].
The MEN1 gene encodes menin, a protein that is pri-
marily nuclear localized and has been shown to inter-
act with a variety of other proteins [7]. In particular,
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its interaction with several transcriptional factors and
co-factors suggests that menin may act as an adap-
tor protein that is involved in the regulation of gene
expression. Indeed, menin has recently been shown to
physically interact with beta-catenin [8,9] and to be
required for Wnt/beta-catenin signalling in islet tumour
cells [8]. Additionally, Dreijerink et al . reported a
physical and functional interaction between menin and
oestrogen receptor alpha (ERα), the former acting as
a co-activator of ER-mediated transcriptional activ-
ity through recruitment of a histone methyltransferase
complex on ERα target genes [10]. The existence of a
link between the Men1 gene and hormone-dependent
tissues was further suggested by a study by Crab-
tree et al . in which one prostate cancer developed
in their heterozygous Men1 mouse cohort [11]. Sim-
ilarly, three cases of mammary carcinomas and six
prostate cancer cases have been observed in our pre-
viously analysed cohort of heterozygous Men1 mutant
mice [12,13].
In the present study, we conditionally disrupted
the Men1 gene in luminal mammary epithelial cells
in mice to study the effects of menin inactivation
on mammary tissues. We found that a signiﬁcantly
higher proportion of mutant mice developed mammary
intraepithelial neoplasia (MIN), which suggests that
Men1 disruption has a role in the predisposition of
mice to pre-cancerous mammary lesions. Interestingly,
a decrease in menin expression was also observed
in a substantial proportion of breast cancers in two
independent cohorts of patients.
Materials and methods
Transgenic mice
Heterozygous Men1 mutant mice and mice carrying
two ﬂoxed alleles of the Men1 gene (Men1 F/F)
were generated in a mixed C57BL6-129/Sv genetic
background as previously described [14]. WapCre
transgenic mice were obtained from the Human
Cancers Consortium Mouse Repository [B6.Cg-
Tg(WapCre)11738Mam, strain number 01XA8] [15]
and they expressed Cre under the control of the
whey acidic protein promoter. Mice were maintained
on a 12-h light/12-h dark cycle with free access
to water and standard mouse chow and housed in
pathogen-free facilities. Mammary samples from
Men1loxP/loxP/Rip-Cre+ female mice [16] were har-
vested by M Auret from Dr Nick Hayward’s team
at the Queensland Institute of Medical Research,
Australia and examined histologically by our pathol-
ogist. Genotyping and recombination analysis are
described in the Supplementary materials and
methods.
All animal experiments were approved by the
Regional Animal Experiments Committee of Cen-
tre National de la Recherche Scientiﬁque (CNRS)
and were conducted in accordance with the ethical
guidelines.
Histology and serum prolactin dosage
Female mice were exclusively used in the experi-
ments. Dissected organs were ﬁxed in 4% neutral
buffered formalin for at least 24 h at room temper-
ature and were then embedded in parafﬁn and sec-
tioned at 3 μm. They were stained with H&E and
microscopic histological analysis was performed by a
pathologist (L Frappart), including the samples from
Men1loxP/loxP/Rip-Cre+ female mice. Histopathological
analyses were based on the criteria described by the
Annapolis Pathology Panel [3]. The classiﬁcation of the
World Health Organization was also taken into account.
Immunohistochemical (IHC) staining and 5-bromo-2′-
deoxyuridine incorporation detection were performed
as described in the Supplementary materials and meth-
ods. Blood was collected from control and mutant
females by intracardiac puncture immediately after cer-
vical dislocation, and serum was isolated. The circu-
lating prolactin level was measured using a mouse/rat
Prolactin ELISA kit (Calbiotech, Inc. San Diego, Cali-
fornia, USA) following the manufacturer’s instructions.
Western blot analysis of human breast cancers
A panel of 26 specimens of primary human breast
tumours, collected before therapy from patients who
were diagnosed between 1992 and 1999 and underwent
surgery at the Centre Le´on Be´rard (Lyon, France), was
obtained from the Biological Resources Department of
Centre Le´on Be´rard (French agreement number DC-
2008-99).
TMA analysis of human breast cancers
Breast cancers were obtained from 121 patients (M0)
who underwent surgery at the Centre Le´on Be´rard
(CLB) in 1998 and 1999. The corresponding formalin-
ﬁxed, parafﬁn-embedded tumours were inserted as
triplicates (600 μm each) into four tissue micro-array
(TMA) blocks. Menin expression was assessed using
IHC; the intensity of nuclear staining was graded as
either 1 (low) or 2 (normal). Distribution of clinical
parameters was compared between patients showing
low or normal menin nuclear staining. Overall survival
(OS), deﬁned as the time from diagnosis to death or
date of last follow-up, and progression-free survival
(PFS), deﬁned as the time from diagnosis to death or
progression or to date of last follow-up (for censored
patients), were studied. Survival distributions were
estimated using the Kaplan–Meier method and com-
pared between menin level groups using the log-rank
test. Details are available in the Supplementary
materials and methods.
Results
Menin expression in adult mammary glands
To investigate the possible role of the Men1 gene
in mammary glands, we ﬁrst used immunohistochem-
istry to analyse menin expression during the postnatal
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Figure 1. Menin is expressed in mammary epithelial cells during different stages of postnatal mammary gland development.
Immunohistochemical detection of menin expression was performed in 5-week-old virgin, 15-day pregnant, 11-day lactating, and
7-day involuting mammary glands from Men1 wild-type female mice. Predominantly nuclear expression of menin was detected both in
luminal and in myoepithelial basal cells in the mammary epithelium, as well as in adipocytes, but not in the surrounding stromal cells. The
lower panel is a four-fold magniﬁcation of the upper panel. Scale bars= 50 μm.
development of mammary glands in wild-type female
mice (Figure 1). Menin expression was found both in
the luminal and in the basal (myoepithelial) cell layer
of the mammary epithelium, showing predominantly
nuclear staining, in 5-week-old virgin mice as well as
in mice during pregnancy, lactation, and involution of
the mammary glands.
Breast cancers found in heterozygous Men1 mutant
mice
Three cases of breast cancers were previously detected
among 36 heterozygous Men1 mutant mice older than
19months of age (8.3%) [12]. Menin expression was
completely lost in two of these cancers (Supplementary
Figure 1A), whereas a mammary cancer cell line
that has been successfully established from the third
mammary gland cancer, named TS1, displayed loss
of the remaining wild-type Men1 allele and of menin
expression (Supplementary Figures 1B and 1C).
Mammary-speciﬁc Men1 disruption
To further study the role played by menin in mam-
mary cells, we decided to disrupt the Men1 gene
speciﬁcally in mammary epithelial cells. For this pur-
pose, mice carrying ﬂoxed Men1 alleles (Men1 F/F) [14]
were crossed with WapCre transgenic mice express-
ing Cre recombinase under the control of the whey
acidic protein (Wap) promoter, known to be expressed
speciﬁcally in luminal mammary epithelial cells during
pregnancy and lactation (Figure 2A) [15]. To check the
mammary speciﬁcity of WapCre-mediated Men1 dis-
ruption, we collected mammary glands from 3-month-
old virgins and from parous female mice at lactation
day 15 after their ﬁrst, second or third pregnancy.
WapCre-mediated Men1 disruption was validated by
the detection of PCR fragment shift, which was spe-
ciﬁc for the Men1 deleted allele (), resulting from
the excision of the ﬂoxed exon 3 (Figure 2B). As
expected, Men1 disruption occurred in the mammary
glands of the WapCre-Men1+/F mice having undergone
pregnancies, as illustrated by the increased intensity
of the -speciﬁc PCR product. Of the three virgin
WapCre-Men1+/F mice analysed, one presented with
unexpected, but weak -speciﬁc PCR product, indi-
cating the WapCre transgene leakage in the mammary
glands. As previously described [15], the leakage of
this transgene was observed in the brains in all tested
mice. Surprisingly, we also noted previously undocu-
mented WapCre leakage in the pituitary glands of two
of the three tested mice (Figure 2B). Men1 disruption
was not detected in any of the other tested organs (data
not shown). Men1 disruption in mammary cells was
further assessed in WapCre-Men1 F/F mice by menin
detection with IHC. Loss of menin expression was seen
in a subset of mammary luminal epithelial cells in vir-
gin mice (10–20%, data not shown), in approximately
half of luminal cells during the ﬁrst pregnancy, and in
nearly 90% of luminal cells after the third pregnancy
(Figure 2C).
Normal mammary gland development in
WapCre-Men1F/F mice
To investigate whether Men1 disruption had an impact
on the physiology of the mammary glands, we per-
formed morphological analysis of both those glands
from the Men1 F/F and WapCre-Men1 F/F virgin female
littermates at 3months of age, at day 15 of pregnancy
(P15), and 7 days after weaning (involution day 7, I7)
for up to three pregnancies (G1, G2, G3). Although
menin inactivation occurred in a substantial propor-
tion of the cells (see above) in the mutant mice,
we did not notice any macroscopic or microscopic
morphological differences between control and mutant
mice (Figure 3A). Consistent with these observations,
WapCre-Men1 F/F female mice were able to breastfeed
their pups and all pups showed normal survival and
growth (data not shown). To assess whether Men1
disruption resulted in epithelial proliferation modiﬁ-
cations, we evaluated the incorporation of BrdU into
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Figure 2. Men1 conditional ablation in mouse mammary luminal cells. (A) Structure of the wild-type (+), ﬂoxed (F), and deleted ()
murine Men1 alleles. Exons are indicated by black boxes with corresponding numbers. Red arrows represent the loxP sequences. Blue
arrowheads indicate the position of the primers used for PCR genotyping and recombination analyses (3f1, 3r1, 2f0). (B) PCR ampliﬁcation
of wild-type (+, 215 bp), ﬂoxed (F, 280 bp), and deleted (, 300 bp) Men1 allele fragments with genomic DNA extracted from different
organs collected from WapCre-Men1+/F female mice. Mammary glands were obtained from three different virgin mice (MG V) and 15-day
lactating mice during their ﬁrst (#1 MG L15), second (#2 MG L15) or third (#3 MG L15) pregnancy. The Men1 deleted () allele is detected
as expected in mammary glands but also in the brains and pituitary glands of these mice. Genomic DNA extracted from the tails of Men1+/F
(+/F) and Men1+/ (+/) mice was used as a control. MG=mammary gland; Pit= pituitary gland; Ov= ovary; Br= brain; Kid= kidney;
Pa= pancreas. (C) Representative images of menin IHC in the mammary gland from a 12-month-old WapCre-Men1F/F female mouse (after
three rounds of pregnancy). The panel on the right is a four-fold magniﬁcation of the left panel and shows that only basal myoepithelial
cells remain positive for menin expression (arrowheads). Scale bar= 100 μm.
the mammary glands of age-matched controls and
mutant littermate mice during the ﬁrst and the third
pregnancy (Figures 3B and 3C). No signiﬁcant differ-
ence in the number of BrdU-positive epithelial cells
between WapCre-Men1 F/F and Men1 F/F female mice
was detected. Taken together, WapCre-Men1 F/F female
mice did not show any detectable consequence of Men1
disruption on morphological development, physiology,
or mammary gland proliferation during pre- or post-
pubertal development.
High frequency of mammary intraepithelial
neoplasia in WapCre-Men1F/F mice
The effect of Men1 inactivation in mammary gland
tumourigenesis was studied in a cohort of 120 mul-
tiparous female mice. To induce WapCre transgene
expression, 66 WapCre-Men1 F/F female mice, as well
as 28 Men1 F/F and 26 WapCre-Men1+/+ female mice
as the two control groups, underwent three rounds
of pregnancy. Females were then monitored over a
20-month period and necropsied at different age ranges,
speciﬁcally 9–12, 12–15 and> 15months of age. As
summarized in Table 1, control WapCre-Men1+/+ mice
developed no mammary lesions at any age. Addition-
ally, control Men1 F/F mice showed a low but constant
incidence of mammary intraepithelial neoplasia (MIN),
with one case in each of the two older age groups (10%
and 8.3%, respectively), but none in the youngest age
group. On the other hand, MIN lesions were found
in 38.5% of mutant mice in the 9–12months age
group. The incidence increased with age and reached
48.6% and 66.7%, respectively, in both the 12–15 and
the> 15months age groups, with 4.8-fold (p = 0.0548,
non-signiﬁcant) and 8-fold (p = 0.0057) increases com-
pared with the corresponding age groups of the control
Men1 F/F mice. Starting at 12months of age, WapCre-
Men1 F/F mutant mice had an extremely high mortality
rate, due to pituitary tumour development (see below).
Only two mutant mice survived beyond 18months
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Figure 3. Normal mammary gland development and proliferation in young WapCre-Men1F/F female mice. (A) H&E-stained sections of
mammary glands collected from 3-month-old virgin control Men1F/F and mutant WapCre-Men1F/F age-matched female mice, as well
as those during their ﬁrst (G1) and third (G3) pregnancies, 15 days after observation of the vaginal plug (P15) and 7 days after pup
weaning (I7). Note that control and mutant mice present a similar mammary gland structure at all stages of postnatal development.
Scale bar= 200 μm. (B) Representative images of BrdU incorporation in mammary glands harvested from control Men1F/F and mutant
WapCre-Men1F/F age-matched virgin female mice. Scale bar= 50 μm. (C) The percentage of BrdU-positive epithelial cells was calculated
as described in the Materials and methods section. Bars represent the mean percentage± SEM for two mice of each genotype. The
percentage of BrdU-positive epithelial cells was not signiﬁcantly different (p = 0.9866, two-way ANOVA) between Men1F/F (white bars)
and WapCre-Men1F/F (black bars) mice, neither in virgin mice (6.062± 0.699 versus 6.103± 0.809) nor during their ﬁrst and third
pregnancies (G1P15: 10.44± 0.736 versus 11.075± 0.98; G3P15: 6.561± 0.666 versus 5.884± 0.528) or involution (G1I7: 1.206± 0.182
versus 1.437± 0.317; G3I7: 1.656± 0.384 versus 1.395± 0.294).
Table 1. Age-related incidence of mammary lesions in WapCre-Men1F/F females
Genotype Histology 9–12months 12–15months > 15months Overall incidence
WapCre-Men1+/+ Normal 9/9 (100%) 8/8 (100%) 9/9 (100%) 26/26 (100%)
MIN 0/9 (0%) 0/8 (0%) 0/9 (0%) 0/26 (0%)
AdsC 0/9 (0%) 0/8 (0%) 0/9 (0%) 0/26 (0%)
Men1F/F Normal 6/6 (100%) 8/10 (80%) 10/12 (83.4%) 24/28 (85.7%)
MIN 0/6 (0%) 1/10 (10%) 1/12 (8.3%) 2/28 (7.1%)
AdsC 0/6 (0%) 1/10 (10%) 0/12 (0%) 1/28 (3.6%)
PdC 0/6 (0%) 0/10 (0%) 1/12 (8.3%) 1/28 (3.6%)
WapCre-Men1F/F Normal 8/13 (61.5%) 16/35 (45.7%) 6/18 (33.3%) 30/66 (45.5%)
MIN 5/13 (38.5%) 17/35 (48.6%)* 12/18 (66.7%)† 34/66 (51.5%)‡
AdsC 0/13 (0%) 2/35 (5.7%) 0/18 (0%) 2/66 (3%)
Mammary lesions were classiﬁed according to the recommendations of the Annapolis Pathology Panel [2]. MIN=mammary intraepithelial neoplasia;
AdsC= adenosquamous carcinoma; PdC= poorly differentiated carcinoma. The number of mice of each histological category over the total number of the
mice examined is indicated and the corresponding percentage is shown in parentheses.
p values (chi-square test WapCre-Men1F/F versus Men1F/F): *0.0548; †0.0057; ‡< 0.0001.
of age and both developed MIN lesions. The overall
incidence of MIN lesions in WapCre-Men1 F/F mutant
mice was found to be signiﬁcantly (7.2-fold) higher
than that in Men1 F/F control mice (p < 0.0001), with
rates of 51.5% and 7.1%, respectively. The histo-
logical examination also revealed the occurrence of
adenosquamous carcinoma in one Men1 F/F and two
WapCre-Men1 F/F mice (non-signiﬁcant difference). A
poorly differentiated inﬁltrating carcinoma was also
detected in a Men1 F/F mouse.
MIN lesions, known to be potential precursor lesions
of mammary cancer, are focal or multifocal areas
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Figure 4. WapCre-Men1F/F female mice develop mammary neoplasia showing menin inactivation and reduced ER expression. (A)
Representative histological sections (H&E staining, left and middle columns) and IHC detection of menin (right column) for two mammary
intraepithelial neoplasia (MIN) lesions and an adenosquamous carcinoma found in WapCre-Men1F/F mice (18-, 14-, and 13-month-old
mice, respectively). MIN lesions display intraluminal proliferation of cells with nuclear atypia (nuclear enlargement and chromatin
clumping) and prevalent mitoses (black arrowheads). Adenosquamous carcinoma is characterized by the association of glandular tumour
tissue with clusters of squamous metaplasia and signs of invasion into the surrounding stroma. The red arrowhead indicates a tripolar
atypical mitosis. The middle and right columns are four-fold magniﬁcation of the ﬁrst column. Insets show an ampliﬁed view of a portion
of menin-immunostained mammary lesion illustrating the complete loss of menin expression in neoplastic cells, while basal myoepithelial
cells remain menin-positive. Scale bar= 50 μm. (B) In normal mammary glands from multiparous 12-month-old Men1F/F control mice,
ER was detected in approximately 20–30% of epithelial cells but was decreased in lesions detected in WapCre-Men1F/F mice (n = 7).
Representative images of two MIN from multiparous WapCre-Men1F/F mice (14- and 17-month-old mice, respectively) are presented.
Scale bar= 50 μm.
of intraluminal epithelial proliferation with signiﬁcant
nuclear atypia (large pleomorphic nuclei with hyper-
chromasia) and frequent mitosis, but they do not show
evidence of invasion [3] (Figure 4A, top and mid-
dle panels). Taken together, we can conclude that
the development of MIN lesions frequently occurred
in the mutant mice, whereas mammary carcinomas
appeared to be rare and non-signiﬁcant events in
these mice.
Menin expression was absent in 10/13 MIN lesions
and in the two adenosquamous carcinomas that devel-
oped in the WapCre-Men1 F/F mice (Figure 4A, right
column). All three tested MIN lesions and the two
carcinomas found in the Men1 F/F mice demonstrated
menin expression (data not shown). Overall, our data
indicate that Men1 ablation in mammary epithelial
cells signiﬁcantly exacerbated the development of
pre-cancerous MIN lesions, whereas Men1 F/F female
mice are only prone to low-incidence spontaneous MIN
and carcinoma lesions. By IHC analysis of ERα, both
the intensity and the number of ERα-positive cells were
clearly reduced (Figure 4B) in MIN lesions of mutant
mice compared with normal mammary glands.
Prolactinoma development in WapCre-Men1F/F
female mice secondary to pituitary leakage of the
WapCre transgene
WapCre-Men1 F/F mice were found to die signiﬁcantly
earlier (mean survival: 14months) than the other two
genotypes (mean survival: 21months) (Figure 5A).
Necropsies identiﬁed that the cause of death was
highly haemorrhagic pituitary adenomas, consistent
with the detected WapCre leakage in the pituitary.
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Pituitary tumour development started at approximately
9months of age in the WapCre-Men1 F/F mice, reach-
ing an incidence of 61.5% at 9–12months, 94.3% at
12–15months, and 77.8% at> 15months (Table 2).
The pituitary tumours were shown to originate from the
pars distalis by histological examination (Figure 5B).
Immunohistochemistry of menin expression conﬁrmed
that the Men1 gene was completely inactivated. The
expression of growth hormone was almost com-
pletely absent in these tumours, while the number of
prolactin-secreting cells was largely increased, indi-
cating prolactinomas. The serum prolactin level in
WapCre-Men1 F/F mice was two-fold higher than that
of control mice (Figure 5C). Our results showed that
menin inactivation, caused by pituitary leakage of the
WapCre transgene, triggers prolactinoma development
in WapCre-Men1 F/F mice, which is associated with
hyperprolactinaemia and leads to the premature death
of these mice.
Increased incidence of MIN in WapCre-Men1F/F
mice is not completely explained by pituitary
tumour development
Prolactin is a well-known stimulating signal for rodent
mammary epithelial cell proliferation [17], whereas
its importance in the development of human breast
cancer remains controversial. A number of mouse
models have described a potential oncogenic role of
constitutively activated prolactin signalling in mam-
mary glands [18]. To assess the potential effect of
increased serum prolactin levels on the incidence
of MIN observed in our mutant mice, we com-
pared the mean levels of serum prolactin between
WapCre-Men1 F/F mice without any detected mam-
mary lesion and WapCre-Men1 F/F mice that devel-
oped mammary lesions (Figure 5D). We did not
observe a signiﬁcantly higher level of prolactin in
mice with mammary lesions, suggesting the absence
of a correlation between the occurrence of mammary
lesions and hyperprolactinaemia. Furthermore, when
excluding the mutant mice with hyperprolactinaemia
from the analysis of MIN incidence (Supplementary
Table 1), the incidence of MIN lesions in mutant
mice remained virtually the same. The activation of
the prolactin signalling pathway is usually assessed
by the tyrosine residue phosphorylation of the tran-
scription factor STAT5 (signal transducer and activa-
tor of transcription 5) [19]. Therefore, we analysed
phospho-STAT5 expression by immunohistochemistry
in the MIN lesions that had developed in WapCre-
Men1 F/F mice (Figure 5E). When compared with the
intensity of staining in normal mammary glands from
Men1 F/F mice, we found that the level of phospho-
STAT5 expression in the MIN lesions from WapCre-
Men1 F/F mice was signiﬁcantly decreased rather than
increased (Figure 5 F).
To conﬁrm that the increase in MIN lesions observed
in our WapCre-Men1 F/F mice could not be simply
considered a consequence of the hyperprolactinaemia
detected in these mice, we analysed mammary glands
from another Men1 mutant mouse model that devel-
oped prolactinomas [16]. In the Men1loxP/loxP/Rip-Cre+
mice, the authors observed a pituitary leakage of the
Rip-Cre transgene (rat insulin promoter), which also
led to the development of prolactinomas. In that
model, the expression of menin protein was intact in
the mammary glands. Histopathological examination
of the mammary glands was performed in a group of
20 Men1loxP/loxP/Rip-Cre+ female mice 9–16months
of age and six Men1loxP/loxP control mice (age:
11–12months). Among the 20 Men1loxP/loxP/Rip-Cre+
female mice, four developed MIN lesions (20%,
Table 3 and Supplementary Figures 2A–2 F), which
was not statistically signiﬁcant when compared
with control mice (p = 0.38). Hence, our WapCre-
Men1 F/F female mice developed 2.5 times more MIN
lesions than the Men1loxP/loxP/Rip-Cre+ mice, and
the difference in the rates was statistically signiﬁcant
(p = 0.0107). Taken together, the above data sug-
gest that the increased incidence of MIN lesions in
WapCre-Men1 F/F mice is likely to be independent of
prolactinoma development, thereby evoking a more
direct role of Men1 inactivation in the development
of these lesions.
Altered membrane expression of both beta-catenin
and E-cadherin in MIN and carcinomas that
developed in WapCre-Men1F/F mice
The inactivation of cell–cell adhesion factors and the
activation of the Wnt/beta-catenin signalling pathway
have both been described to promote mammary
tumourigenesis, the latter being particularly related
to the development of mammary squamous meta-
plasia [20,21]. Therefore, we investigated whether
E-cadherin expression and beta-catenin expression
were altered in the observed MIN lesions. In con-
trast to the prominent cell membrane expression
of both beta-catenin (Figure 6A) and E-cadherin
(Figure 6G) in the mammary glands of control
mice, cell membrane expression of both beta-catenin
and E-cadherin was nearly absent in the mammary
lesions of WapCre-Men1 F/F mice, with only residual
cytoplasmic expression (Figures 6D–6 F, 6H, and
6I). Decreased cell membrane expression of both
beta-catenin and E-cadherin was also observed in
lesions from Men1 F/F control mice, often accom-
panied by the nuclear activation of beta-catenin in
peripheral cells (Figures 6B and 6C). We further
analysed beta-catenin and E-cadherin expression
upon menin down-regulation by Si-MEN1 in MCF7
cells using western blot. Menin partial inactiva-
tion resulted in decreased E-cadherin expression in
MCF7 cells (Figure 6 J), whereas no altered beta-
catenin expression was detected (data not shown).
Interestingly, neither E-cadherin (Figure 6 J) nor
beta-catenin (data not shown) was detected in the
TS1 cell line derived from the mouse Men1 breast
cancer.
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Figure 5. Pituitary leakage of the WapCre transgene leads to the development of prolactinomas in WapCre-Men1F/F female mice, which
does not completely explain the increased incidence of MIN lesions. (A) Kaplan–Meier analysis determining the survival ratio of female
Men1F/F (blue line, n = 34), WapCre-Men1+/+ (black line, n = 27), and WapCre-Men1F/F mice (red line, n = 75) according to age. Ill and
distressed mice that were killed or died prematurely were counted as a death event. Mice sacriﬁced at the pre-determined time points
were considered to be alive. WapCre-Men1F/F mice were found to die signiﬁcantly earlier due to pituitary tumours, with a mean survival
of approximately 14months, compared with approximately 21months for the other two genotypes (log-rank test, p < 0.0001). (B) The
pituitary adenomas that developed in WapCre-Men1F/F mice were prolactinomas. H&E staining and immunohistochemical detection of
menin, growth hormone (GH), and prolactin expression were performed using a normal pituitary gland from a control 19-month-old
Men1F/F mouse (upper panel) and a pituitary adenoma found in a 12-month-old WapCre-Men1F/F mouse (lower panel). p.d. = pars
distalis; p.n. = pars nervosa. Scale bar= 50 μm. (C) Mean serum prolactin concentration was signiﬁcantly increased in WapCre-Men1F/F
(41.55 ng/ml± 5.653, n = 32) compared with Men1F/F (11.00 ng/ml± 4.008, n = 10) and WapCre-Men1+/+ mice (17.84 ng/ml± 5.885,
n = 10). #p = 0.0323; *p = 0.0056 (unpaired two-tailed t-test). (D) Elevated prolactin levels do not correlate with mammary lesion
development in WapCre-Men1F/F mice. Mean serum prolactin concentrations in WapCre-Men1F/F mice over 9months of age either without
(w/o) mammary lesions (39.91 ng/ml± 9.045, n = 18) or with mammary lesions (43.66 ng/ml± 6, n = 14) were not signiﬁcantly different
(p = 0.7478, unpaired two-tailed t-test). (E) IHC detection of phospho-STAT5. Representative images of normal mammary glands and a MIN
lesion from a 13-month-old control mouse and a 14-month-old WapCre-Men1F/F mouse, respectively, are shown. Scale bar= 50 μm. (F)
Quantitation of luminal cells expressing phospho-STAT5 in control WapCre-Men1+/+ mice (47.01%± 7.809, N = 5) and WapCre-Men1F/F
mutant mice (20.69± 2.444, N = 6). At least 4900 luminal cells were counted for each group. Data are represented as the mean perce
ntage+ SEM (**p = 0.0069, unpaired two-tailed t-test).
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Table 2. Age-related incidence of pituitary adenomas in WapCre-Men1F/F females
Genotype Pituitary histology 9–12months 12–15months > 15months Overall incidence
WapCre-Men1+/+ Normal 0/9 (0%) 0/8 (0%) 0/9 (0%) 0/26 (0%)
Men1F/F Normal 0/6 (0%) 0/10 (0%) 0/12 (0%) 0/28 (0%)
WapCre-Men1F/F Normal 5/13 (38.5%) 2/35 (5.7%) 4/18 (22.2%) 11/66 (16.7%)
Adenoma 8/13 (61.5%) 33/35 (94.3%) 14/18 (77.8%) 55/66 (83.3%)
The number of mice of each histological category over the total number of the mice examined is indicated and the corresponding percentage is shown in parentheses.
Figure 6. Decreased membrane expression of beta-catenin and E-cadherin in MIN lesions and adenosquamous carcinomas in WapCre-
Men1F/F mice. (A–F) Beta-catenin staining was mainly cell membrane-localized with some cytoplasmic localization in normal mammary
glands from control mice (A, an 18-month-old Men1F/F mouse), whereas nuclear beta-catenin staining could be detected in MIN lesions
that developed in Men1F/F mice (B, 8-month-old mouse). In contrast, membrane and cytoplasmic beta-catenin expression was decreased
in MIN lesions and adenosquamous carcinomas that developed in WapCre-Men1F/F mice. Representative photographs show beta-catenin
staining in three MIN lesions (C, D, and E are from an 18-month-old, a 17-month-old, and a 12-month-old mouse, respectively) and an
adenosquamous carcinoma (F, 13-month-old mouse) from the mutant mice. (G–I) E-cadherin staining was localized to the cell membrane
of normal mammary glands from control mice (G, 12-month-old Men1F/F mouse). Membrane expression of E-cadherin was decreased in
MIN lesions (H, 12-month-old mouse) and adenosquamous carcinomas (I, 13-month-old mouse) that developed in WapCre-Men1F/F mice.
The insets show an ampliﬁed view of a section of the mammary lesions. Scale bar= 100 μm. (J) Western blot analysis of E-cadherin
expression in MCF7 cells transfected by either non-targeting siRNA (Si-Ctrl) or anti-MEN1 siRNA (Si-MEN1). NT= not transfected.
Cytoplasmic protein extracts were used for E-cadherin detection and mixed cytoplasmic and nuclear protein extracts were used for menin
detection. The mature E-cadherin form is indicated by the arrow. Protein loading was monitored by actin. The analysis was repeated twice.
Reduced menin expression in human breast cancers
The increased incidence of MIN lesions in WapCre-
Men1 F/F mice prompted us to investigate menin
expression in human sporadic breast cancers. First,
we determined menin expression levels by IHC and
found that 95 of 121 tumours (78.5%) displayed
low menin expression (Figures 7A–7C). We also
performed western blotting to analyse menin expres-
sion in another independent panel of 26 sporadic
breast cancers. Compared with menin expression lev-
els in normal human breast tissue, four of the tested
cancer samples (15%) showed a sharp decrease in
menin expression (Figure 7D). Statistical analyses of
the TMA data showed that neither age, menopausal
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Figure 7. Menin expression is reduced in a large proportion of human breast cancers. (A–C) Representative images of menin IHC in normal
human mammary gland (A: staining intensity 2) and of reduced menin expression in patients with breast cancer (B, C: staining intensity
1). (D) Menin detection by western blot in a panel of 26 ER-positive tamoxifen-treated breast cancer patients. * marks the samples with
clearly reduced menin expression. (E) Comparison of Kaplan–Meier estimates for overall survival in breast cancer patients included in the
TMA analysis showing the survival distribution curves between tumours showing normal expression of menin (staining intensity 2, red
curve) and low menin nuclear staining (intensity 1, blue curve). Corresponding numbers of patients at risk are indicated below the curves.
Table 3. Incidence of mammary lesions in Men1loxP/loxP/Rip-Cre+
female mice developing prolactinomas
Normal 16/20 (80%)
MIN 4/20 (20%)
Carcinoma 0/20 (0%)
Mammary lesions were classiﬁed according to the recommendations of the
Annapolis Pathology Panel [2]. MIN=mammary intraepithelial neoplasia. The
number of mice of each histological category over the total number of the
mice examined is indicated and the corresponding percentage is shown in
parentheses. Analysed females were aged from 9 to 16months.
status, histological grade, lymph node involvement,
hormonal status nor cancer subtype was signiﬁcantly
correlated with low menin expression (Table 4).
Furthermore, neither overall survival (OS, log-rank
test p = 0.5181) nor progression-free survival (PFS,
log-rank test p = 0.3702) was signiﬁcantly different
between low (intensity grade 1) or normal (intensity
grade 2) menin-staining tumour groups (Figures 7E and
7 F). Together, these results suggest that menin expres-
sion is not a prognostic biomarker for patient outcome
in this cohort of breast cancer patients.
Discussion
By disrupting the Men1 gene speciﬁcally in mammary
luminal cells, the present study assessed the potential
role of Men1 inactivation in mammary tumourige-
nesis. Men1 ablation in mammary luminal cells did
not result in any obvious defects in the postnatal
development of mammary glands, whereas it did
predispose mice to the development of pre-cancerous
lesions. Our data therefore provide a strong indication
of an important and hitherto unknown role of the Men1
gene in mammary cells. We noticed a low incidence of
similar pre-cancerous lesions in Men1 F/F control mice.
The fact that WapCre-Men1+/+ mouse littermates did
not show a similar phenotype does not support the
view that the mouse genetic background could be
the factor causing the predisposition to MIN lesions
as previously reported [22–24]. Rather, although the
ﬂoxed Men1 allele has previously been proven to
be both functional and non-hypomorphic [12,14], we
cannot exclude the possibility that some unknown
disturbance of the ﬂoxed Men1 allele could interfere
with menin’s function in mammary cells. Importantly,
the process of mammary lesion development appeared
to be different in mutant mice compared with Men1 F/F
control mice, as evidenced by its early appearance
and increasing incidence over time in the former. At
the molecular level, the pattern of phosphorylated
STAT5 and beta-catenin expression were substantially
different in MIN lesions found in the mutant mice
compared with those rarely observed in Men1 F/F
control mice, suggesting that the few MIN lesions
found in Men1 F/F control mice may be caused by
different molecular mechanisms.
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Table 4. Comparison of the distribution of clinical parameters between breast cancer patients (TMA cohort) whose tumours show either
low (intensity 1) or normal (intensity 2) menin nuclear staining
Intensity of menin nuclear staining
1 2 All
N = 95 N = 26 N = 121 Test
Age at diagnosis (years)
Mean (std) 58.33 (12.73) 60.20 (11.47) 58.74 (12.44) Wilcoxon
p = 0.458Median (min–max) 56.00 (37.60–87.40) 61.30 (41.60–77.90) 56.30 (37.60–87.40)
Q1–Q3 48.60–66.20 50.80–70.60 48.80–68.00
Menopausal status
No 31 (32.6%) 6 (23.1%) 37 (30.6%) Chi2
p = 0.349Yes 64 (67.4%) 20 (76.9%) 84 (69.4%)
Tumour size
< 30 mm 60 (63.2%) 16 (61.5%) 76 (62.8%) Chi2
p = 0.880≥ 30 mm 35 (36.8%) 10 (38.5%) 45 (37.2%)
Histological type
Lobular 10 (10.5%) 0 (0.0%) 10 (8.3%) Fisher exact
p = 0.231Ductal 76 (80.0%) 24 (92.3%) 100 (82.6%)
Others 9 (9.5%) 2 (7.7%) 11 (9.1%)
Histological grade (SBR)
1 20 (21.1%) 3 (11.5%) 23 (19.0%) Fisher exact
p = 0.6202 41 (43.2%) 12 (46.2%) 53 (43.8%)
3 34 (35.8%) 11 (42.3%) 45 (37.2%)
Lymph node involvement
N0 42 (44.2%) 10 (38.5%) 52 (43.0%) Fisher exact
p = 0.703Micro-metastases 15 (15.8%) 6 (23.1%) 21 (17.4%)
Macro-metastases 38 (40.0%) 10 (38.5%) 48 (39.7%)
ER: % marked cells
< 10% 12 (12.6%) 5 (19.2%) 17 (14.0%) Fisher exact
p = 0.69810–50% 7 (7.4%) 1 (3.8%) 8 (6.6%)
> 50% 76 (80.0%) 20 (76.9%) 96 (79.3%)
PR: % marked cells
< 10% 24 (25.3%) 5 (19.2%) 29 (24.0%) Fisher exact
p = 0.50410–50% 22 (23.2%) 4 (15.4%) 26 (21.5%)
> 50% 49 (51.6%) 17 (65.4%) 66 (54.5%)
HER2 status
Missing 2 0 2 Fisher exact
p = 1.0000/+ 83 (89.2%) 24 (92.3%) 107 (89.9%)
++/+++ 10 (10.8%) 2 (7.7%) 12 (10.1%)
Cancer subtype
Luminal A 57 (60.0%) 13 (50.0%) 70 (57.9%) Fisher exact
p = 0.611Luminal B 26 (27.4%) 8 (30.8%) 34 (28.1%)
HER2 2 (2.1%) 1 (3.8s%) 3 (2.5%)
Triple negative 10 (10.5%) 4 (15.4%) 14 (11.6%)
ER= oestrogen receptor; PR= progesterone receptor.
The possible interplay between the occurrence of
mammary lesions and pituitary tumour development in
the mutant mice is a complex issue. Importantly, our
data indicate that (1) we found no correlation between
the serum prolactin level and MIN development; (2)
the expression of phospho-STAT5 was signiﬁcantly
diminished in the MIN lesions of the mutant mice;
(3) in another Men1 mouse model that developed
prolactinomas but with intact mammary expression of
menin [16], the incidence of MIN was not signiﬁcantly
increased compared with control mice. Altogether, our
data support that Men1 disruption in mammary cells
played a role in MIN development.
Mammary glands are not known to be affected
in patients with MEN1 syndrome. However, several
observations have provided meaningful clues that sug-
gest a possible role of MEN1 in mammary tissues.
An epidemiological study revealed that 7% of patients
with sporadic breast cancer were also diagnosed with
hyperparathyroidism [25]. Because MEN1 mutations
account for approximately 30% of sporadic parathyroid
adenomas, one could speculate that a minor proportion
of breast cancer cases could also be related to a
MEN1 mutation. Consistent with this clinical observa-
tion, we and others previously detected several cases of
breast and prostate cancer in older heterozygous Men1
mutant mice [11–13]. Taking into account the above-
mentioned observations and the interaction between
menin and ERα, the high incidence of MIN devel-
opment in Men1 mammary-speciﬁc mutant mice is,
after all, not an unexpected phenotype. Instead, the
long latent period before MIN onset and the incomplete
penetrance of this mutation suggest that Men1 inacti-
vation itself may not be a major breast cancer-inducing
event. However, Men1 inactivation appears to create a
cancer-prone context that requires other participating
factors that lead to tumourigenesis.
Cell–cell adhesion is part of the basic machinery
involved in the organization of epithelial tissues. Mul-
tiple lines of evidence suggest that its deregulation
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plays a role in breast cancer initiation and progres-
sion [20,21,26–30]. Interestingly, we observed clearly
reduced membrane expression of beta-catenin and E-
cadherin in MIN lesions from mutant mice. Previ-
ous work, including ours, provided evidence that E-
cadherin and beta-catenin membrane expression was
reduced in mice with Men1 inactivation-induced islet
lesions [8,14]. Our current data suggest that menin’s
role in regulating cell–cell adhesion may also be
involved in the control of normal mammary cell growth
and proliferation, although the underlying mechanism
needs further investigation.
Interestingly, our analyses of two series of human
breast cancers demonstrated that a large proportion
of breast cancers displayed reduced menin expression.
This is consistent with a previous report by Imachi
et al . [31]. It is noted that these authors described
a correlation between menin expression and a worse
prognosis in affected patients, whereas we could not
ﬁnd any similar correlation in our samples. The dis-
crepancy between our data and those of Imachi et al .
could be explained by different populations of breast
cancer patients used in the studies. Further analyses
using larger clinical cohorts are needed to better eval-
uate the role of menin expression in breast cancer
occurrence and progression.
Taken together, by speciﬁcally disrupting the Men1
gene in mammary gland cells, we have provided
compelling evidence that menin inactivation in mice
results in a high incidence of pre-cancerous mammary
lesions. The discovery of this unknown role of menin
may shed light on the complex molecular mechanisms
of mammary tumourigenesis. In this regard, mice
in which Men1 was disrupted speciﬁcally in the
mammary glands are a tool to identify and study
additional factors that are important for the initiation
and progression of breast cancer.
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Figure S1. Menin inactivation in mammary gland carcinomas detected in heterozygous Men1 mutant mice.
Figure S2. Histological sections of mammary lesions found in Men1loxP/loxP/Rip-Cre+ mice presenting with prolactinoma development.
Table S1. Incidence of MIN lesions in WapCre-Men1 F/F females without hyperprolactinaemia.
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MafB, a member of the large Maf transcription factor
family, is essential for the embryonic and terminal
differentiation of pancreatic a- and b-cells. However, the
role of MafB in the control of adult islet-cell proliferation
remains unknown. Considering its oncogenic potential in
several other tissues, we investigated the possible altera-
tion of its expression in adult mouse b-cells under different
conditions of proliferation. We found that MafB, in
general silenced in these cells, was reexpressed in B30%
of adaptive b-cells both in gestational female mice and in
mice fed with a high-fat diet. Importantly, reactivated
MafB expression was also observed in the early b-cell
lesions and insulinomas that developed in b-cell speciﬁc
Men1 mutant mice, appearing in >80% of b-cells in
hyperplasic or dysplastic islets from the mutant mice >4
months of age. Moreover, MafB expression could be
induced by glucose stimulation in INS-1 rat insulinoma
cells. The induction was further reinforced following
Men1 knockdown by siRNA. Furthermore, MafB over-
expression in cultured bTC3 cells enhanced cell foci
formation both in culture medium and on soft agar,
accompanied with the increased expression of Cyclin B1
and D2. Conversely, MafB downregulation by siRNA
transfection reduced BrdU incorporation in INS-1E cells.
Taken together, our data reveal that Men1 inactivation
leads to MafB reexpression in mouse b-cells in vivo, and
provides evidence that deregulated ectopic MafB expres-
sion may have a hitherto unknown role in adult b-cell
proliferation and Men1-related tumorigenesis.
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Recent studies highlight that the adult pancreatic b-cells
have, in general, limited capacity for cell replication
(Teta et al., 2007). However, in certain circumstances,
such as during gestation or under high-caloric diet, they
may undergo adaptive cell proliferation. The identiﬁca-
tion of molecular mechanisms underlying the control of
b-cell proliferation is a major issue in the ﬁeld of islet
biology, as their deregulation may lead to both
metabolic and tumor disorders. Among different path-
ways and factors known to be involved in the control of
b-cell proliferation, menin, the protein encoded by the
MEN1 gene, is of particular interest. It is not only
known as a tumor suppressor in islet cells (Yang and
Hua, 2007), but also for its role in adaptive
b-cell proliferation (Karnik et al., 2007). Menin is
considered as a cofactor of transcriptional regulation,
capable of interacting with many transcription factors
and other protein partners. Although it has been
demonstrated that menin inactivation led to acute
b-cell proliferation (Schnepp et al., 2006; Yang et al.,
2010), several studies of mouseMen1 insulinoma models
highlighted the fact that the menin-related tumorigenesis
procedure may need the participation of other
factors apart from Men1 inactivation (Bertolino et al.,
2003b; Crabtree et al., 2003; Lofﬂer et al., 2007; Yang
and Hua, 2007).
Among different candidate genes that may participate
in the control of b-cell proliferation by menin, the large
Maf family in particular has drawn our attention, owing
to their involvement both in oncogenesis and adult
islet-cell function. Although their oncogenic role
appears to depend on cell type and tissue (Pouponnot
et al., 2006; Rocques et al., 2007), several reports
including their translocation in human multiple myelo-
ma (Chesi et al., 1998) have ﬁrmly established the large
Maf family members, MafA, MafB and c-Maf, as
bona ﬁde protooncogenes (Eyche`ne et al., 2008). It was
shown that Maf proteins can transform primary cells
(Nishizawa et al., 2003; Pouponnot et al., 2006). Their
oncogenic activity was also demonstrated in multiple
myeloma cell lines (Hurt et al., 2004) and in mice
(Morito et al., 2006, 2011).
During mouse development and adulthood, the
expression of large Mafs in the endocrine pancreas is
tightly regulated. MafA is only expressed in insulin-
producing cells during development and in adult life,
and has been demonstrated as a critical factor in the
regulation of genes crucial for adult b-cell function
(Zhang et al., 2005). MafB is expressed in both
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glucagon- and early insulin-secreting cells during em-
bryonic development, whereas its expression is restricted
to a-cells in the adult (Artner et al., 2007). Constitutive
MafB loss of function mutations in mice showed
reduced number of cells expressing insulin and gluca-
gon, and the blockade of b-cell maturation (Artner
et al., 2007; Nishimura et al., 2008), indicating that
MafB possesses an essential function in cell proliferation
and differentiation of both a- and b-cells at the
embryonic stage. Moreover, MafB has been recently
shown to be induced in the islets of e15.5 pregnant
female mice (Pechhold et al., 2009), suggesting its
relevant role in adult adaptive b-cell proliferation.
However, the role of large Maf members in the control
of adult islet-cell tumorigenesis remains unknown.
To gain insight into this issue, we decided to
investigate the expression of Maf family members in
mouse b-cells under different physiological and patho-
logical conditions of proliferation. We ﬁrst examined the
in vivo expression of large Mafs in normal pancreas
during the embryonic stage and adulthood. At E14.5,
consistent with previous reports (Artner et al., 2006;
Nishimura et al., 2006), MafA was detected only in
insulinþ cells (Supplementary Figure S1a), whereas
MafB was expressed in both glucagonþ and insulinþ
cells (Supplementary Figure S1b). c-Maf was not
detectable in the embryonic pancreas even at E17,5
(Supplementary Figure S1c). In 2-month-old islets,
MafA was expressed in >95% of b-cells (Supplemen-
tary Figure S1d), whereas MafB expression was
restricted to a-cells (Supplementary Figure S1e). c-Maf
was weakly and strongly expressed in the endocrine and
exocrine pancreas, respectively (Supplementary Figure
S1f), and, therefore, not pursued for further investigation.
Next, we examined MafA and MafB expression in
b-cells that underwent adaptive proliferation triggered
by physiological or pathological needs, using islet
sections from either pregnant or high-fat-fed mice. We
observed that, albeit the expected MafA expression in
b-cells (data not shown), MafB was aberrantly reex-
pressed in 31±4.2% of b-cells in the islets of C57BL/6
female mice (n¼ 6) on pregnant day 14.5 (Figure 1a)
where adaptive b-cell proliferation reaches its highest
level (Karnik et al., 2007). Our data are consistent with
recent ﬁndings by Pechhold et al. (2009). We noticed
that the appearance of MafB reexpression was accom-
panied with an increase in Ki67þ cell number (Figures
1a and b). Interestingly, as shown in Figure 1c, most of
Ki67þ b-cells co-expressed MafB. No MafB reexpres-
sion was found in the age-matched non-pregnant female
littermates. Similarly, a substantial number of b-cells
reexpressing MafB was found in all tested high-fat-fed
adult mice as compared with the control mice (Figure 1d).
Due to their diet, the former displayed increased body
weight, normal fasting glucose and impaired glucose
tolerance by IPGTT analysis (Figures 1e–g) and b-cell
hyperplasia (Figure 1d). Taken together, the above results
suggest a possible link between adaptive b-cell prolifera-
tion and reactivated MafB expression.
The above ﬁndings prompted us to question whether
MafB was also ‘switched-on’ in mouse Men1 insulino-
mas, another condition of pathological b-cell prolifera-
tion. We addressed this issue in insulinomas that
developed in Men1F/F-RipCreþ mice, a b-cell-speciﬁc
Men1 knockout model previously generated in our
laboratory (Bertolino et al., 2003a, b). Unexpectedly, in
insulinomas from 12-month-old mutant mice, MafB was
found to be reexpressed in tumors with menin inactiva-
tion at both the mRNA (Figure 2a) and protein levels,
latter being conﬁrmed by western blot (Figure 2b) and
immunostaining (Figure 2c). In contrast, Arx, another
a-cell-speciﬁc transcription factor, and glucagon were
virtually undetectable in the same insulinomas (Figures
2a and c), because of the disappearance of normal
a-cells in tumor lesions. Therefore, our data excluded
the responsive a-cell proliferation due to hypoglycemia
as the cause of MafB reexpression.
To determine whether MafB reexpression is an early
event in insulinoma development, we examined young
Men1F/F-RipCreþ mice (Figure 2d). Interestingly, MafB
expression was already detectable in a substantial
number of b-cells in mice at 2 months of age
(23±3.8%, n¼ 4), with the number of MafB-expressing
b-cells increasing sharply at 4 months (86±4.2%, n¼ 4).
Immunoﬂuorescent staining clearly showed that the
majority of MafB-positive cells seen in the lesions did
not express glucagon (Figure 2d) but insulin (data not
shown). Double immunoﬂuorescent staining using anti-
Pdx1 and MafB antibodies further conﬁrmed the results,
indicating that they are indeed b-cells as opposed to
a-cells (Supplementary Figure S2).
As MafB reexpression was found to be induced in both
adaptive b-cell proliferation and tumorigenesis related to
menin inactivation, we sought to better deﬁne the
interplay between menin expression, metabolic loading
and MafB reexpression. To this end, INS-1E rat
insulinoma cells (Merglen et al., 2004) were ﬁrstly
subjected to Men1 knockdown by siRNA transfection
under normal culture conditions (Figure 3a, Supplemen-
tary Figures S3a and b). Menin downregulation in these
cells resulted in a 2.7-fold increase in MafB expression
(Figure 3a). As menin was previously reported to be
downregulated during adaptive b-cell proliferation
(Karnik et al., 2007), we also examined menin expression
and its potential correlation with MafB reexpression in
pregnant (Supplementary Figure S4) or high-fat-fed mice
(data not shown). No decrease in menin expression was
evident in both conditions, consistent with a recent report
where menin expression levels in islets were found
unchanged in mice fed with a high-fat diet (Yang et al.,
2010), thus no correlation could be found between
ectopic MafB expression and menin expression levels.
To gain further insight into MafB regulation, INS-1E
cells were subjected to glucose stimulation, after Men1
knockdown by siRNA. After having assessed MafB
expression in different glucose concentrations in INS-1E
cells (Supplementary Figures S5a and b), we adopted a
commonly used glucose-stimulation protocol with an
overnight starvation in 0.1mM glucose medium followed
by a 6-h stimulation in 11mM glucose medium (da Silva
Xavier et al., 2010), in order to examine the effect of
Men1 knockdown on MafB expression upon glucose
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stimulation. Six hours after acute glucose exposure,
INS-1E cells treated with the non-targeting siRNA
showed a marked 2.0-fold increase in MafB expression
compared with the initial expression levels, whereas no
signiﬁcant change was detected in menin expression
(Figure 3a). These data suggest that glucose stimulation
alone can activate MafB expression without altering
menin expression under the current experimental con-
ditions. More interestingly, Men1 knockdown by
siRNA in these cells further increased glucose-induced
MafB expression by a 2.7-fold increase (Figure 3a).
Similar results were obtained using INS-rb cells (Wang
and Iynedjian, 1997), another subclone of INS-1 cells
(data not shown). Using real-time RT–PCR analysis, an
increase in MafB mRNA level was detected in all INS-
1E cells with Men1 knockdown cultured with different
glucose concentrations (Figure 3b), suggesting that
menin downregulation affects MafB transcription. This
is reminiscent of what was observed in mouse Men1
insulinomas (Figure 2a). Taken together, our data
suggest that both glucose stimulation and menin down-
regulation can independently induce MafB reexpression
Figure 1 MafB is ectopically expressed in proliferative b-cells during pregnancy and in obesity. (a) Representative images of
immunoﬂuorescent staining from 14.5-dpc pregnant mice and non-pregnant female littermates using anti-MafB (1:4000, Bethyl,
Montgomery, TX, USA), Ki67 (1:100, Santa Cruz Biotech, Santa Cruz, CA, USA) and insulin (1:500, DAKO, Carpinteria, CA, USA)
antibodies. Immunoﬂuorescent staining was performed as described previously (Fontaniere et al., 2008; Lu et al., 2010). Pregnant C57BL/
6 wild-type mice were generated by timed-mating. (b, c) Graphs show the percentage of Ki67-positive b-cells per islet and the distribution
of MafB-positive and MafB-negative b-cells over total Ki67-positive b-cells, respectively. (d) MafB expression in islets from high-fat-fed
obese mice by immunoﬂuorescent staining as in (a). 2-month-old male C57BL/6 mice purchased from Charles River Laboratories (St-
Germain-sur-l’Arbresle, France) and fed with a high-fat diet (45 kcal% fat, 35 kcal% carbohydrate and 20 kcal% protein) (Research
Diets, North Brunswick Township, NJ, USA) or a chow diet for 16 weeks were subject to the monitoring of body weight (e) and serum
glucose levels after 5 h of fasting (f) and IPGTT (g, 2mg per g body weight) (n¼ 6). *Po0.05 (Student’s t test). The data are presented as
means±s.e.m. All animal experiments carried out in the current study were approved by the Regional Animal Experiments Committee of
Centre National de la Recherche Scientiﬁque and were conducted in accordance with the ethical guidelines.
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in INS-1 cells, whereas they exert a synergistic effect
when applied simultaneously.
To understand the biological signiﬁcance of MafB
reexpression in the control of b-cell proliferation, we
overexpressed human MAFB protein in the bTC3-cell
line that has no detectable endogenous MafB expres-
sion. Colony formation assay showed that exogenous
MAFB overexpression signiﬁcantly increased cell pro-
liferation by B30% as compared with the control
(Figures 3c and 4a). We further investigated the effect of
MAFB overexpression on anchorage-independent
growth and found that MAFB-overexpressing bTC3-
cells formed more than eightfold more colonies in soft
agar compared with control cells (Figure 3d). Further-
more, as shown in Figure 4a, we observed that MAFB-
overexpressing bTC3-cells displayed the upregulated
expression of both Cyclin D2, a previously identiﬁed
MafB target gene in myeloma cells (van Stralen et al.,
2009), and Cyclin B1 (Figure 4a). Factors in both Cyclin
D and Cyclin B families were previously reported to be
upregulated in mouse Men1 insulinomas (Fontaniere
et al., 2006) and in mouse b-cells, with acute Men1-
ablation (Yang et al., 2010). To conﬁrm the above
results, MafB was knocked-down by siRNA transfec-
Figure 2 MafB is ectopically expressed in insulinomas and early b-cell lesions developed in Men1F/F-RipCreþ mice. (a) Analysis of
MafB, Arx andMen1 expression in islets from 12-month-old mutant and 10 littermate control mice (CT, sevenMen1þ /þ -RipCreþ and
three Men1F/F-RipCre mice, respectively) by real-time RT–PCR was carried out as previously described (Fontaniere et al., 2006).
Results are from representative experiments performed in triplicate. Bars represent the mean. Student’s t tests were used to compare
means between two groups. *Po0.05 and ***Po0.001. (b) Menin and MafB expressions in insulinomas derived from two 12-month-
old Men1F/F-RipCreþ mice were analyzed and compared with two independent pools of islets from age-matched control mice by
western blot analyses using anti-menin (1:8000, Bethyl), MafB (1:2000, Bethyl) and b-actin antibodies (1:50 000, Santa Cruz). (c) MafB,
Arx and menin protein detection in islets from mutant and control mice by immunostaining. Representative images of
immunohistochemical analysis using anti-MafB and Arx antibodies, respectively (1:1000, given by Pr Jacques Philippe) and triple-
immunoﬂuorescence analysis using anti-menin (1:4000, Bethyl), insulin and glucagon antibodies. (d) Detection of MafB expression in
early b-cell lesions. Graphs show the percentage of MafBþInsþ cells over total b-cell number. Representative images of double
immunoﬂuorescent staining of MafB and glucagon in the pancreas from 2- (left) and 4-month (right)-oldMen1F/F-RipCreþ and control
mice. The results represent the mean of three independent experiments±s.e.m. **Po0.01 (Student’s t test).
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tion in INS-1E cells. We found signiﬁcantly less BrdU
incorporation and less Cyclin D1 and D2 expression
levels in the cells with reduced MafB expression
(Figure 4b). Interestingly, co-expression analysis of
Cyclin D2 and MafB in islets from gestational mice
(Figures 4c and d) or from the high-fat-fed mice (data
not shown) revealed that >60.5% of MafB-reexpressing
b-cells co-expressed Cyclin D2, whereas only 11.8% of
MafB-negative b-cells expressed Cyclin D2. Taken
together, these data suggest that MafB overexpression
promotes b-cell proliferation by controlling the expres-
sion of important cell cycle regulators.
In the present study, we showed that MafB, which is
normally ‘switched-off’ in normal adult b-cells, was
reexpressed in both pregnant and high-fat-fed mice. We
further demonstrated that MafB reexpression also
occurred in the early neoplastic lesions of menin-
deﬁcient b-cells and in mouse Men1 insulinomas. Our
work strongly suggests that MafB reexpression could be
a key factor for b-cell proliferation, both in the context
of physiopathological metabolic needs and that of
tumorigenesis. Although previous reports have identi-
ﬁed several genes with altered expression in mouseMen1
insulinoma (Fontaniere et al., 2006; Mould et al., 2007),
the current study describes for the ﬁrst time the altered
expression of a transcription factor known to have a
critical role during normal islet development in early
Men1 b-cell neoplastic lesions. Considering the known
oncogenic function of MafB in other tissues (Eyche`ne
et al., 2008) and the effects of its overexpression on
growth behavior of bTC3-cells observed in this study,
we believe that MafB reexpression may fulﬁll a tissue-
speciﬁc molecular link between menin inactivation and
b-cell proliferation by increasing the expression of the
cell cycle regulators. It should be noted that the lack of
speciﬁc anti-human-MafB antibodies prevented us from
extending our current investigation into human MEN1
insulinomas and proliferative b-cells.
In particular, our data demonstrated for the ﬁrst time
that silenced MafB expression in b-cells can be
reactivated not only by glucose stimulation but also by
menin inactivation. MafB reactivation has been re-
ported in adaptive b-cells (Pechhold et al., 2009),
although the underlying mechanism remains elusive.
We may speculate that both glucose and insulin path-
ways could be involved. It appears that menin inactiva-
tion is the major factor leading to MafB reactivation in
Men1 mouse insulinomas, as the glucose levels are
decreased in the mutant mice because of high insulin
levels (Bertolino et al., 2003b), precluding a causal role
for hyperglycemia. In contrast, the in vivo MafB
reexpression in adaptive b-cells appears to be mainly
dependent on the metabolic needs rather than that of
menin expression, as no correlation was detected
Figure 3 MafB expression in cultured b-cells. (a) MafB expression can be induced by acute glucose exposure and is further activated
byMen1 knockdown. INS-1E cells were seeded in 6-well plates and transiently transfected by either non-targeting siRNA or anti-Men1
siRNA (Thermo Scientiﬁc, Waltham, MA, USA) in RPMI1640 medium containing 5mM glucose (ND). After 48 h, cells were starved
overnight in a deprivation medium containing 0.1mM glucose. This was replaced by a stimulation medium containing 11mM glucose
and the cells were harvested at 0 and 6 h. A total of 10 mg cellular extracts in RIPA buffer (Santa Cruz) were used in western blot
analysis. Quantiﬁcation of densitometrically analyzed protein bands in different conditions and indicated time points, from four
independent experiments. The data represent mean±s.e.m. analyzed by Mann-Whitney U-tests. (b) Analysis ofMafB mRNA levels in
INS-1E cells by real-time RT–PCR was carried out as mentioned above using primers MafB-FW: 50-CACCTGCGGGGCTTCACC-30
and MafB-Rev: 50-GCTGCTCCACCTGCTGAATG-30. Results were from a representative experiment performed in triplicate. Bars
represent the mean. Mann–Whitney U-tests were used to compare means between two groups with *Po0.05 considered as signiﬁcant.
(c, d) MafB ectopic expression in bTC3 line promotes cell proliferation. Colony formation test (c) was carried out as previously
described (Hussein et al., 2007). Cells were either untransfected (NT) or transfected with 2mg empty vector pcDNA3.1 or with 2mg
pcDNA-MafB. After 14 days of G418 selection, giemsa-stained colonies were photographed. The results represent the mean of two
independent experiments±s.e.m. *Po0.05. (d) Soft agar test was performed as previously described (Pouponnot et al., 2006). Graphs
show the quantiﬁcation of colony number of three independent experiments performed in triplicate±s.e.m. *Po0.05 (Student’s t test).
MafB reactivation and b-cell proliferation
J Lu et al
3651
Oncogene
Figure 4 Altered MafB expression in b-cell lines deregulates the expression of Cyclins. (a) MafB-overexpressing bTC3-cells displayed
increased expression of Cyclins. Total cell lysates of the above bTC3-cells were analyzed for MAFB and Cyclin expression by western
blot with anti-MAFB, Cyclin D2 (1:2000, Santa Cruz) and Cyclin B1 (1:1000, Santa Cruz). Quantiﬁcation of densitometrically
analyzed bands from four independent experiments were analyzed by Mann–Whitney U-test, *Po0.05, #Po0.001. (b) MafB
knockdown in INS-1E cells resulted in decreased cell proliferation and Cyclin expression. INS-1E cells transiently transfected by either
non-targeting siRNA or anti-MafB siRNA (Thermo Scientiﬁc) were subjected to BrdU incorporation assay and detection of Cyclin
expression by real-time RT–PCR (Cyclin D1-FW: 50-GGATTCAGGACGACTCTT-30, Cyclin D1-Rev: 50-AACCTTCCCAATAAA-
TACTCTTC-30; Cyclin D2-FW: 50-TTTACACCGACAATTCTG-30, Cyclin D2-Rev: 50-TAGGATGTGCTCAATGAA-30). Note
that, in order to better illustrate MafB knockdown, MafB detection by western blot was performed with a protein loading threefold
more than that used in Figure 3a. The results represent the mean of three independent experiments±s.e.m. *Po0.05 (Student’s t test).
(c) Detection of MafB and Cyclin D2 expression in proliferative b-cells from 14.5-dpc pregnant mice and non-pregnant female
littermates using anti-MafB, Cyclin D2 (1:5000, Santa Cruz) and insulin antibodies. (d) Graph shows the percentage of Cyclin D2-
expressing cells in MafBþInsþ and MafBInsþ cell populations, respectively. ***Po0.001 (Student’s t test).
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between ectopic MafB expression and menin expression
levels. To better understand the regulation of MafB
expression by menin, we attempted to investigate the
potential inﬂuence of menin overexpression on the
known MafB promoter (Huang et al., 2000) by
luciferase reporter assay in INS-1E cells. However, we
were unable to detect any effect (data not shown). This
could be because of the MafB promoter tested in the
current study or the complex nature of MafB regulation,
including likely indirect regulation of MafB by menin.
Therefore, it will be relevant to elucidate how menin
participates in the regulation of MafB expression in
b-cells in the future and to determine whether MafB
reexpression is essential for the Men1 insulinoma
development in vivo.
In conclusion, our results demonstrate that the
silenced MafB expression is reactivated in Men1
insulinomas in mice, and establish a correlation between
MafB expression level and cell proliferation capacity of
b-cell lines. Considering the speciﬁc function of MafB in
islets, the current ﬁnding could be useful for better
understanding the tissue-speciﬁcity of MEN1 pathology.
Further studies elucidating the underlying mechanisms
involved in this process may provide insights into the
regulation of b-cell proliferation, which is vital for
treating both metabolic diseases and tumors affecting
b-cells.
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BACKGROUND & AIMS: The tumor suppressor me-
nin is recognized as a key regulator of pancreatic islet
development, proliferation, and -cell function, whereas
its role in  cells remains poorly understood. The pur-
pose of the current study was to address this issue in
relation to islet tumor histogenesis. METHODS: We
generated  cell–speciﬁc Men1 mutant mice with Cre/loxP
technology and carried out analyses of pancreatic lesions
developed in the mutant mice during aging. RESULTS:
We showed that, despite the -cell speciﬁcity of the GluCre
transgene, both glucagonomas and a large amount of insu-
linomas developed in mutant mice older than 6 months,
accompanied by mixed islet tumors. Interestingly, the
cells sharing characteristics of both  and  cells were
identiﬁed shortly after the appearance of menin-deﬁcient
 cells but well before the tumor onset. Using a genetic
cell lineage tracing analysis, we demonstrated that insu-
linoma cells were directly derived from transdifferentiat-
ing glucagon-expressing cells. Furthermore, our data in-
dicated that the expression of Pdx1, MafA, Pax4, and
Ngn3 did not seem to be required for the initiation of
this transdifferentiation. CONCLUSIONS: Our work
shows cell transdifferentiation as a novel mechanism
involved in islet tumor development and provides
evidence showing that menin regulates the plasticity
of differentiated pancreatic  cells in vivo, shedding
new light on the mechanisms of islet tumorigenesis.
Keywords: Men1 Ablation; Pancreatic  Cells; Transdiffer-
entiation; Insulinoma.
Previous clinical studies have highlighted the com-plexity of pancreatic islet tumors, at least one-third
of all functioning islet tumors secreting multiple hor-
mones, and have suggested controversial hypotheses
about their histogenesis.1–3 Despite their rarity, islet tu-
mors have long been attractive for clinicians and inves-
tigators because of the insights they may provide into
islet-cell replication, survival, regeneration, and the ac-
tions of islet hormones in glucose homeostasis.
The most important insights on the molecular patho-
genesis of islet tumors have come from the studies of
inherited pancreatic endocrine tumor syndromes.4 Among
the involved genetic factors, menin, encoded by the MEN1
gene, has drawn particular attention. Menin is a tumor
suppressor, and its mutation causes multiple endocrine
neoplasia type 1 (MEN1), characterized by multiple oc-
currences of endocrine tumors affecting the parathyroid,
endocrine pancreas, and anterior pituitary.5,6 Malignant
islet tumors account for the main cause of death in
patients with MEN1.7  cell–speciﬁc Men1 disruption in
mice, which results in the development of insulinomas,
has conﬁrmed the function of menin as a tumor suppres-
sor in these cells.8–10 Studies of MEN1 syndrome have
deﬁned menin’s role solely in the context of tumor
pathogenesis. However, recent progress enlarged this
view. Interestingly, Karnik et al11 reported that, during
pregnancy, menin was down-regulated by prolactin in
maternal islets, which led to islet mass expansion to meet
the increased metabolic demand. Recently, we showed
that, during embryogenesis, Men1 ablation in mice led to
the abnormal development of both pancreatic  and 
cells, which was accompanied by a decrease in the size of
the neuroginin3 (Ngn3) cell population.12
Although menin has been recognized as a key regulator
in -cell proliferation and endocrine function by exten-
sive studies,13,14 its potential role in  cells remains un-
known. Recent advances highlighted the pathophysiol-
ogy of the  cell in hyperglucagonemia, representing an
important component of the metabolic abnormalities
associated with diabetes mellitus.15,16 In addition to its
effect on insulin secretion, glucagon has also been sug-
gested to play a role in the development of  cells17 and
islet microcirculation.18 Thus, studying the mechanisms
that regulate -cell growth and endocrine function is
useful to better understand the biology of these cells and
the related diseases.
Among islet tumors that develop in patients with
MEN1, glucagonomas only rarely occur. Intriguingly,
Perren et al19 and Anlauf et al20 have shown that in
patients with MEN1, most of the early islet lesions with
Abbreviations used in this paper: -gal, -galactosidase; KO, knock-
out; MEN1, multiple endocrine neoplasia type 1; Ngn3, neuroginin 3;
PCR, polymerase chain reaction.
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a loss of heterozygosity at chromosome 11q13 were glu-
cagon positive, whereas the advanced hormone-secreting
islet tumors detected in these same patients were mainly
insulinomas, suggesting that the glucagon-positive early
lesions may be replaced or overtaken by insulinomas and
mixed islet tumors during tumorigenesis.
To investigate the role of menin in the pancreatic 
cells and further to study MEN1 pathology, we generated
an  cell–speciﬁc Men1 knockout (KO) mouse model.
Surprisingly, in addition to glucagonomas, insulinomas
and mixed glucagon- and insulin-expressing islet tumors
developed in these Men1 mutant mice. A comparative
analysis showed that these insulinomas displayed a dif-
ferent expression proﬁle of endocrine pancreatic markers
than that seen in the insulinomas that developed in a 
cell–speciﬁc Men1 mutant mouse model.8 Further analy-
ses have shown that Men1 ablation in  cells resulted in
their proliferation, thereby triggering the transdifferen-
tiation of menin-deﬁcient  cells into insulin-expressing
cells and the insulinoma formation. Therefore, our study
highlights the role played by menin in the control of
-cell plasticity and establishes transdifferentiation as a
novel mechanism involved in islet tumor development.
Materials and Methods
Animals
Men1/, Men1F/F, Men1F/F-RipCre, GluCre, and
R26R mice have been previously described.8,21–24 Mice
were housed in pathogen-free facilities. All animal exper-
iments were approved by the Regional Animal Experi-
ments Committee of Centre National de la Recherche
Scientiﬁque and were conducted in accordance with the
ethical guidelines.
Histologic and Immunostaining Analyses
Pancreata were harvested at different ages and
ﬁxed in 4% buffered formaldehyde. Immunohistologic
analyses were performed on parafﬁn serial section as
described previously.12 For more information, see Sup-
plementary Materials and Methods.
Quantitative PCR Analysis
Total RNA extraction was done on 2- to 10-
month-old hand-picked islets with the use of an RNeasy
Mini kit (QIAGEN, Courtaboeuf, France) according to
the manufacturer’s instructions. Quantitative real-time
polymerase chain reactions (PCRs) were performed as
previously described.25 Primer sequences are provided in
Supplementary Materials and Methods.
Metabolic Measurements
Serum glucagon and insulin measurements were
analyzed from collected blood with the use of a mouse
endocrine kit (LINCOplex, Multiplexed Biomarker Im-
munoassays; Linco Research, St. Charles, MO). Animals
were deprived of food 5 hours before blood collection,
and duplicate measurements were repeated twice for each
sample.
Double Immunoelectron Microscopy
Pancreata were ﬁxed overnight in 4% paraformal-
dehyde and 0.1% glutaraldehyde and then processed as
described in Supplementary Materials and Methods.
Statistical Analysis
All results were reported as means standard errors
of the mean. Each variable was analyzed with the unpaired
Student’s t test. For all analyses, P values of .05 were
considered signiﬁcant. All analyses were performed with the
use of GraphPad Prism software (GraphPad Software Inc,
San Diego, CA).
Results
Generation of an  Cell–Speciﬁc Men1
Knockout Mouse Model
To disrupt the Men1 gene in the pancreatic  cells,
Men1F/F mice8 were crossed with GluCre mice expressing
Cre recombinase driven by the Proglucagon promoter.23
We ﬁrst checked the -cell speciﬁcity of GluCre in the
endocrine pancreas with the use of GluCre-R26R mice21
(Figure 1A). Consistent with previous reports,26,27 -
galactosidase (-gal) expression was exclusively detected
in the glucagon-producing cells in the pancreata of
GluCre-R26R mice either at embryonic day 18.5 or at 5
months of age (Figure 1B). No labeling was found in
insulin-producing cells (Figure 1B) or in , pancreatic
polypeptide, or acinar cells (data not shown).
Cell-speciﬁc Men1 ablation was then examined in
Men1F/F-GluCre mice. As expected, the excision of the
ﬂoxed Men1 allele was detected by PCR analysis in the
pancreatic islets and intestinal tissues isolated from
6-week-old Men1F/F-GluCre mice but not in other tissues
(Figure 1C). Men1 inactivation was further conﬁrmed by
quantitative reverse transcription–PCR (Figure 1D) and
immunoﬂuorescence (Figure 1E). Menin expression was
lost in 35% of glucagon-expressing cells in the pancreas of
Men1F/F-GluCre mice at 6 weeks of age. Conversely, the
insulin-expressing cells remained menin positive at this
stage. Altogether, the results conﬁrmed  cell–speciﬁc
Men1 disruption in the mutant mice.
 Cell–Speciﬁc Men1 Ablation Leads to
Glucagonoma, Insulinoma, and Mixed Islet
Tumor Development
Men1F/F-GluCre mice were monitored over a 12-
month period and necropsied at different ages. At 2 to 3
months of age, -cell proliferation was clearly observed in
Men1F/F-GluCre mice, with a 40% increase in the propor-
tion of glucagon-expressing cells over total islet cells.
Menin detection showed that the increased number of 
cells was due to the expansion of menin-deﬁcient  cells
(Supplementary Figure 1A and B). Glucagonomas were
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detected from 7 months of age (Supplementary Table 1;
Figure 2A; Supplementary Figure 1C).
Surprisingly, islet adenomas nearly exclusively express-
ing insulin were also detected in Men1F/F-GluCre mice
starting at 7 months of age (Supplementary Table 1;
Figure 2A), whereas no pancreatic polypeptide– or soma-
tostatin-secreting islet tumors were found (data not
shown). There were also a substantial number of islet
Figure 1.  cell–speciﬁc disruption of the Men1 gene in Men1F/F-GluCre mice. (A) Schematic view of the experimental strategy. R26R mice were
crossed with both GluCre and Men1F/F-GluCre mice to trace recombined  cells. (B) Representative images of the lineage-tracing analysis with
the use of immunoﬂuorescence in E18.5 embryonic and 5-month-old islets of GluCre-R26R mice. Note -gal is expressed only in glucagon (Glu)–
but not in insulin (Ins)–expressing cells. Scale bars, 20 m. (C) PCR analysis of tissue-extracted DNA from 6-week-old Men1F/F-GluCre mice. ,
deleted Men1 allele; F, ﬂoxed Men1 allele;, wild-type Men1 allele (n 4). (D) Men1 mRNA level assessed by quantitative reverse transcription–PCR
analysis in pancreatic islets of 2- to 10-month-old Men1F/F-GluCre mice (n  6 for each group). (E) Immunoﬂuorescence analysis of menin
expression in 6-week-old Men1F/F-GluCre and control pancreatic islets (n  5). Arrows indicate menin-deﬁcient glucagon-expressing cells. Scale
bars, 20 m.
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tumors expressing both insulin and glucagon (Figure
2A). At 8 months of age, the proportion of islet tumors
exclusively expressing glucagon or both insulin and glu-
cagon was 15% and 55%, respectively. However, these
proportions decreased to 4%–5% and 29%–26%, respec-
tively, at 10 to 12 months of age. In contrast, the pro-
portion of insulinomas markedly increased over the same
period (Figure 2B). No islet tumors were observed in
Men1/-GluCre (Supplementary Table 1) or Men1F/F-
GluCre control mice (data not shown). The insulinomas
expressed both proprotein convertase 1/3 and glucose
transporter 2, 2 mature -cell markers (Supplementary
Figure 2A). To examine islet cell proliferation, we as-
sessed bromodeoxyuridine incorporation and Ki67 ex-
pression in 10-month-old Men1F/F-GluCre mice. Com-
pared with the control mice, the number of cells
positively labeled was increased, respectively, by 11- and
10-fold in the islet tumors (Supplementary Figure 2B).
No difference in the level of bromodeoxyuridine and
Ki67 labeling was observed between the insulinomas and
glucagonomas (data not shown).
Hyperglucagonemia was detected in mutant mice at
the age of 2 months and increased with age (Figure 2C),
whereas hyperinsulinemia was found starting from 6
months of age (Figure 2D). The blood glucose concen-
tration was increased in young Men1F/F-GluCre mice but
decreased, starting at 6 months of age, and reached the
same concentration as that in the control by 10 months
of age (Supplementary Figure 2C). Intraperitoneal glu-
cose tolerance tests conducted in 2-month-old mice in-
dicated a mildly impaired glucose tolerance in mutant
mice (Supplementary Figure 2D), whereas the impaired
glucose tolerance was no longer present in mutant
mice older than 10 months (data not shown). Taken
together, the hormonal and metabolic alterations ob-
served in the mutant mice were consistent with the
early -cell proliferation and late insulinoma develop-
ment in these mice.
Figure 2. Disruption of the
Men1 gene in  cell leads to
glucagonoma, insulinoma, and
mixed islet tumor development.
(A) Representativemicrographs of
H&E, glucagon, and insulin stain-
ings, showing, from left to right, a
normal islet from a control mouse,
an -cell hyperplasia (4 months
old), a glucagonoma, an insuli-
noma, and a mixed islet tumor
from 10-month-old mutant mice.
Scale bars, 50 m. (B) Propor-
tions of the different islet tumors
observed at 8, 10, and 12months
of age and older in Men1F/F-Glu-
Cremice (n 5–10 for each age
group). (C–D) Increase in gluca-
gon (C) and insulin (D) serum con-
centration in Men1F/F-GluCre
mice (n  8), compared with the
control Men1/-GluCre mice
(n  6). Data are presented as
means  standard errors of the
mean; *P .05, **P .01.
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Occurrence of Insulinomas Is Not Due to
Adaptive -Cell Proliferation or Cell Fusion
Because -cell growth can be triggered by physio-
logic needs,11,28 we asked whether the development of
insulinoma in Men1F/F-GluCre mice could be due to
adaptive -cell proliferation that was triggered by the
hyperglycemia that occurred in young mutant mice. To
this end, we analyzed menin expression and the status of
the Men1 gene in the insulinomas, because the insuli-
noma cells with eventual adaptive proliferation should
not be subjected to Men1 ablation. As shown in Figure
3A, menin was not expressed in insulinomas. Genotyping
Figure 3. Insulinoma develop-
ment is not due to adaptive -cell
proliferation or to GluCre trans-
gene misexpression. (A) Men1
inactivation is found in insulino-
mas that developed in Men1F/F-
GluCre mutant mouse. Shown
are 2 representative triple-immu-
noﬂuorescence micrographs of
insulin (Ins), glucagon (Glu), and
menin (menin) immunoreactivity
in pancreatic sections of a 12-
month-old mutant mouse. Scale
bars, 50 m. (B) Deletion of the
Men1 allele () detected by PCR
in both microdissected - and
-cell tumors. F, ﬂoxed Men1 al-
lele. (C) Representative confocal
micrograph of insulin (Ins), gluca-
gon (Glu), and menin expression
in control and Men1F/F-GluCre
2-month-old mice (M2). The ar-
row indicates menin-deﬁcient in-
sulin-expressing cells. Scale bars,
20 m. (D) The number of menin-
deﬁcient insulin (Ins)– or gluca-
gon (Glu)–expressing cells are
presented as the percentage of
the total number of menin-deﬁ-
cient islet cells. For each animal,
100 (E17.5 embryos) or 400 (P12,
12 days old; M2, M4, M6, and
M12 are, respectively 2-, 4-, 6-
and 12-month-old mice) islet cells
were analyzed (n3mice per age
group). (E) Homogenous expres-
sion of Pdx1 and MafA in insulino-
mas that developed in 12-month-
old Men1F/F-RipCre mutant mice.
Representativemicrographsofpan-
creatic sections stained for H&E,
menin, MafA, Pdx1, Glu, and Ins.
Scale bars, 50 m. (F) Heteroge-
neous expression of pancreatic
endocrine cell markers in the insu-
linomas developed in Men1F/F-
GluCre. Three different subtypes
(I to III) were categorized for Pdx1,
MafA, and MafB expression.
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of microdissected insulinomas further showed that the
insulinoma cells, similar to the glucagonoma cells, con-
tained the deleted Men1 allele, whereas the exocrine pan-
creatic cells uniquely displayed the intact ﬂoxed Men1
allele (Figure 3B). The data indicate that the insuli-
noma cells underwent the same genetic modiﬁcation
of the Men1 gene as the glucagonoma cells, which
excludes the possibility that the insulinoma develop-
ment in Men1F/F-GluCre mice resulted from adaptive
-cell proliferation.
To further detail insulinoma development in mutant
mice, we investigated the appearance of menin-deﬁcient
glucagon- (meninGlu) and insulin-expressing (meninIns)
cells with the use of immunoﬂuorescence (Supplementary
Table 2). MeninIns cells were not detectable in Men1F/F-
GluCre mice until 2 months of age and accounted for2%
of the total menin-deﬁcient cells and only 1% of the total
Ins cells in 2-month-old Men1F/F-GluCre mice (Figure 3D;
Supplementary Table 2). At the same stage, nearly half of
the  cells lacked menin expression. In 4-month-old mutant
mice, meninIns cells accounted for approximately 20% of
the total menin-deﬁcient cells, and the percentage in-
creased sharply thereafter. Overall, meninIns cells
appeared after the proliferation of menin-deﬁcient glu-
cagon-expressing (meninGlu) cells but before the devel-
opment of islet tumors. The number of meninIns cells
increased with age and gradually exceeded the number of
meninGlu cells.
Furthermore, no multinucleated meninIns cells were
observed in Men1F/F-GluCre mice at different ages (data not
shown). In addition, there was no irregular nuclear menin
expression in insulinomas (Figure 3A). These results suggest
that the development of insulinomas in mutant mice was
not caused by cell fusion.
Heterogeneous Expression of - and -Cell
Markers in Insulinomas
We next asked whether the altered cellular context
resulting from Men1 disruption in  cells could lead to
the mis-expression of the GluCre transgene in the  cells
of Men1F/F-GluCre mice. We reasoned that, if this was
indeed the case, the insulinomas that developed should
be similar to the insulinomas that developed in Men1F/F-
RipCre mice, which is a  cell–speciﬁc Men1 KO model,
because the initial genetic event (Men1 ablation) would be
the same. Therefore, we compared the expression proﬁle
of pancreatic endocrine markers between the insulinomas
from these 2 models. Both Pdx1 and MafA, 2 -cell markers,
were homogeneously expressed in all of the tested insulino-
mas from Men1F/F-RipCre mice (Figure 3E). In contrast, the
insulinomas that developed in Men1F/F-GluCre mice dis-
played a heterogeneous expression of these markers (Figure
3F; Supplementary Figure 3), with at least 3 different ex-
pression proﬁles detected. One subtype (type I) expressed
MafB and Pdx1, but not MafA, a typical -cell marker. The
second subtype (type II) expressed Pdx1 and MafA, but not
MafB, whereas the third subtype (type III) expressed all 3
markers. Such a heterogeneous expression proﬁle of pan-
creatic endocrine markers, particularly the type I insuli-
noma (Pdx1MafAMafB), makes these insulinomas
largely different from those that developed in the  cell–
speciﬁc Men1 mutant mice. Therefore, it is unlikely that
these insulinomas were caused by the leaky expression of
the transgene in the  cells of Men1F/F-GluCre mice.
Appearance of Menin-Deﬁcient Cells Having
the Characteristics of Both  and  Cells in
Young Mutant Mice
Another potential explanation for the develop-
ment of insulinomas in Men1F/F-GluCre mice is that
Men1 disruption results in not only -cell proliferation
but also the transdifferentiation of menin-deﬁcient 
cells into insulin-expressing cells. If this is the case, we
should be able to detect intermediate menin-deﬁcient
cells sharing characteristics of both  and  cells during
the transdifferentiation procedure. With the use of triple
immunoﬂuorescence staining, 2 types of intermediate
cells were observed in pancreata of young mutant mice:
(1) menin-deﬁcient cells coexpressing glucagon and insu-
lin (meninGluIns, designated as A1 cells), that started
to appear in 3- to 4-month-old mutant mice (Figure 4A
middle), and (2) menin-deﬁcient cells expressing only in-
sulin (meninGluIns, namely A2 cells), localized in the
same islet area with meninGluIns cells together with
some residual A1 cells and found in 4- to 6-month-old mice
(Figure 4A right). Noticeably, the meninGluIns (A2) cells
displayed a sharp and narrow insulin-staining pattern, re-
sembling that seen in neighboring meninGluIns cells,
but completely distinct from the diffuse insulin staining
seen in normal  cells. This pattern was never detected in
normal control islets (Figure 4A left). Therefore, the sequen-
tial appearance of menin-deﬁcient cells coexpressing gluca-
gon/insulin and cells expressing insulin in young Men1F/F-
GluCre mice was observed before the development of islet
tumors.
To further conﬁrm the existence of meninGluIns
cells, ultrastructural double immunogold staining for
glucagon and insulin was analyzed by electronic micros-
copy. In control mice,  cells contained only the typical
high-density  granules that were positively stained with
antiglucagon antibody, whereas  cells contained only
the  granules stained with anti-insulin antibody (Figure
4B left). In 3- to 5-month-old mutant mice, the density
and structure of these secretary granules were altered
compared with the controls (Figure 4B middle and right).
Furthermore, we observed granules stained with both
glucagon and insulin antibodies (Figure 4B right), as well
as granules either glucagon or insulin positive within the
same cells (Figure 4B middle). These data provided the
further evidence for the existence of intermediate cells
during transdifferentiation.
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Menin-Deﬁcient Ins Cells Are Derived From
Glucagon-Expressing Cells
The transdifferentiation of menin-deﬁcient  cells
into insulin-expressing cells was further conﬁrmed with a
genetic cell lineage–tracing analysis. The Men1F/F-GluCre-
R26R mice allowed us to trace all cells derived from
Men1-deﬁcient glucagon-expressing cells. -Gal expres-
sion was never detected in insulin-expressing cells from
GluCre-R26R control mice (Figure 5A), nor in Men1F/F-
GluCre-R26R mutant mice younger than 2 months (Fig-
ure 5B). However, it could be detected in a few insulin-
expressing cells in Men1F/F-GluCre-R26R mutant mice,
starting at 2 months of age, the proportion of -galIns
cells increasing with age in the mutant mice. In fact, -gal
staining was seen in all the islet lesions found in these
mice, including the initial menin-deﬁcient  -cells (Figure
5B), the early islet lesions containing meninGluIns or
meninGluIns cells (Figure 5C), the insulinomas (Fig-
ure 5D; Supplementary Figure 4), and the glucagonomas
(data not shown). These data indicate that the identiﬁed
menin-deﬁcient insulin-expressing cells are derived from
glucagon-expressing pancreatic endocrine cells, conﬁrming
therefore the origin of insulinoma cells in the mutant mice.
This interesting ﬁnding in  cell–speciﬁc Men1 KO
mice prompted us to explore whether the transdifferen-
tiation could also occur in heterozygous Men1 mutant
mice (Men1/), particularly in menin-deﬁcient lesions
with -cell proliferation. Note that these Men1 mutant
mice were generated without the use of any Cre trans-
gene. We analyzed insulin and glucagon expression in the
Figure 4. -cell Men1 disrup-
tion leads to the sequential ap-
pearance of meninGluIns
and meninGluIns cells. (A)
Menin-deﬁcient islet lesions dis-
play unusual hormone expression
patterns. Representative immu-
noﬂuorescence micrographs of
glucagon (Glu), insulin (Ins), and
menin expression in control and
mutant mice. Note the menin-
deﬁcient cells coexpressing glu-
cagon and insulin (A1) in early le-
sions (3- to 4-month-old mutant
mice) (middle). Shown in the
right panel are micrographs of
sections from 6-month-old mu-
tant mice displaying dysplasia le-
sions with mixed insulin (A2) or
glucagon-expressing cell popu-
lations as well as residual cells
coexpressing insulin and gluca-
gon. Magniﬁed views of the
dashed area are shown in the
lower panel. Scale bars, 20 m.
(B) Representative pictures of
ultrastructural double-immuno-
gold staining for insulin (5 nm;
Ins) and glucagon (20 nm; Glu)
performed on pancreas sec-
tions. Note the presence in mu-
tant mice of islet cells containing
secretary granules with immuno-
reactivity both to glucagon and
insulin (right) or positively stained
by either glucagon or insulin
(middle; granules with green as-
terisk). Scale bars, 200 nm.
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glucagon-positive islet lesions from 9- to 24-month-old
Men1/ mice.22 Remarkably, coexpression of insulin and
glucagon was indeed detected in 5 of 6 Men1/ mice.
The lesions ranged from early lesions almost uniquely
consisting of menin-deﬁcient  cells (Supplementary Fig-
ure 5A) to glucagonomas and mixed islet tumors (Sup-
plementary Figure 5B and C, respectively). These obser-
vations suggest that the transdifferentiation from  cells
to insulin-expressing cells is a common phenomenon in
Men1-related -cell tumorigenesis.
Early Transdifferentiating Cells Express
MafB, but Not Pdx1, MafA, Pax4, or Ngn3
To gain insights into the molecular mechanisms
of the transdifferentiation, the expression of several pan-
creatic endocrine cell–speciﬁc transcriptional factors was
further examined throughout the tumor development
procedure. Noticeably, the early transdifferentiating cells,
including both meninGluIns (A1 cells; Figure 6A) and
meninGluIns cells (A2 cells; Supplementary Figure 6A),
expressed MafB, but neither Pdx1 nor MafA. Importantly,
this expression proﬁle was different from that of normal 
cells (Figure 6A) but was identical to that of normal and
menin-deﬁcient  cells (Supplementary Figure 6B). More-
over, meninGluInsMafBMafAPdx1 cells have never
been detected in the insulinomas that developed in  cell-
speciﬁc Men1 KO mice (see above). Therefore, our data
provide further evidence that both meninGluIns and
meninGluIns cells are closely related to meninGluIns
cells and that the former cells may be derived from the latter
through transdifferentiation.
Given the important role played by Ngn3 in the dif-
ferentiation of pancreatic endocrine cells during develop-
ment,29,30 we examined its expression in Men1F/F-GluCre
mice. No Ngn3 expression was detected in the pancreata
of 3- or 8-month-old mutant mice (data not shown). Pax4
is another important factor essential for -cell differen-
tiation in the mammalian pancreas.31 Moreover, a recent
study reported the effect of ectopic Pax4 expression lead-
ing to the conversion of  cells into insulin-secreting
cells.32,33 We examined therefore Pax4 expression in the
mutant mice at 2–12 months of age. The data showed
that Pax4 expression was found expressed in most nor-
mal  cells, but neither in initial menin-deﬁcient  cell nor
in the early transdifferentiating cells in mutant mice at 3–6
months of age, whereas its expression could be detected in
insulinomas in the mutant mice older than 7 months (Fig-
ure 6B; Supplementary Figure 7). Altogether, our data indi-
cated that the initiation of the transdifferentiation from
menin-deﬁcient  cells into insulin-expressing cells may not
imply Pdx1, MafA, Pax4, and Ngn3 expression.
Discussion
Here we demonstrate that  cell–speciﬁc Men1
ablation in mice leads to the development of glucagono-
Figure 5. Insulinoma cells origi-
nate from glucagon-expressing
cells in Men1F/F-GluCremice. Lin-
eage-tracing study with Men1F/F-
GluCre-R26R mice showed that
bothmenin-deﬁcient  and  cells
were positively stained with a
-gal–speciﬁc antibody. Shown
are -gal, insulin (Ins), and gluca-
gon (Glu) triple immunoﬂuores-
cence micrographs in control
mouse (A), a very early lesion (B;
6-week-old), a typical early lesion
(3-month-old) with A1 and A2
cells (C), andan insulinoma (D; 10-
month-old) from Men1F/F-Glu-
Cremice. Magniﬁed views of the
dashed area are shown in the 3
right panels. Scale bars, 20 m.
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Figure 6. Gene expression analyses of islet cell–speciﬁc
transcriptional factors in early menin-deﬁcient lesions. (A)
Representative immunoﬂuorescence images of 3-month-
old mutant mouse showing menin-deﬁcient cells that either
coexpress insulin and glucagon (A1) or express glucagon
or insulin (A2) in addition to MafB, but neither Pdx1 nor
MafA. Bottom panels are magniﬁed views of the yellow and
blue dashed areas. N, normal  cells. Scale bars, 20 m.
(B) Representative immunoﬂuorescence images of Pax4
expression in 6-month-old control and in mutant mice, re-
spectively, at 4 (M4), 6 (M6), and 8 (M8) months of age.
Magniﬁed views of the dashed areas are shown in the
bottom panel. Scale bars, 20 m. For the detection of the
above factors, at least 5 islets from each mouse (n  3–5
mice per age group) were analyzed.
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mas, insulinomas, and mixed islet tumors, and all the
cells of islet lesions derive from cells having previously
expressed the Proglucagon gene. The GluCre-mediated lin-
eage tracing analyses, together with the sequential ap-
pearance of meninGluInsMafBPdx1MafA and
meninGluInsMafBPdx1MafA cells before tumor
development, provided strong evidence showing that
menin-deﬁcient  cells transdifferentiate into insulin-
expressing cells with time (Figure 7), which further de-
velop into insulinomas. Our work establishes for the ﬁrst
time menin as an in vivo regulator of pancreatic -cell
plasticity, and the transdifferentiation, induced by the
deregulation of -cell plasticity because of menin inacti-
vation, as a novel mechanism involved in islet tumor
development. Interestingly, the reverse phenomenon, ie, a
- to -cell transdifferentiation, was not observed in 
cell–speciﬁc Men1 KO mice (data not shown).
The complexity of MEN1 and non-MEN1 pancreatic
endocrine tumors is well known, and their histogenesis
remains elusive.19,34,35 The tumor phenotype found in
Men1F/F-GluCre mice, characterized by glucagon-positive
early lesions, islet tumors secreting multiple hormones,
and the occurrence of insulinomas in aged mice, is rem-
iniscent of the recent clinical observations.19,20 Therefore,
the ﬁnding of involvement of transdifferentiation in islet
tumor histogenesis in our study paves new ground for
further investigation of the complex nature of islet tu-
mors. Transdifferentiation is seldom mentioned as an
underlying mechanism of tumorigenesis. Nevertheless,
epithelial-to-mesenchymal transition, a form of transdif-
ferentiation, plays an important role in cancer formation
and progression.36 Squamous metaplasia, seen in breast
and prostate cancers, and other forms of metaplasia
observed in esophageal and stomach cancers are well-
known precancerous lesions.37 However, the transdiffer-
entiation between different hormone-secreting cell types
has never been experimentally established in the frame-
work of endocrine tumors.
The plasticity of fully mature cells in the pancreas has
been an attractive research area and of controversy. Re-
cent studies implied that several types of mature pancre-
atic cells may possess more potential in cell plasticity
than previously thought.38–40 Interestingly, both massive
loss of  cells41,42 and the blockade in -cell function by
either gene targeting43 or glucagon receptor antago-
nists44 resulted in cells coexpressing glucagon and insu-
lin. Although hormonal coexpression per se is not a proof
of cell lineage conversion, these studies may have pro-
vided some hints on -cell plasticity. By different analy-
ses, we have shown that glucagon-expressing cells can
indeed transdifferentiate into insulin-expressing cells on
menin inactivation. Note that the transdifferentiation
that we report here relates to islet tumorigenesis. Never-
theless, common features may exist among transdiffer-
entiation events occurring in different contexts.
The ﬁnding of meninGluInsMafBPdx1MafA
cells in the early lesions that developed in Men1F/F-Glu-
Cre mice is intriguing, because they have been seen
neither in normal adult islet cells nor in  cell–speciﬁc
Men1 mutant mice. The lack of Ngn3, Pdx1, and MafA
expression in these cells makes them more similar to the
immature MafBIns cells that have been documented
during development.45 However, further work is needed
to clarify the similarities and the differences between the
transdifferentiated cells observed in the current study and
the MafBIns cells that occur during development. Inter-
estingly, Collombat et al32 recently reported that ectopic
Pax4 expression could convert pancreatic progenitors to 
cells and subsequently into  cells. The occurrence of such
a conversion is associated with -cell deﬁciency, Ngn3 re-
expression, and ectopic Pax4 expression.32,33 We noticed
that this is manifestly different from the transdifferen-
tiation reported in the current work which is featured by
-cell proliferation and lack of Ngn3 and Pax4 expression
in the initial transdifferentiating cells. Markedly, their
work highlighted the importance of the balance among
islet-speciﬁc transcriptional factors in specifying cell fate.
Considering the known functions of menin, we speculate
that the deregulation of these factors could be involved
in the mechanisms leading to the transdifferentiation
observed in the current work. It will be important in the
future to identify the genetic and epigenetic factors in-
volved in the procedure.
In conclusion, the current study shows that menin
regulates -cell growth and, more importantly, -cell
plasticity. Our results provide, therefore, novel insights
into the genetic events that regulate plasticity in differ-
entiated  cells and shed new light on the histogenesis
Figure 7. Schematicmodel depicting the development of insulinomas by
transdifferentiation on cell–speciﬁcMen1disruption. In adultmice, cells
produce glucagon and express MafB, but not Pdx1, MafA, or Pax4. -cell
Men1 ablation leads to the proliferation of  cells but also to -cell trans-
differentiation. Initially, someof the Men1-deﬁcient cells coexpress insulin
and glucagon and then become insulin-expressing cells. Menin-deﬁcient
insulin-expressing cells that have a proﬁle similar to  cells subsequently
develop into insulinomas that have a proﬁle closer to  cells with the vari-
able expression of pancreatic endocrine cell markers.
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and biology of multihormone-secreting islet tumors. In
addition, given the need for cell-replacement therapy for
diabetes, we believe that the modulation of -cell plas-
ticity could be explored in the future to develop alterna-
tive strategies for -cell regeneration.
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2010.01.046.
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Supplementary Materials and Methods
Glucose Tolerance Test
Glucose tolerance tests were performed after de-
priving animals of food. Animals were injected (intraperi-
toneally) with dextrose 2 g/kg of body weight (Sigma-
Aldrich, St. Louis, MO). Glucose concentrations were
measured from tail blood collected immediately before
and 5, 15, 30, 60, and 120 minutes after the injection.
Quantitative PCR Analysis
Primer sequences were used as follows: Men1-fw
5=-GAAGATCATGCTTGGGTGGT-3=, Men1-rev 5=-CAG-
GTCTGCCAAGTTCCCTA-3=, Hprt-fw 5=-TGTTGTTGGA-
TATGCCCTTG-3=, and Hprt-rev 5=-AACTTGCGCTCATC-
TTAGGC-3=.
Antibodies and Reagents for Histologic
Analyses
Antibodies used for immunochemistry are as fol-
low: menin (1:2000; Santa Cruz Biotechnology, Santa
Cruz, CA), insulin (1:4000; Dako, Carpinteria, CA), glu-
cagon (1:5000; NovoCastra, Newcastle, United Kingdom),
bromodeoxyuridine (BrdU; 1:1000; Sigma-Aldrich), Ki67 (1:
500; Santa Cruz Biotechnology). For immunoﬂuorescence
analysis, primary antibodies against insulin (1:1000,
guinea-pig, Dako; 1:2000, mouse, Sigma-Aldrich); gluca-
gon (1:2000, rabbit, Linco Research, St Charles, MO;
1:1000, mouse, Abcam, Cambridge, MA); MafA, MafB,
and menin (1/4000, rabbit, Bethyl Laboratories, Mont-
gomery, TX); glucose transporter 2 (Glut2; 1:2000, rabbit,
Chemicon International, Temecula, CA); Pdx1 and anti–
proprotein convertase 1/3 (PC1/3; 1:1000, rabbit, kind
gifts from Dr Raphaël Sharfmann); Pax4 (1:500, rabbit,
kind gift from Dr Beatriz Sosa-Pineda); -galactosidase
(-gal; 1:1000, rabbit, Cortex Biochem, San Leandro, CA)
were used in combination with cyanine 2 (Cy-2)–, Cy-3–,
and Cy-5–conjugated secondary antibodies (1/200; Jack-
son ImmunoResearch Laboratories Inc, West Grove, PA)
as appropriate. Tyramide ampliﬁcation (PerkinElmer
Waltham, MA) was used according to the manufacturer’s
instructions.
Double Immunoelectron Microscopy
Immunoelectron microscopy was performed on
ultrathin pancreas sections (70-nm thick) cut on a Reichert
ultracut E ultramicrotome (Leica, Wetzlar, Germany) and
mounted on polylysine-coated 200-mesh nickel grids. Gold
immunolabeling was carried out at room temperature in 1%
bovine serum albumin (BSA). Grids carrying samples
were blocked (10 minutes in 1% BSA) and incubated 30
minutes with anti–glucagon primary antibody (1/1000,
mouse, Abcam). The grids were subsequently washed in
phosphate-buffered saline (PBS; 4 times, 15 minutes) and
incubated with 20 nm gold-conjugated goat anti–mouse
immunoglobulin G (IgG; 1/80; Tebu-bio, Le Perray en
Yvelines, France) for 20 minutes. Grids were post ﬁxed 5
minutes in 0.2% glutaraldehyde and washed in PBS/0.15
M glycine prior to the incubation with the anti-Insulin
antibody (1/1000, guinea-pig, Dako). 5 nm gold-conju-
gated anti-guinea-pig IgG (1/80, Tebu-bio) were subse-
quently applied. Finally, the labeled grids were contrasted
on ice in 0.3% uranyl acetate (Electron Microcopy Sci-
ences, Hatﬁeld, PA) within 2% methyl cellulose (Sigma-
Aldrich) for 10 minutes and observed on a JEM-1400
transmission electron microscope (JEOL, Tokyo, Japan).
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